An Open-label Phase II Study of BKM120 in Subjects With Relapsed and Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma
Phase: PHASE2
Conditions: Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Sponsor: Novartis Pharmaceuticals

Clinical Development
BKM120
Protocol CBKM120Z2402 / NCT01693614
An open-label phase II study of BKM120 in patients with 
relapsed and refractory diffuse large B-cell lymphoma, 
mantle cell lymphoma and follicular lymphoma
Authors
 
Document type
Amended Protocol Version
EUDRACT number
2012-002208-41
Version number
04 (Clean)
Development phase
II
Document status
Final
Release date
09-Aug-2016
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis

Novartis
Confidential
Page 2
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table of contents
Table of contents .................................................................................................................2
List of figures ......................................................................................................................6
List of tables ........................................................................................................................6
List of abbreviations............................................................................................................8
Glossary of terms...............................................................................................................10
Amendment 4 (09-Aug-2016)...........................................................................................11
Summary of previous amendments ...................................................................................13
Protocol summary:.............................................................................................................23
1
Background........................................................................................................................25
1.1
Overview of disease pathogenesis, epidemiology and current treatment..............25
1.1.1
Overview of diffuse large B cell lymphoma.........................................25
1.1.2
Overview of mantle cell lymphoma......................................................26
1.1.3
Overview of follicular lymphoma.........................................................27
1.1.4
The PI3K pathway.................................................................................27
1.1.5
The PI3K/mTOR/Akt pathway and NHL .............................................29
1.2
Introduction to investigational treatment(s) and other study treatment(s).............32
1.2.1
Overview of BKM120...........................................................................32
2
Rationale............................................................................................................................40
2.1
Study rationale and purpose...................................................................................40
2.2
Rationale for the study design ...............................................................................41
2.3
Rationale for dose and regimen selection..............................................................41
2.4
Rationale for choice of combination drugs............................................................41
2.5
Rationale for choice of comparators drugs............................................................41
3
Objectives and endpoints...................................................................................................41
4
Study design ......................................................................................................................43
4.1
Description of study design ...................................................................................43
4.2
Timing of interim analyses and design adaptations...............................................44
4.3
Definition of completion of the study....................................................................44
4.4
Early study termination..........................................................................................44
5
Population..........................................................................................................................45
5.1
Patient population..................................................................................................45
5.2
Inclusion criteria ....................................................................................................45
5.3
Exclusion criteria...................................................................................................46
6
Treatment...........................................................................................................................49
6.1
Study treatment......................................................................................................49

Novartis
Confidential
Page 3
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
6.1.1
Dosing regimen.....................................................................................49
6.1.2
Ancillary treatments..............................................................................50
6.1.3
Rescue medication ................................................................................50
6.1.4
Guidelines for continuation of treatment ..............................................50
6.1.5
Treatment duration................................................................................50
6.2
Dose escalation guidelines.....................................................................................50
6.3
Dose modification..................................................................................................50
6.3.1
Dose modification and dose delay ........................................................50
6.3.2
Treatment interruption and treatment discontinuation..........................51
6.4
Concomitant medications ......................................................................................61
6.4.1
Permitted concomitant therapy .............................................................62
6.4.2
Prohibited concomitant therapy ............................................................63
6.5
Patient numbering, treatment assignment or randomization .................................65
6.5.1
Patient numbering .................................................................................65
6.5.2
Treatment assignment or randomization...............................................65
6.5.3
Treatment blinding................................................................................65
6.6
Study drug supply..................................................................................................66
6.6.1
Study drug preparation and dispensation ..............................................66
6.6.2
Study drug packaging and labeling.......................................................66
6.6.3
Drug supply and storage........................................................................66
6.6.4
Study drug compliance and accountability ...........................................67
6.6.5
Disposal and destruction .......................................................................67
7
Visit schedule and assessments .........................................................................................68
7.1
Study flow and visit schedule................................................................................68
7.1.1
Molecular pre-screening........................................................................74
7.1.2
Screening...............................................................................................74
7.1.3
Run-in period ........................................................................................75
7.1.4
Treatment period...................................................................................75
7.1.5
End of treatment visit including study completion and premature 
withdrawal.............................................................................................75
7.1.6
Follow up period ...................................................................................76
7.2
Assessment types...................................................................................................78
7.2.1
Efficacy assessments.............................................................................78
7.2.2
Safety and tolerability assessments.......................................................80
88
7.2.4
Other assessments .................................................................................90

Novartis
Confidential
Page 4
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
8
Safety monitoring and reporting........................................................................................90
8.1
Adverse events.......................................................................................................90
8.1.1
Definitions and reporting ......................................................................90
8.1.2
Laboratory test abnormalities................................................................92
8.2
Serious adverse events...........................................................................................92
8.2.1
Definitions.............................................................................................92
8.2.2
Reporting...............................................................................................93
8.3
Emergency unblinding of treatment assignment ...................................................94
8.4
Pregnancies............................................................................................................94
8.5
Warnings and precautions......................................................................................94
8.6
Data Monitoring Committee..................................................................................94
8.7
Steering Committee ...............................................................................................94
9
Data collection and management.......................................................................................95
9.1
Data confidentiality ...............................................................................................95
9.2
Site monitoring ......................................................................................................95
9.3
Data collection.......................................................................................................96
9.4
Database management and quality control............................................................96
10 Statistical methods and data analysis ................................................................................96
10.1
Analysis sets ..........................................................................................................97
10.1.1
Full Analysis Set ...................................................................................97
10.1.2
Safety Set ..............................................................................................97
10.1.3
Per Protocol Set.....................................................................................97
10.1.4
Dose-determining analysis set...............................................................97
10.1.5
Pharmacokinetic analysis set.................................................................97
10.2
Patient demographics/other baseline characteristics .............................................98
10.3
Treatments (study treatment, concomitant therapies, compliance) .......................98
10.4
Primary objective...................................................................................................98
10.4.1
Variable.................................................................................................98
10.4.2
Statistical hypothesis, model, and method of analysis..........................98
10.4.3
Handling of missing values/censoring/discontinuations.......................98
10.4.4
Supportive analyses...............................................................................99
10.5
Secondary objectives .............................................................................................99
10.5.1
Key secondary objective(s)...................................................................99
10.5.2
Other secondary efficacy objectives .....................................................99
10.5.3
Safety objectives ...................................................................................99
10.5.4
Pharmacokinetics ................................................................................101

Novartis
Confidential
Page 5
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
101
102
102
102
10.7
Interim analysis....................................................................................................103
10.8
Sample size calculation........................................................................................103
10.9
Power for analysis of key secondary variables....................................................104
11 Ethical considerations and administrative procedures ....................................................104
11.1
Regulatory and ethical compliance......................................................................104
11.2
Responsibilities of the investigator and IRB/IEC/REB.......................................104
11.3
Informed consent procedures...............................................................................104
11.4
Discontinuation of the study................................................................................105
11.5
Publication of study protocol and results.............................................................105
11.6
Study documentation, record keeping and retention of documents.....................105
11.7
Confidentiality of study documents and patient records .....................................106
11.8
Audits and inspections.........................................................................................106
11.9
Financial disclosures............................................................................................106
12 Protocol adherence ..........................................................................................................106
12.1
Amendments to the protocol................................................................................107
13 References (available upon request)................................................................................108
14 Appendices ......................................................................................................................111
14.1
Appendix 1 - List of prohibited CYP3A inhibitors and inducers........................111
14.2
Appendix 2 - List of CYP450 substrates to be used with caution.......................112
14.3
Appendix 3 - List of prohibited QT prolonging drugs ........................................113
14.4
Appendix 4 - List of QT prolonging drugs to be used with caution....................114
14.5
Appendix 5 - Guideline for efficacy evaluation in lymphoma studies (based 
on Cheson response criteria)................................................................................116
14.5.1
Introduction.........................................................................................116
14.5.2
Definitions and criteria for normalization...........................................116
14.5.3
Efficacy assessments...........................................................................117
14.5.4
Efficacy analysis definitions ...............................................................125
14.5.5
Data handling and programming conventions ....................................131
14.5.6
References (available upon request) ...................................................133
14.5.7
Appendices..........................................................................................134

Novartis
Confidential
Page 6
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
List of figures
Figure 1-1
Schematic representation of the PI3K pathway ....................................29
Figure 4-1
Study Design Overview ........................................................................43
Figure 14-1
Appendix A - Definition of index nodal lesion, non-index nodal 
lesion, index extranodal lesion, non-index extranodal lesion .............134
Figure 14-2
Appendix B - Calculation of the response for index lesions...............135
Figure 14-3
Appendix C - Calculation of the response for non-index lesions .......136
Figure 14-4
Appendix D - Calculation of the overall disease response .................137
List of tables
Table 1-1
Most frequent AEs (at least 15%) related to study drug in study 
CBKM120X2101 (n=81):.....................................................................35
Table 1-2
Numbers of patients with mood disorders occurred at 100 mg/day 
in ongoing BKM120 studies .................................................................37
Table 1-3
Number of patients with hyperglycemia occurred at 100 mg/day in 
ongoing BKM studies ...........................................................................38
Table 3-1
Objectives and related endpoints ..........................................................42
Table 6-1
Dose and treatment schedule.................................................................49
Table 6-2
Dose reduction steps for BKM120........................................................51
Table 6-3
Criteria for interruption and re-initiation of BKM120 treatment..........52
Table 6-4
Management of Pneumonitis.................................................................58
Table 6-5
Packaging and labeling .........................................................................66
Table 7-1
Visit evaluation schedule ......................................................................69
Table 7-2
Ann Arbor staging classification1 .........................................................75
Table 7-3
ECOG performance scale......................................................................81
Table 7-4
Clinical laboratory parameters collection plan .....................................82
Table 7-5
Classification of severity based on mood questionnaire scores............86
Table 7-6
GAD-7 anxiety scale.............................................................................87
Table 7-7
PHQ-9 depression scale ........................................................................87
88
89
Table 10-1
Rejection criteria and power for different sample sizes......................104
Table 14-1
List of prohibited CYP3A inhibitors and inducers .............................111
Table 14-2
List of CYP450 substrates to be used with caution.............................112
Table 14-3
List of prohibited QT prolonging drugs..............................................113
Table 14-4
List of QT prolonging drugs to be used with caution .........................114

Novartis
Confidential
Page 7
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table 14-5
Radiological status based on SPD calculation for all index lesions....121
Table 14-6
Radiological response criteria for index extranodal lesions in case 
of CR in index nodal lesions...............................................................122
Table 14-7
Radiological response for index lesions..............................................122
Table 14-8
Response criteria for non-index lesions (nodal, splenic and/or 
hepatic nodules and other extranodal lesions) ....................................123
Table 14-9
Overall radiological response at each assessment...............................124
Table 14-10
Censoring reasons ...............................................................................129
Table 14-11
Options for event dates used in PFS, TTP, duration of response........130

Novartis
Confidential
Page 8
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
List of abbreviations
AE
Adverse Event
ALP
Alkaline phosphatase
ALT
Alanine aminotransferase/glutamic pyruvic transaminase/GPT
ANC
Absolute neutrophil count
AST
Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
b.i.d.
bis in diem/twice a day
BLRM
Bayesian Logistic Regression Model
CPK
Creatine Phosphokinase
CR
Complete Response
CRF
Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO
Contract Research Organization
CSP
Clinical study protocol
CSR
Clinical study report
CTCAE
Common Terminology Criteria for Adverse Events
DILI
Drug-induced liver injury
DLBCL
Diffuse large B-cell lymphoma
DLT
Dose Limiting Toxicity
DS&E
Drug Safety and Epidemiology
EBV
Epstein-Barr Virus
ECG
Electrocardiogram
ECOG
Eastern Cooperative Oncology Group
EOT
End of Treatment
FAS
Full Analysis Set
FL
Follicular lymphoma
FPFV
First Patient First Visit
FPG
Fasting plasma glucose
GABA
Gamma amino-butyric acid
GI
Gastrointestinal
HbA1c
Glycosylated Hemoglobin
HBsAg
Hepatitis B surface Antigen
HBV
Hepatitis B Virus
HCV
Hepatitis C Virus
HER2
Human epidermal growth factor receptor 2
Hgb
hemoglobin
HIAA
Hydroxyindoleacetic acid
HIV
Human immunodeficiency virus
HSV
Herpes Simplex Virus
i.v.
intravenous(ly)
ICH
International Conference on Harmonization
IEC
Independent Ethics Committee
IgG
Immunoglobulin G
IgM
Immunoglobulin M
INR
International Normalized Ratio
IRB
Institutional Review Board

Novartis
Confidential
Page 9
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
IRT
Interactive Response Technology that includes Interactive Voice Response System and 
Interactive Web Response System
LPFV
Last Patient First Visit
MAP
Master Analysis Plan documents project standards in the statistical methods which will be 
used within the individual clinical trial RAP documentation
MCL
Mantle cell lymphoma
MTD
Maximum Tolerated Dose
mTOR
Mammalian target of rapamycin
NHL
Non-Hodgkin lymphomas
o.d.
omnia die/once a day
ORR
Overall response rate
OS
Overall Survival
p.o.
Per os/by mouth/orally
PD
Progressive Disease
PFS
Progression free survival
PHI
Protected Health Information
PI3K
Phosphatidylinositol-3-Kinase
PPS
Per-Protocol Set
PR
Partial Response
RAP
The Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analyses
SAE
Serious Adverse Event
SEC
Safety Event Categories
SOP
Standard Operating Procedure
TBL
Total bilirubin
TLS
Tumor lysis syndrome
ULN
Upper limit of normal
VAP
Validation Analysis Plan

Novartis
Confidential
Page 10
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Glossary of terms
Assessment
A procedure used to generate data required by the study
Cohort
A group of newly enrolled patients treated at a specific dose and regimen (i.e. 
treatment group) at the same time
Cycles
Number and timing or recommended repetitions of therapy are usually 
expressed as number of days (e.g.: q28 days)
Dose level
The dose of drug given to the patient (total daily or weekly etc.) 
Enrollment
Point/time of patient entry into the study; the point at which informed consent 
must be obtained (i.e. prior to starting any of the procedures described in the 
protocol)
Investigational drug
The study treatment whose properties are being tested in the study; this 
definition is consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug.”
Investigational treatment
Drug whose properties are being tested in the study as well as their 
associated placebo and active treatment controls (when applicable). This also 
includes approved drugs used outside of their indication/approved dosage, or 
that are tested in a fixed combination. Investigational treatment generally does 
not include other study treatments administered as concomitant background 
therapy required or allowed by the protocol when used in within approved 
indication/dosage
Medication number
A unique identifier on the label of each study treatment package which is 
linked to one of the treatment groups of a study
Other study treatment
Any drug administered to the patient as part of the required study procedures 
that was not included in the investigational treatment
Patient Number 
A unique identifying number assigned to each patient/subject/healthy 
volunteer who enrolls in the study
Premature patient withdrawal
Point/time when the patient exits from the study prior to the planned 
completion of all study treatment administration and/or assessments; at this 
time all study treatment administration is discontinued and no further 
assessments are planned, unless the patient will be followed for progression 
and/or survival
Stage related to study timeline
A major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc.
Stage in cancer
The extent of a cancer in the body. Staging is usually based on the size of the 
tumor, whether lymph nodes contain cancer, and whether the cancer has 
spread from the original site to other parts of the body
Stop study participation
Point/time at which the patient came in for a final evaluation visit or when 
study treatment was discontinued whichever is later
Study treatment
Includes any drug or combination of drugs in any study arm administered to 
the patient (subject) as part of the required study procedures, including 
placebo and active drug run-ins.
In specific examples, it is important to judge investigational treatment 
component relationship relative to a study treatment combination; study 
treatment in this case refers to the investigational and non-investigational 
treatments in combination.
Study treatment discontinuation
Point/time when patient permanently stops taking study treatment for any 
reason; may or may not also be the point/time of premature patient withdrawal
Treatment group
A treatment group defines the dose and regimen or the combination, and may 
consist of 1 or more cohorts. Cohorts are not expanded, new cohorts are 
enrolled.
Variable
Identifier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified timepoints

Novartis
Confidential
Page 11
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Amendment 4 (09-Aug-2016)
Amendment rationale
The main purpose of this protocol amendment is to:

Provide a clarification on the measures to follow when a patient exhibits suicidal ideation 
regardless of the response to question 9 of the PHQ-9 questionnaire (as has been 
described in the BKM120 Investigator’s Brochure Ed. 9.0).
Rationale: Patient Health Questionnaire-9 (PHQ-9) is used to increase the sensitivity of 
identifying potential depression and suicidal thoughts via positive response to “question 9”. 
However, it has not been consistently predictive for suicidal ideation or attempt in BKM120 
trials, as some patients who exhibited suicidal ideation or attempt, reported as an adverse 
event, either had a negative response to question 9 or did not answer it. Hence, measures to be 
followed for any adverse event of suicidal ideation regardless of the response to question 9 or 
the total score of PHQ-9 have been specified in the Investigator’s Brochure Ed. 9.0/dated 29-
Apr-2016.
A prospective suicidality assessment in clinical trials with BKM120 is important and i s  
facilitated using question 9 of the PHQ-9 questionnaire. A timely interview with the
patient after the questionnaire completion is recommended. Patients with a positive response
to question 9 (as indicated by selecting “1”, “2” or “3”), or otherwise exhibiting any suicidal
ideation must immediately interrupt the BKM120/placebo treatment and must be assessed by
a psychiatrist. This is regardless of the response or lack of response to question 9 or total 
PHQ-9 score or CTCAE grading of the suicidal ideation.
Additional changes
Update to the guidelines for BKM120 administration related to food intake

Rationale: A clinical pharmacology study [CBKM120C2108] investigating the food effect 
of both a low fat low calorie meal (LFLC) or a high fat, high calorie meal (HFHC) on the 
pharmacokinetics of BKM120 in healthy volunteers showed that intake of food 
concomitantly with BKM120 led to a delayed and reduced Cmax without a meaningful 
impact on exposure (AUCinf) compared to fasting administration (BKM120 Investigator’s 
Brochure Ed. 9.0). Based on these findings, BKM120 can be administered with or without 
food and accordingly the guidelines had been updated.
Update to the section on BKM120 dosing, without regard to food intake:

Removal of the requirement that BKM120/placebo be taken with regard to food intake.
Changes in the section on management and follow-up for mood alteration:

Clarification on measures to be followed (interruption of BKM120 and psychiatric 
consultation) for any patient who presents with suicide ideation of any grade

Novartis
Confidential
Page 12
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Changes to the study assessments:

The inclusion of a statement that regardless of grade or response to question number 9 in 
PHQ-9 questionnaire, any patient who presents with suicide ideation must interrupt 
BKM120 and be referred for a psychiatric consultation.

Adding a statement to require the investigator to assess the patient for suicidal ideation 
regardless of the answer to question 9 of PHQ-9 or if the patient did not respond to 
question 9 in PHQ-9 questionnaire.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
The following sections have been changed in the amended protocol:

Section 6.1.1 Dosing regimen: removal of the requirement that BKM120 be taken with 
regard to food intake

Table 6-3 Criteria for interruption and re-initiation of BKM120 treatment / Mood 
alteration (depression, anxiety): for grade 1 and 2 the inclusion of a statement that any 
patient who presents with suicide ideation must be referred for a psychiatric consultation

Section 6.3.2.1.5 Guidelines for the treatment of study drug induced psychiatric disorders. 
Adding a statement that any patient who presents with suicide ideation must interrupt 
BKM120/placebo and be referred for a psychiatric consultation regardless of grade or 
response to question 9 in the PHQ-9 questionnaire

Section 7.2.2.8 GAD-7 and PHQ-9 Questionnaires:

Adding a statement that any patient who presents with suicide ideation must interrupt 
BKM120 and be referred for a psychiatric consultation regardless of grade or 
response to question 9 in the PHQ-9 questionnaire

Adding a statement requiring assessment of suicidal ideation for any patient who does 
not answer question 9 or the whole PHQ-9.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis
Confidential
Page 13
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Summary of previous amendments
Amendment 3
Amendment rationale
The purpose of this protocol amendment is to provide additional guidance to investigators 
around management of liver toxicities.
Alterations in liver function tests (LFTs) have been commonly observed in clinical trials with 
BKM120 as an investigational agent. These include mostly transient increases in transaminase 
enzymes (ALT and/or AST), which often occur during the first 6 to 8 weeks of BKM120 
(buparlisib) treatment, and rarely are associated with signs/symptoms of impaired liver 
function. Current BKM120 protocols have conservative inclusion criteria for baseline LFTs 
with close monitoring guidelines to be followed during the treatment and stringent dose 
modification/interruption criteria.
In March 2015, a search for potential drug-induced liver injury (DILI) cases in BKM120 
Novartis-sponsored trials using conservative biochemical criteria (e.g. AST/ALT >3.0x ULN 
and total bilirubin (TBL) >2.0xULN at any time during the treatment period, regardless of 
causality) has been conducted. Upon medical review, most of these occurred in the context of 
disease progression in advanced cancer patients and/or were confounded by other causes. 
However, six of these DILI candidates were consistent with Hy’s law criteria (e.g. 
AST/ALT >3.0x ULN and TBL >2.0xULN in the absence of cholestasis and other 
explanatory causes). Five of these cases were in combination with fulvestrant in study 
CBKM120F2302, and one in combination with the investigational drug LDE225 (sonidegib) 
in study CLDE225X2114. All patients have recovered upon treatment discontinuation except 
one patient for whom the outcome is not available because the patient refused to return for 
safety follow-up. Of note, with the exception of the first case reported as Investigator 
notification (IN) back in April 2014, it is unknown at this stage whether the remaining 
patients received BKM120 or placebo as the trial remains blinded. Updated liver safety 
including the identified DILI/Hy’s law candidates for the randomized, blinded studies 
CBKM120F2302 and CBKM120F2303 were further presented to the Data Monitoring 
Committee (DMC) in April-2015; the DMC noted no change or additional liver safety 
concerns and recommended continuing the respective studies as planned.
An Aggregated Safety Finding Report was submitted to Health Authorities and all 
investigators participating in BKM120 studies in May 2015 informing them about the liver 
findings including a brief summary of the six Hy’s law cases. In addition, Novartis decided to 
update the current liver-related safety measures in ongoing protocols to enhance patient safety. 
Therefore, the purpose of this protocol amendment is to provide additional guidance to 
investigators around management of liver toxicities as outlined below.
Changes to the background section:

Update of the clinical background section on liver toxicity to align with the protocol 
amendment rationale.

Novartis
Confidential
Page 14
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Changes to the exclusion criteria:

Exclusion of patients with an acute viral hepatitis or with a history of chronic or active 
HBV or HCV infection (testing not mandatory)
Changes in the section on management and follow-up for selected toxicities:

Addition of hepatotoxicity management guidelines
Changes to the visit schedule and assessments:

Clarification of laboratory parameters collection plan and viral hepatitis testing.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The following sections have been changed in the amended protocol:
Section 1.2.1.2 Clinical experience: addition of the outcome from a recent medical review for 
the liver toxicity.
Section 5.3 Exclusion criteria: Addition of exclusion Criteria #24 to exclude patients with an 
acute viral hepatitis or a history of chronic or active HBV or HCV infection.
Section 6.2 - Table 6-3 (Criteria for interruption and re-initiation of BKM120 treatment): 
Clarification of the management of AST or ALT side effects.
Section 6.3.2.2 (Additional management and follow-up for selected toxicities): New section 
added “Management of hepatotoxicity (ALT and/or AST >3.0x ULN and total bilirubin >2.0x 
ULN) in patients receiving BKM120” including detailed liver event follow-up assessments 
and close monitoring measures.
Section 7.1 Study flow and visit schedule - Table 7-1 (Visit evaluation schedule): addition of 
hepatotoxicity follow-up testing/procedures.
Section 7.1.2.3 (Patient demographics and other baseline characteristics): addition of viral 
hepatitis serology.
Section 7.2.2.5 (Laboratory evaluations) and Table 7-4 (Clinical laboratory parameters 
collection plan): addition of hepatotoxicity follow-up testing and procedures (Note: testing not 
mandatory).
Section 7.2.2.5.8: New section added “Viral hepatitis serology and other tests for 
hepatotoxicity follow-up”.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.

Novartis
Confidential
Page 15
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment 2
Amendment rationale
The main purpose of this protocol amendment is to update and align the management of 
selected adverse events across the BKM120 program and with the last [Investigator’s 
Brochure version 6], specifically psychiatric disorders, hyperglycemia grade 2, skin rash and 
stomatitis (details outlined below).
In addition, a cap of N=28 patients has been added for each cohort to limit over enrollment. 
Despite proactive planning for cohort closure, rapid enrollment into the DLBCL cohort 
resulted in several additional patients in screening who then ethically had to be enrolled on 
trial. A similar situation might arise for MCL and FL cohorts. Hence, maximum number of 
patients per cohort will be capped at N = 28 patients, in case of over enrollment. The method 
of statistical analysis remains the same, knowing that the power and rejection rule may change 
with the final number of patients enrolled as described in Table 10-1.
Modification in the BKM120 interruption period to recover from an adverse event is extended 
from 21 to 28 days before the patient has to be permanently discontinued from study 
treatment. The maximum allowed treatment interruption for BKM120 after which the 
treatment has to be permanently discontinued will be increased from 21 to 28 days since the 
recovery to ≤ grade 1 has been reported to take longer for some of the side effects (e.g. skin 
rash, transaminase increase). This will allow sufficient time for recovery, implementation of 
appropriate clinical management and/or external consultation (e.g. involvement of a 
psychiatrist for psychiatric disorders, etc.) should this be needed. Grade 4 AEs will still 
continue to lead to permanent discontinuation for most AEs (irrespective of recovery time). 
Patients who experience treatment interruptions because of an adverse event will further 
resume treatment with a reduced dose after recovery in most cases (see specific tables for dose 
adjustment guidelines). In addition, the investigator may decide to discontinue the patient at 
any time if this is in the best interest of the patient.
Moreover, to improve clarity, changes have been implemented to the inclusion/exclusion 
criteria, definition of post-menopausal status, collection of outcomes from pregnant partners 
of male study participants, as well as editorial changes.

Novartis
Confidential
Page 16
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Changes to the inclusion/exclusion criteria:

Clarification that inclusion of patients with total bilirubin values below the lower limit of 
normal is allowed as such values are considered not clinically relevant for the purpose of 
entry into the study [inclusion criterion #8].

Patients with active severe personality disorders will be excluded to align with changes 
within the program based on clinical experience from ongoing BKM trials as reflected in 
the updated information in the current IB version 6.0 issued on 13-Nov-2013, and with 
additional feedback from earlier advisory boards [exclusion criterion #8].

Postmenopausal status definition has been clarified and aligned with the NCCN guidelines 
[National Comprehensive Cancer Network 2012- www.nccn.com]. Postmenopausal range 
for hormone levels is either serum FSH >40 mIU/mL and estradiol <20 pg/mL, or 
according to the respective postmenopausal range definition used by the laboratory 
involved [exclusion criterion #26].
Changes to the management of psychiatric disorders, hyperglycemia grade 2, skin rash and 
stomatitis:

To align with changes within the program based on clinical experience from ongoing 
BKM trials as reflected in the updated information in the current IB version 6.0 issued on
13-Nov-2013, and with additional feedback from earlier advisory boards, the following 
changes are implemented to simplify the evaluation of psychiatric disorders. Psychiatric 
disorders must be based on clinical assessment only, according to NCI-CTC 4.03; 
independently from patient self-reported mood questionnaires.

Patients with active severe personality disorders will now be excluded, and Section 
6.3.2 has been revised to clarify the dose modification and interruption for mood 
alterations. In addition, specific guidelines for the treatment of study drug induced 
psychiatric disorders has been added (Section 6.3.2.1.5).

Section 7.2.2.8 is revised to clarify that the grading of psychiatric disorders must be 
based on clinical assessment only, according to NCI-CTC 4.03, independently from 
patient self-reported mood questionnaires.

Section 7.2.2.8 is revised to clarify that patients who answer positively to question 9 
of PHQ-9 (suicidal risk) must omit treatment with BKM120 and must be referred for 
psychiatric consultation to mitigate potential suicide risk. Psychiatric consultation will 
confirm if study drug should be interrupted or permanently discontinued. Moreover, 
psychiatric consultation is further required for patients who develop CTC AE grade 3 
or 4 psychiatric disorders

Hyperglycemia is a common side effect of BKM120 treatment. However, there is no 
immediate or subacute safety risk for patients experiencing grade 2 hyperglycemia. 
Therefore, the management guideline for grade 2 hyperglycemia has been amended and 
closer aligned with the recently published NCI task force guidelines on hyperglycemia and 
metabolic disorders associated with mTOR/PI3K inhibitors (Busaidy et al 2012). This will 
better allow installing appropriate anti-glycemic therapy. No changes are made for 
symptomatic, or grade 3 or 4 hyperglycemia, which are still managed conservatively.

Novartis
Confidential
Page 17
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

Skin rash is a common side effect associated with BKM120 treatment which can be severe 
and potentially lead to treatment interruption or discontinuation. Thus, more conservative 
dose interruption/modification guidelines are instituted for grade 2 and 3 skin rash.

Stomatitis is occurring in up to 25% of patients receiving BKM120 monotherapy 
[Investigator Brochure version 6]. Guidelines are added to support investigators in the 
management of this adverse event.
Update to prohibited concomitant medications:

Wording added in the prohibited concomitant therapy section to clarify the wash-out 
period for prohibited concomitant therapies (e.g. prohibited concomitant therapy should be 
stopped at least 5 half-lives or 7 days before start of study treatment (Cycle 1 Day 1).
As of December 11, 2013, 52 patients have been enrolled in the study CBKM120Z2402.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Protocol Summary Exclusion criteria: mTOR inhibitors was removed from the first exclusion 
criterion listed. This should have been removed in Amendment 1 when the change was made.
Protocol Summary Efficacy Assessments: “Objective response rate” updated to “Overall
response rate”. Overall response rate is the proportion of patients with best overall response of 
CR or PR. This is also referred to as “Objective response rate”. All instances of “objective 
response rate” have been updated to “overall response rate” for consistency.
Protocol Summary Data analysis: updated to clarify that maximum number of patients per 
cohort will be capped at N = 28 patients, in case of over enrollment.
Table 3-1: Updated to include definitions of endpoints as per protocol.
Figure 4-1: Note added that maximum number of patients per cohort will be capped at N = 28 
patients, in case of over enrollment.
Section 5.2: Inclusion # 8 was updated to clarify that calcium levels should be corrected for 
albumin. The lower normal limit constraint for total bilirubin was removed and further 
clarification was provided regarding Gilbert Syndrome.
Section 5.2: Exclusion criteria #8: Addition to specify that patients with active severe 
personality disorders (defined according to DSM-IV) are not eligible.
Section 5.2: Exclusion criteria #20: Additional examples, including immunocompromised, 
chronic pulmonary disease including dyspnea at rest or interstitial lung disease, uncontrolled 
hypertension, have been added for clarification.
Section 5.2 Exclusion criteria #26: Clarification on the definition of postmenopausal status to 
align with NCCN guidelines.
Section 6.1.1.1: To limit the potential impact of H2 antagonists, in this study BKM120 will be 
administered at least one hour before or 10 hours after H2 antagonists (or proton pump 
inhibitor, antacid, etc.) administration.

Novartis
Confidential
Page 18
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Section 6.3.2: Clarifications provided related to additional exams in Table 6-3. Updated
number of days permitted for study treatment interruption.
Section 6.3.2.1: Criteria for BKM120 dose modification and Table 6-2 modification
Section 6.3.2.1: Table 6-3: Criteria for interruption and re-initiation of BKM120 treatment. 
Modification for FPG, Mood alteration, Fatigue, Rash and addition of criteria for 
Stomatitis/Oral mucositis.
Section 6.3.2.1.3: Guidelines for the treatment of study drug induced stomatitis/oral mucositis:
Addition of Section 6.3.2.1.5: Guidelines for the treatment of study drug induced psychiatric 
disorders.
Addition of Section 6.3.2.1.6: Minor changes in wording on guidelines for the treatment of 
study drug induced skin toxicity.
Section 6.4.2: Clarified that prohibited concomitant therapy should be stopped at least 5 half-
lives or 7 days before cycle 1 day 1 and must not be used while the patient is on study.
Section 
6.4.2.6, 
Table 
14-3
and 
Table 
14-4
updated 
to 
include 
website 
(http://crediblemeds.org/) for a comprehensive list of agents that prolong the QT interval
Section 7.1.5.1: Updated number of days permitted for study treatment interruption.
Section 7.2.1.2: Updated maximum number of days from tumor assessment to first dose of 
study drug to be consistent with Visit Schedule. Changed from 21 days to 28 days.
Section 7.2.2.5.7: Updated the definition of postmenopausal status to align with NCCN 
guidelines.
Section 7.2.2.8: Description of mood alteration questionnaires and their administration.
Management of mood alterations: Toxicity grading table was deleted to add the severity 
classification table instead. Specification that for patients who indicate a positive response by 
selecting “1, 2, or 3” to the question number 9 in the PHQ-9 questionnaire must stop treatment 
with BKM120 and must be referred for psychiatric consultation. Clarification of severity 
based on mood questionnaire score Table 7-5 updated.
Section 8.1.1: Updated Death form to EOT/SEC/Survival Information eCRF pages.
Section 8.4: Included guidelines for the collection of pregnancy outcomes for the female 
partners of any males who took study drug in this study.
Section 10: Updated to clarify that the maximum number of patients per cohort will capped at 
N = 28 patients, in case of over enrollment and removed pharmacokinetic measurements.

Novartis
Confidential
Page 19
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Section 10.5.2: Updated to clarify that duration of response is defined as the time from the 
date of first occurrence of CR or PR to the date of the first documented progressive disease 
(PD) or death due to lymphoma per Cheson criteria.
Section 10.5.3.4: Updated to include safety analysis of mood questionnaires.
Section 10.8: Updated to include the over enrollment scenario. In addition, a cap of N=28 
patients has been added for each cohort to account for over enrollment. Due to the rapid 
enrollment into the DLBCL cohort and despite early planning for cohort closure, the study 
team encountered too many additional patients already in screening who could not be declined 
enrollment due to ethical reason. Also similar situation might arise for MCL and FL cohorts. 
Hence, maximum number of patients per cohort will be capped at N = 28 patients, in case of 
over enrollment. The method of statistical analysis remains the same, knowing that the power 
and rejection rule may change with the final number of patients enrolled as described in Table 
10-1.
Table 14-1: Reference was mentioned twice. Typo was corrected.
Table 14-2: First asterisk in footer was removed since it did not correspond to anything within 
the table.
Section 14.5.1: Updated to clarify that Appendix 5 consists of general guidelines some of 
which have been modified for this protocol:

Only patients with measurable disease at baseline are being considered for this study

Randomization is not applicable to the study since it is a non-randomized trial. All 
responses will be calculated from start of treatment.

If a lesion splits during the study, the sub-lesions will not be measured separately. Instead, 
such lesions which have split into sub-lesions will be measured as one lesion with all sub-
lesions contributing to the overall SPD.

Central Blinded Review of radiological response will not be used for this study. 
Responses will be assessed by the Investigator.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.
Amendment 1
Amendment rationale
The primary purpose for amending the protocol is to include monitoring for evidence of tumor 
lysis syndrome during treatment with BKM120. Tumor lysis syndrome (TLS) may occur 
during treatment for diffuse large B-cell lymphoma; therefore the protocol and visit schedule 

Novartis
Confidential
Page 20
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
are being amended to include appropriate monitoring for evidence of TLS during the first 72 
hours of study treatment.
In addition, the requirement for not allowing previous treatment with mTOR inhibitors has 
been removed from the exclusion criteria. Temsirolimus, an mTOR inhibitor, is approved in 
some countries for mantle cell NHL. Since BKM targets PI3K and not mTOR, there is no 
reason to exclude these patients. Removing this exclusion would also broaden eligibility for 
this population that has significant unmet medical need and potentially no anticipated impact 
on study results.
This amendment also includes a correction to the exclusion criterion regarding types of 
effective contraception which can be used throughout the study. Hormonal contraceptives 
may be affected by cytochrome P450 interactions, and are therefore not considered effective 
for this study, since induction of CYP3A4 may not be excluded in patients receiving BKM120. 
Hormonal contraception must not be used during BKM treatment and has been removed from 
the list of acceptable contraceptives.
Several other exclusion criteria have been modified to provide further information or 
clarification. One additional exclusion criterion has been added to exclude patients who are
currently receiving warfarin or other coumarin derived anti-coagulant for prophylaxis.
In addition, this amendment includes other administrative corrections and clarifications.
The study has not yet opened and is not currently enrolling patients.
Changes to the protocol
Section 4.1: End of treatment visit will occur within 7 days following discontinuation of 
BKM120.
Section 5.2: The upper limit of normal (ULN) associated with International Normalized Ratio 
(INR) has been removed from inclusion criterion #8 as no ULN is specified for INR.
Section 5.3

Previous treatment with mTOR inhibitors has been removed from exclusion criterion #1. 
Patients who have had previous treatment with mTOR inhibitors may be enrolled.

Exclusion criterion #19 has been clarified to exclude patients receiving increasing or 
chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent, as 
chronic administration of corticosteroids (> 5 days) can induce CYP3A4.

Exclusion criterion #21 has been updated to exclude patients unable to grant consent.

Novartis
Confidential
Page 21
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

Exclusion criterion #22 has been updated to include clarification as to when strong 
CYP3A4 inducers and inhibitors must be discontinued prior to start of treatment has.
Patients must have discontinued strong inducers for at least one week and must have 
discontinued strong inhibitors before the start of treatment

An additional exclusion criterion (#23) has been added to exclude patients who are
currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, 
prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), 
or fondaparinux is allowed.

The use of hormonal contraception has been removed from the list of acceptable forms of 
effective contraception provided in exclusion criterion #26. Hormonal contraception must 
not be used during BKM treatment as stated in Section 6.4.2.9. The criterion has also been 
updated to clarify that female partners of male study subjects should use contraception 
through 16 weeks after final dose of male subject.

Exclusion criterion #27 has been clarified to exclude patients with a known 
hypersensitivity to any of the excipients of BKM120.
Section 6.4: Paclitaxel has been removed as the study involves only one treatment (BKM120).
Section 6.4.1.5 (Bisphosphonates) has been removed since these are not part of the standard 
management of NHL patients.
Section 6.4.1.7: Allopurinol or rasburicase have been added as permitted concomitant therapy. 
Allopurinol and rasburicase may be used at the physician’s discretion in DLBCL patients at 
risk for tumor lysis syndrome.
Section 6.5.1 has been updated to include additional information about re-screening patients.
Re-screening is permitted for patients as long as all screening procedures are performed 
within the specific time window. Any re-screened patient must retain the same Subject No.
Re-screening of patients is only allowed once per patient.
Section 7.1: Safety follow-up visit window has been updated to +7 days.
Section 7.1.5: The window for the end of treatment visit has been updated. The end of 
treatment visit and evaluations must occur within 7 days from treatment discontinuation.
Table 7-1 and Section 7.2.2.5.2: The visit evaluation schedule (Table 7-1) and section have
been revised to include assessments for TLS during the initial 72 hours of study treatment in
patients with diffuse large B-cell lymphoma. Blood tests for uric acid, potassium, sodium, 
calcium, inorganic phosphorus and serum creatinine will be assessed on days 2, 3 and 4 of the 
first cycle in DLBCL patients only.
Section 7.2.2.5.2 has also been updated to include further details regarding the frequency of 
laboratory evaluations.
Section 7.2.2.5.7 has been updated to clarify that only serum pregnancy testing will be 
performed throughout the study. Urine pregnancy testing is not permitted.
Section 7.2.2.8 has been made consistent with the visit evaluation schedule. The mood 
questionnaires (PHQ-9 and GAD-7) must be completed at all study visits. This section has 
also been updated with additional details and clarifications regarding the questionnaires.

Novartis
Confidential
Page 22
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Section 8.7 has been updated to include a Steering Committee.
Section 14.5 Appendix 5 has been updated to remove comments and notes.
Additional minor editorial corrections have been made throughout the protocol.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.

Novartis
Confidential
Page 23
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Protocol summary:
Protocol number
CBKM120Z2402
Title
An open-label phase II study of BKM120 in patients with relapsed and refractory 
diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma
Brief title
Study of BKM120 in relapsed and refractory NHL
Sponsor and
Clinical Phase
Novartis
Phase II
Investigation type
Drug
Study type
Interventional
Purpose and rationale
The purpose of this study is to explore therapeutic efficacy of BKM120 in three 
selected types of NHL, including DLBCL, MCL and FL, and the safety/tolerability of 
patients.
Inhibitors of the PI3K/mTOR/Akt pathway, including BKM120, may be 
therapeutically effective in NHL patients based on the observations from both pre-
clinical and early phase clinical trials with either selective or non-selective inhibitors 
of the PI3K/mTOR/Akt pathway. As pan class I PI3K inhibitors demonstrate 
evidence of efficacy in solid tumor patients and since there are several p110 
isoforms detected in B cell NHLs, this presents an intriguing opportunity for further 
evaluation of BKM120.
Primary Objective(s) and 
Key Secondary Objective
To determine the efficacy of BKM120 in patients with relapsed/refractory Non-
Hodgkin Lymphoma in the three different histological subgroups
Secondary Objectives
To evaluate the safety and tolerability in the three different histological subgroups
To assess progression free survival in the three different histological subgroups
To assess the duration of response in the three different histological subgroups
To assess overall survival in the three different histological subgroups
Study design
This is an open label phase II study in patients with relapsed and refractory Non-
Hodgkin Lymphoma including 3 histological subgroups (cohorts): diffuse large B-
cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma 
(FL). The primary efficacy and safety analysis for each cohort will be performed 
when all patients included in the corresponding cohort experienced progression, 
discontinued early or 6 months after the last patient has started the first cycle of 
treatment. An update of the analyses will be conducted after all enrolled patients 
have completed the study.
Population
Patients with histologically confirmed relapsed or refractory diffuse large B cell 
lymphoma, mantle cell lymphoma and follicular lymphoma.

Novartis
Confidential
Page 24
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Inclusion criteria
1. Patient has a histologically confirmed diagnosis of mantle cell lymphoma, 
follicular lymphoma, or diffuse large B cell lymphoma.
2. Patient has relapsed or refractory disease and received at least one prior 
therapy
3. Patient with diffuse large B cell lymphoma has received or is ineligible for 
autologous or allogeneic stem cell transplant. This does not apply to patients with 
mantle cell lymphoma and follicular lymphoma.
4. Patient has at least one measurable nodal lesion (≥2 cm) according to Cheson 
criteria (Cheson et al 2007). In case where the patient has no measurable nodal 
lesions ≥ 2 cm in the long axis at baseline, then the patient must have at least one 
measurable extra-nodal lesion.
5. Patient has an Eastern Cooperative Oncology Group (ECOG) performance 
status ≤ 2
6. Patient has adequate bone marrow and organ function
Exclusion criteria
1. Patient has received previous treatment with PI3K inhibitors
2. Patient has evidence of graft versus host disease (GVHD)
3. Patient has active or history of central nervous system (CNS) disease
4. Patient has a concurrent malignancy or has a malignancy within 3 years of 
study enrollment (with the exception of adequately treated basal or squamous cell 
carcinoma or non-melanomatous skin cancer)
5. Patient has a score ≥ 12 on the PHQ-9 questionnaire.
6. Patient has a GAD-7 mood scale score ≥ 15.
7. Patients with an acute viral hepatitis or a history of chronic or active HBV or 
HCV infection
Investigational and 
reference therapy
BKM120
Efficacy assessments
- Overall Response rate (ORR)
- Progression Free Survival (PFS)
- Duration of Response
- Overall Survival (OS)
Safety assessments
- Frequency and severity of adverse events; other safety data as considered 
appropriate
Other assessments
Data analysis
The primary endpoint of the study is Overall Response Rate (ORR) defined the 
proportion of patients with a best overall response of CR or PR according to 
Cheson criteria (Cheson et al 2007). The analysis for each cohort will be based on 
an exact binomial test comparing the ORR to the reference level of 10%. The test 
for each cohort will use a significance level of 5%. A significant test result is 
achieved when at least 6 responses are observed among the 22 patients in each 
cohort. Maximum number of patients per cohort will be capped at N = 28 patients, 
in case of over enrollment. The ORR will be presented together with an exact 95% 
Clopper-Pearson confidence interval.
Key words
PI3K inhibitor, BKM120, Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, 
mantle cell lymphoma, follicular lymphoma

Novartis
Confidential
Page 25
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
1
Background
1.1
Overview of disease pathogenesis, epidemiology and current 
treatment
The Non-Hodgkin lymphomas (NHL) are a heterogeneous group of lymphoproliferative 
malignancies with differing patterns of behavior and responses to treatment (Armitage 1993). 
Like Hodgkin lymphoma, NHL usually originates in lymphoid tissues and can spread to other 
organs. NHL, however, is much less predictable than Hodgkin lymphoma and has a far 
greater predilection to disseminate to extranodal sites.
NHL represents 4% of all types of cancer. The risk of NHL during a person’s life time is one 
in 50 people (about 2%). Men have slightly higher chances than women to have NHL 
(American Cancer Society 2012). There are estimated 70,130 new cases of NHL and about 
18,940 deaths in the United States in 2012 (National Cancer Institute 2012). NHL can occur at 
any age and is often marked by lymph nodes that are larger than normal, fever, and weight 
loss. NHL is now the 5th leading cause of cancer in both men and women. NHL is a disease 
of aging; for unclear reasons, the incidence of NHL continues to increase. With the increasing 
age of the population, NHL is an important cause of morbidity and mortality in adults.
NHL can be divided into aggressive (fast-growing) and indolent (slow-growing) types, and 
can arise from either B-cells or T-cells. B-cell NHL represents 85% of all NHL, and include 
Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 
diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), immunoblastic large cell 
lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma (MCL).
Though considered a curable disease, about 50% of NHL patients are not cured with available 
therapy, and this remains an important cause of morbidity and mortality in adults. Novel 
therapies with unique mechanisms of action unaffected by common drug resistance 
mechanisms must be developed to improve treatment outcomes. The current 5-year and 10-
year survival rates for lymphoma are 63-67% and 51-55%, respectively (American Cancer 
Society 2012).
The diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma are 
among of those most commonly seen NHLs, and are the malignancies targeted in this study.
1.1.1
Overview of diffuse large B cell lymphoma
DLBCL comprises more than 30% of all newly diagnosed NHL cases. Majority (over 80%) 
are aggressive lymphomas, and more than half of these patients are older than 60 years. The 
outcome for patients with DLBCL has significantly improved over the last decade and around 
50% of DLBCL patients can be cured with rituximab and chemotherapy. The other 50% of 
DLBCL patients, especially the poor risk patients (International Prognostic Index of 3, 4 or 5 
factors), will relapse or progress despite a good initial response to the front line immuno-
chemotherapy. High-dose chemotherapy with autologous stem-cell transplantation (ASCT) is 
an established treatment option for poor-prognosis patients who are 65 or younger and 
refractory to front line therapy. Nevertheless, more than half of these patients will relapse 

Novartis
Confidential
Page 26
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
following ASCT/high dose chemotherapy and die of the disease. The prognosis among 
patients who are not transplant candidates is even more dismal.
Novel drug therapy with different mechanisms to prolong duration of disease remission in 
poor risk patients and eventually to improve long term survival among these patients is a 
pressing need.
Single agent everolimus (AFINITOR®, RAD001), an inhibitor of the mammalian target of 
rapamycin (mTOR) has demonstrated substantial anti-tumor activity in relapsed aggressive 
NHL and other types of relapsed or refractory lymphomas, including MCL, indolent and other 
uncommon lymphomas.
1.1.2
Overview of mantle cell lymphoma
MCL has been classified as a subgroup of aggressive diffuse low grade B cell lymphomas. 
MCL is a unique subtype of NHL characteristic with the t(11;14) (q13;q32) balanced 
chromosomal translocation of the cyclin D1 gene (bcl-1) on chromosome 11 to the 
immunoglobulin heavy chain (IGH) enhancer region on chromosome 14, which results in 
Cyclin D1 over expression and increased cell proliferation of the tumor cells (Witzig et al 
2005). With a prevalence of 5% to 6% of all NHL, MCL accounts for up to 8000 newly 
diagnosed NHL cases in US and EU each year.
With the exception of rare patients who enjoy long term disease-free survival after non-
myeloablative allogeneic stem cell transplantation, patients with MCL have the worst 
prognosis of all NHL subtypes. Most MCL patients are treated with rituximab 
(Rituxan®/Mabthera®), directed against CD20 (a B lymphocyte specific antigen), in 
combination with different chemotherapy regimens. The initial treatment usually yields a high 
response rate, however, most patients relapse following initial therapy and their median 
survival is about 1-2 years (Fisher et al 2006). As there is no standard therapy for newly 
diagnosed or relapsed patients with MCL and the treatment remains suboptimal, new agents 
are beginning to emerge.
Bortezomib (Velcade®) is an intravenous proteasome inhibitor that was approved in the US in 
2006 for treatment of MCL in patients with a history of one prior treatment. The response rate 
to Velcade® therapy was 33%, including 8% complete responses. The median time to 
progression (TTP) was 6.2 months. With an average follow-up of 13.4 months, the median 
overall survival (OS) was not reached (Fisher et al 2006). Velcade® has not been approved for 
treatment of MCL in the EU, however it is approved by the European health authorities for 
treatment of patients with multiple myeloma.
Data on the efficacy and safety of temsirolimus (Torisel®, CCI-779), an intravenous mTOR 
inhibitor, as a single agent in patients with relapsed or refractory MCL have been published 
by (Witzig et al 2005). Thirty-five patients were treated in this study with temsirolimus 250 
mg intravenously every week as a single agent. Patients had previously received a median of 3 
prior therapies and 54% had been refractory to the last therapy. The overall response rate was 
38% (95% CI: 22% to 56%), with one complete response and 12 partial responses. Median 
time to progression was 6.5 months (95% CI: 2.9 to 8.3 months). The authors concluded that 
single-agent temsirolimus has substantial antitumor activity in relapsed MCL. A similar 

Novartis
Confidential
Page 27
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
response rate of 29% (4 out of 14) has been observed in a phase II trial of 10 mg daily 
everolimus in patients with MCL (Reeder & Gornet ASH 2007). In a multicenter phase II trial 
of single-agent everolimus in patients with relapsed or refractory mantle cell lymphoma, 
complete response (CR) was achieved in two patients and partial response (PR) in five 
patients, resulting in an objective response of 20% (95% CI 8-37%) and an additional 17 
patients (49%) achieved disease stabilization (SD) (Renner et al 2012). A large international 
trial (PILLAR-1) with everolimus in relapsed/refractory MCL has completed enrollment and 
data are awaited.
1.1.3
Overview of follicular lymphoma
FL is the second most common form of NHL prevailing in the United States. Despite an 
advanced stage, the clinical course of disease is usually indolent and patients are highly 
responsive to various combinations of standard chemotherapy drugs. The disease, however, is 
not curable with available treatment, and most patients tend to relapse after treatment with 
shorter intervals of remission in between. In approximately 30% of patients, the disease 
progresses more rapidly with transformation into DLBCL and early death. The molecular 
biology underlying this phenomenon and the factors associated with the risk of transformation 
are not entirely known.
The incorporation of effective and well-tolerated monoclonal antibodies, such as rituximab, 
into chemo-immunotherapeutic strategies provided the first evidence that survival of these 
patients could be prolonged. A relatively small pivotal phase II study in 166 patients with 
relapsed FL resulted in rituximab being the first FDA approved monoclonal antibody for the 
treatment of cancer. The combination of rituximab and chemotherapy (R-Chemo) has resulted 
in greatly improved response rates, progression free survival and also overall survival, to such 
an extent that R-Chemo is now worldwide the standard induction treatment in first line as well 
as for relapsed advanced stage FL.
Nevertheless, FL remains incurable and characterized by recurrent relapses requiring 
additional treatment. An increasing number of effective drugs are now being evaluated either 
alone or in combinations including the chemotherapy drugs bendamustine and bortezomib. 
More targeted agents include monoclonal antibodies and their derivatives such as drug-
antibody conjugates and small modular immunopharmaceuticals. Other agents inhibit various 
cellular pathways including those triggered by the B-cell receptor, including spleen tyrosine 
kinase (Syk) and Bruton’s tyrosine kinase, and other intracellular pathways such as the mTOR, 
Phosphatidylinositol-3-Kinase (PI3K), and apoptosis, and drugs that target the tumor 
microenvironment. This abundance stresses the unremitting need for clinical trials aimed at 
answering the many open questions as to optimal treatment strategies in advanced FL 
(Cheson 2011).
1.1.4
The PI3K pathway
The phosphatidylinositol-3-kinase (PI3K) signaling regulates diverse cellular functions, 
including cell proliferation, survival, translational regulation of protein synthesis, glucose 
metabolism, cell migration, and angiogenesis (Katso et al 2001). PI3K signaling also serves a 
central role in the pathogenesis of numerous forms of neoplasia. At the structural level, the 
enzyme PI3K is composed of a 110-kDa catalytic subunit and an 85-kDa adaptor subunit. The 

Novartis
Confidential
Page 28
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
PI3K signaling is modulated by multiple regulators, including growth factors (such as EGF, 
IGF-1, and FGF), hormones (such as estrogen and thyroid hormone), integrins, intracellular 
calcium levels, and RAS signaling. PI3K signaling is negatively regulated at the level of PIP3 
clearance by phospholipid phosphatases, such as the phosphatase and tensin homologue 
(PTEN) protein and the inositol 5-phosphatase-2 (SHIP2) protein.
Constitutive activation of PI3K signaling is known to be a critical step in mediating the 
transforming potential of oncogenes and tumor suppressors and in many tumor types (Liu et al 
2009). Resistance to a variety of therapeutic interventions, including chemotherapy, hormonal 
therapy and anti-HER2 therapies, can also be linked to constitutive activation of the PI3K 
pathway (McCubrey et al 2006). Moreover, preliminary data suggest that activation of the 
PI3K pathway may be a predictor of poor prognostic outcome in many cancers.
Molecular changes leading to constitutive activation of the PI3K pathway are diverse and 
include, but are not limited to,
a. Gain-of-function mutations of PI3K subunits (PIK3CA encoding the PI3K catalytic 
subunit p110α; genes encoding the p85 regulatory subunit) or oncogenes encoding 
positive regulators of PI3K (e.g., HER2, EGFR, RAS, Src-family proteins) or
b. Loss-of-function mutations or epigenetic alterations affecting negative regulators of PI3K 
signaling (e.g., loss of PTEN expression or function) (Chow & Baker 2006, Cully et al 
2006)
Together these observations suggest that PI3K pathway could be a critical therapeutic target 
for the treatment of patients with advanced solid malignancies who often have limited 
therapeutic options beyond institutional standard of care. Hence, the pan-PI3K inhibitor 
BKM120 treatment potentially addresses an unmet medical need in such patients
A schematic representation of these PI3K components is shown in Figure 1-1.

Novartis
Confidential
Page 29
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Figure 1-1
Schematic representation of the PI3K pathway
1.1.5
The PI3K/mTOR/Akt pathway and NHL
Pre-clinical and early-phase clinical studies support the rationale of inhibiting the PI3K 
pathway for NHL.
1.1.5.1
Observations from pre-clinical studies
The PI3K pathway is an intracellular component of the B-cell receptor signaling pathway that 
regulates the cell cycle and is implicated in the development of many malignancies, including 
lymphoma, leukemia, and many solid tumor malignancies. Unregulated activation of Akt has 
been demonstrated in MCL, both in cell lines and in patient samples. Also, PI3K inhibition 
decreased expression of NF-κB and CyclinD1, and induced apoptosis (Rudelius et al 2006). 
Additionally, overexpression of phosphorylated Akt by immunohistochemistry was observed 
in tissue samples from patients with MCL. There was decreased expression of downstream 
targets of Akt and increased apoptosis when these cells were exposed to a PI3K inhibitor (Dal 
Col et al 2008). Akt upregulation is also demonstrated in tissue samples of follicular 
lymphoma (FL) (Zha et al 2004), while expression of pAKT was observed in 52-72% primary 
DLBCL samples, indicating activation of the pathway in these histological subtypes of NHL. 
Reduction, or loss of PTEN expression was also reported in 76/215 (37%) primary DLBCL 
samples (Baohua et al 2008, Abubaker et al 2007, Uddin et al 2006).

Novartis
Confidential
Page 30
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Preclinical data suggests that targeting any of the PI3K/Akt/mTOR components can induce 
tumor cell death in a variety of lymphoid malignancies.BKM120, the investigational 
compound in this study, is a pan class I oral PI3K inhibitor, including the p110α, β, γ, and δ 
isoforms. It has demonstrated its activity in lymphoma cell lines, including mantle cell 
lymphoma, where it resulted in at least a 2-fold down-regulation of the myc-dependent 
proliferation, measured by gene expression (Walsh et al 2009).
The pan-PI3K inhibitor, SF1126 exhibited >90% decrease in pAkt and pGSK-3 beta. SF1126 
induced apoptosis in a dose and time dependent manner confirmed by flow cytometry. 
SF1126 induced G1 cell cycle to suppression of cell proliferation. The cell cycle protein 
cyclin D1, a hallmark of MCL was significantly decreased by SF1126 demonstrating that 
SF1126 potently inhibits the constitutively activated PI3K/mTORC/Akt pathway in 
aggressive B-cell NHL cell lines with consequent suppressive effects on cell cycle 
progression, cell proliferation and induction of apoptosis in aggressive B-cell NHL 
(Mahadvan et al 2011).
CAL-101, a selective inhibitor of the p110δ isoform of PI3K, has shown activity in vitro 
against B-cell malignancies. Treatment of cell lines from CLL and MCL also demonstrated 
significant reduction in Akt, indicative of inhibition of the pathway. In addition, in FL cell 
lines demonstrating increased pAkt at baseline, there was a concentration-dependent reduction 
in pAkt and the downstream target pS6 when treated with CAL-101 (Lannutti et al 2011). 
CAL-101 could disrupt signals from the microenvironment, induce apoptosis, and enhance the 
antitumor activity of everolimus in MCL. The pAkt decrease was associated with growth 
suppression and induction of apoptosis in all MCL cell lines. CAL-101 decreased cyclin D1 
levels in MCL cell lines (Meadows et al 2011).
While the p110δ isoform of PI3K is found in B cells, it could become a suitable target for a 
selective PI3K inhibitor (i.e. CAL-101). As additional isoforms such as p110α and p110β are 
also found in B cells, given their association with the B cell receptor signaling pathway, these 
isoforms would potentially be additional targets for B-cell lymphoma therapy. In fact, 
treatment of MCL cell lines with a selective inhibitor of p110α as well as with a non-selective 
PI3K inhibitor induced tumor cell growth inhibition, while a selective inhibitor of p110δ did 
not (Zhou et al 2010).
1.1.5.2
Observations from early phase clinical trials
CAL-101 was also tested in early phase clinical trials in patients with NHL. In a Phase I study, 
CAL-101 was evaluated for its safety and clinical activity in patients with select hematologic 
malignancies including relapsed/refractory CLL or select B-cell NHL. Approximately 12 
patients each with CLL, indolent NHL, aggressive NHL, and AML were to be enrolled. CAL-
101 was administered orally twice daily continuously for 28 days per cycle. Clinical response 
was evaluated at the end of Cycles I and 2 and every 2 cycles thereafter. To date, 43 patients 
have been enrolled and followed for at least 4 weeks, consisting of 17 patients with CLL 9 
patients with indolent NHL, 10 patients with aggressive NHL and 7 patients with AML. The 
demographic and disease characteristics were 33% female, mean age 65 (60% over age 65), 
49% had refractory disease and the median number of prior regimens was 5. The median
duration of treatment at data cutoff was 3 cycles (range 1 to 10). Two patients discontinued 
early due to adverse events, one for acute on chronic renal failure and one for abnormal liver 

Novartis
Confidential
Page 31
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
function tests (LFTs). DLTs were observed in 5 patients with increases in LFTs, which 
resolved following discontinuation of CAL-101 dosing. No patient had grade 4 hematological 
toxicity. Serious infections were reported in 9 patients, with pneumonia being the most 
frequent. 41 patients were evaluable for clinical response. At data cutoff, the response rate in 
NHL was 10/18 (56%); all were partial responses (PR). Of the 9 patients with indolent NHL, 
5 patients had PR and 2 patients had stable disease (SD) and remained oil study. Of the 9 
patients with aggressive NHL, 5 patients had PR (all with mantle cell lymphoma) and 1 
patient had SD on study. At data cutoff, the longest duration of response was 9 months in a 
patient with follicular lymphoma. Enrollment is continuing (Flinn et al 2009). Kahl and 
colleagues reported clinical safety and activity in a Phase 1 study of CAL-101 in patients with 
relapsed or refractory NHL. At data cutoff, the study had enrolled 55 patients with NHL; 28 
patients had indolent NHL: FL n=15, small lymphocytic lymphoma n=6, Waldenstrom's 
macroglobulinemia n=4, marginal zone lymphoma n=3, and 27 had aggressive NHL: MCL 
n=18, DLBCL n=9. Patient characteristics included 69% males (38 vs. 17 females); median 
age [range] of 68 [32-82] years, 44% with refractory disease and 56% with relapsed disease.
Symptomatic adverse events were infrequent, usually low-grade, and not clearly CAL-101-
related. Grade >= 3 hematological laboratory abnormalities included neutropenia n= 5 (9%); 
lymphopenia n=3 (5%), and thrombocytopenia n=3 (5%) with uncertain relationship to CAL-
101. Grade >= 3 ALT/AST elevations occurred in 18 (33%) patients with onset 2-8 weeks 
after CAL-101 initiation and resolution 2-4 weeks after CAL-101 interruption. Partial 
responses were observed at all dose levels, with respective overall n/N (response rates) in 
evaluable patients of 15/24 (63%) for indolent NHL, 10/16 (62%) for MCL and 0/9 (0%) for 
DLBCL. Respective response rates, by relapsed or refractory status were 9/13 (69%) and 6/11
(55%) for indolent NHL and 8/11 (73%) and 2/5 (40%) for MCL. 5 Patients have had 
response durations of >= 6 months with response durations ranging to >16 months. The 
median [range] duration of response was 3 months [1 month to 8 months] in MCL (Kahl et al 
2010).
SAR245409 (S09) was another potent orally administered inhibitor of pan class I PI3K 
isoforms (alpha, beta, gamma, and delta) and mTOR. In a Phase I dose expansion cohort 
study, patients with refractory or relapsed lymphomas were enrolled in a lymphoma-specific 
expansion cohort to receive SAR245409 orally. The duration of each cycle was 28 days. 
Tumor response was assessed every 8 weeks. Sixteen patients with NHL were enrolled: MCL 
n=6, FL n=5. DLBCL n=2, HD n=1, follicular transformed lymphoma n=1, and anaplastic T-
cell/null cell lymphoma n=1. There were 12 males/4 females with a median age of 69 years 
(range, 20-90). Among 15 patients, 10 (66.7%) had received 3 or more prior regimens. The 
most common related adverse events (> 10% of patients) were nausea (25%), diarrhea 
(12.5%), and elevated liver enzymes (ALT 18.8% and AST 18.8%). Drug-related grade >= 3 
ALT elevation occurred during the second cycle in 2 patients (12.5%) and resolved with drug 
discontinuation. This study is ongoing (Papadopoulos et al 2011).
Additionally, pan class I PI3K inhibitors have been evaluated in Phase I trials with several 
demonstrating an acceptable safety profile while stabilizing the disease, even in patients 
whose disease has been refractory to multiple lines of treatment (Bendell et al 2012, Von Hoff 
et al 2011, Chiorean et al 2009).

Novartis
Confidential
Page 32
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
mTOR, a kinase downstream of PI3K, has emerged as important therapeutic target for cancer 
treatment. The mTOR inhibitors, temsirolimus and everolimus, have been extensively tested 
as single agents and found to have activity in lymphoma. A phase-II study of temsirolimus 
(CCI-779) in patients with relapsed mantle cell lymphoma showed a 44% response rate and 
demonstrated clinical activity in a variety of NHL subtypes (Smith et al 2010). Similarly, a 
phase-II study with the oral mTOR inhibitor everolimus has demonstrated activity in NHL, 
reporting an overall response rate of 30% (range from 30 to 38% depending on NHL types), 
with a median duration of response 5.7 months (Witzig et al 2011).
1.2
Introduction to investigational treatment(s) and other study 
treatment(s)
1.2.1
Overview of BKM120
NVP-BKM120 (BKM120) is a potent and highly specific oral pan-class I PI3K inhibitor that 
is a 2,6-dimorpholino pyrimidine derivatives. This compound has been studied extensively in 
non-clinical models and is currently being evaluated in clinical trials.
1.2.1.1
Non-clinical experience
1.2.1.1.1 Pharmacodynamics
BKM120 inhibits wild-type PI3K(IC50: 35 nM), with at least 50-fold selectivity towards 
this target compared to other protein kinases as well as against somatic PI3Kactivating 
mutants (H1047R-, E542K-, and E545K-p110), the other three PI3K paralogs as well as the 
direct downstream effector AKT. BKM120 does not inhibit the related kinases, mTOR, or 
Vps34, nor does it inhibit other receptors and ion channels profiled (IC50 >10 M).
BKM120 demonstrates significant tumor growth inhibition in relevant tumor xenografts in 
mice and rats when administered orally, including models of renal cell cancer (RENCA, 786-
0, Caki-1), glioblastoma multiforme (U87MG), prostate cancer (PC3M), lung cancer (A549, 
NCI-H1975), ovarian cancer (A2780), colorectal cancer (HCT116, HCT-15) and melanoma 
(A2058, A375). In vivo PK/PD analyses of tumor tissues shows a good correlation between 
exposure, PI3K pathway blockade (S473P-Akt levels), and anti-tumor activity.
1.2.1.1.2 Nonclinical pharmacokinetics and metabolism
BKM120 showed favorable pharmacokinetic properties in all animal species tested. The 
absorption of [14C]-BKM120-related radioactivity was >84% in the rat. Oral bioavailability 
was high in rats (73%), was complete in dogs, and was moderate in monkeys (42%). The 
estimated steady state plasma volume of distribution (Vss) was high (3.0-3.5 L/kg) in all 
species tested, suggesting a wide tissue distribution. BKM120 was found to cross the blood 
brain barrier in rats with a tissue-to-plasma ratio of approximately 2 (Novartis internal data). 
BKM120 is moderately bound to plasma protein in all species examined (about 80%).
In vitro metabolism studies using human liver microsomes showed that oxidative phase I 
metabolism of BKM120 was predominantly mediated by CYP3A4 (estimated fm > 0.9). 
Formation of a BKM120 N-glucuronide conjugate (Phase II metabolism) via the UDP-
glucuronosyltransferase-1 family, polypeptide A4 (UGT1A4) was also observed in human 

Novartis
Confidential
Page 33
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
liver microsomes supplemented with uridine 5'-diphospho-glucuronic acid (UDPGA). 
BKM120 and metabolites have a low potential for covalent binding to protein.
BKM120 was determined to be a weak reversible inhibitor of CYP3A4 (IC50 = 8 µM, Ki = 
13.4 µM unbound) at concentrations reached in the clinic. BKM120 very weakly inhibited the 
CYP2C family (2C8, 2C9 and 2C19) with IC50 values ranging from 35-65 μM (34-59 μM 
unbound). BKM120 did not show time-dependent inhibition of CYP450 enzymes. In GLP 
toxicology studies, BKM120 exposure in terms of AUC0-24h and Cmax increased in a dose 
proportional manner in rat and dog. Results from the rat ADME study showed that 
radioactivity was mainly excreted into the feces. Renal excretion was minor. There was no 
noticeable drug accumulation in dog or male rats after 13 weeks of daily dosing. There was a 
slight accumulation in female rat (< 2 fold).
Further information concerning the pharmacokinetic and pharmacodynamics properties of 
BKM120 may be found in the [Investigator’s Brochure].
1.2.1.1.3 Safety pharmacology and toxicology
Safety pharmacology studies in rats revealed no effects on neuronal (behavior) or respiratory 
functions. Cardiac safety studies, conducted in vitro and in vivo did not indicate a prominent 
electrophysiological risk. No relevant electrophysiological effect was seen in dogs. The only 
effect considered relevant was a trend towards an increase in systolic and diastolic blood 
pressure, which was observed in two dog telemetry studies. In rats and dogs, clinical 
pathology and histopathology findings showed quantitative reductions of lymphoid and 
erythroid counts and lymphoid tissue hypoplasia.
The pancreas was seen to be affected by treatment with BKM120, particularly in dogs, where 
acinar cell toxicity was seen in the exocrine part of this organ. At higher doses in the 2-week 
dose-range-finding study in rats, there were histopathological findings in both the endocrine 
as well as the exocrine pancreas.
Male sexual organs and associated tissues were found to be targets of toxicity in both rats and 
dogs. Changes included minimal to slight germ cell depletion, formation of spermatic giant 
cells and abnormal spermatids, and cellular debris in epididymal tubules. Testicular toxicity 
did not fully reverse after the 4-week treatment-free period in rats (highest dose), although a 
clear trend towards recovery was seen. In individual female rats, minimal to slight cyst 
formation occurred in the Graafian follicles. In dogs, there was no effect on female sexual 
organs.
Glucose homeostasis was affected in various species (mice, rats, dogs), as expected from the 
mode of action of BKM120. However, these effects were minimal in both rats and dogs at the 
doses used in the 4-week studies.
Other safety considerations include:

After up to 2 weeks of treatment with up to 2.5 mg/kg/day of BKM120, alterations in the 
levels of multiple brain neurotransmitters were seen in rats.

No evidence for a direct DNA interaction was found in an Ames test and two chromosome 
aberration tests in vitro with BKM120. However, evidence of a genotoxic potential with 
BKM120 has been seen in vitro and in vivo and is likely due to an aneugenic effect.

Novartis
Confidential
Page 34
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

No phototoxic potential or any effect on wound healing has been identified with BKM120 
in pre-clinical studies.
In conclusion, the majority of the observed effects were related to the pharmacological 
activity of BKM120 as an inhibitor of PI3K, such as a potential influence on glucose 
homeostasis and the risk of increased blood pressure.
Please refer to the [Investigator’s Brochure] for additional information on the preclinical 
testing of BKM120.
1.2.1.2
Clinical experience
As of September 2011, a total of 251 patients were enrolled into eight Novartis sponsored 
clinical studies of BKM120 for oncology indications other than NHL:

Phase I single agent studies [CBKM120X2101] (First in man dose escalation in solid 
tumors) and [CBKM120X1101] (Japanese dose escalation in solid tumors)

Phase II single agent studies [CBKM120C2201] (endometrial cancer) and 
[CBKM120D2201] (non-small cell lung cancer)

Phase I combination studies [CBKM120B2101] (BKM120 plus GSK1120212), 
[CBKM120X2107] (BKM120 plus trastuzumab), [CBEZ235A2118] (BKM120 plus 
paclitaxel), and [CMEK162X2101] (BKM120 plus MEK162).
1.2.1.2.1 Human safety and tolerability data
Study recruitment in study [CBKM120X2101] has been completed with forty (40) patients 
included in the dose escalation phase at 6 dose levels (all once daily) (12.5 mg (1 patient); 25 
mg (2), 50 mg (5), 80 mg (11), 100 mg (17), 150 mg (4)) (Bendell et al 2012). Dose limiting 
toxicities were hyperglycemia, skin rash, epigastric pain, mood disorder, joint pain. The MTD 
for BKM120 given as single agent, once daily was established at 100 mg/day. Forty-three 
additional patients were treated in the expansion cohort at 100 mg/day. At the cut-off date of 
4-Jul-2011 patient characteristics of 82 patients analyzed were as follows: median age 55 
years (range 30–78); ECOG performance status 0/1/2 for 35/46/1 patients, respectively. The 
safety experience for this single agent trial of BKM120 is described in Table 1-1.

Novartis
Confidential
Page 35
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table 1-1
Most frequent AEs (at least 15%) related to study drug in study 
CBKM120X2101 (n=81):
Event
All grades
Grade 3/4
Fatigue/asthenia
31(38.3%)
3 (3.7%)
Decreased appetite
24 (29.6%)
-
Diarrhea
24 (29.6%)
3 (3.7%)
Hyperglycemia
24 (29.6%)
4 (4.9%)
Nausea
24 (29.6%)
-
Rash
22 (27.2%)
4 (4.9%)
Mood altered/emotional disorder/affective disorder
17 (21.0%)
4 (4.9%)
Transaminases increased
16 (19.8%)
9 (11.1%)
Anxiety
14 (17.3%)
1 (1.2%)
Depression
14 (17.3%)
1 (1.2%)
A second single agent trial, [CBKM120X1101] was a phase I dose escalation study in 
Japanese patients with advanced solid tumors with dose levels ranging from 25 to 100 mg/day 
(Doi et al 2011). Enrolment of 15 patients has been completed, including 9 patients at 100 
mg/day. One DLT (G4 hepatic function abnormal) was observed in the 100 mg/day group. 
The most common G3 or G4 adverse events occurring in at least 2 patients were hepatic 
function abnormal in 6 patients including transaminase increase in 2 patients, G3 anemia in 2 
patients, hypokalemia in 2 patients. The recommended phase 2 dose (RP2D) for Japanese has 
been determined at 100 mg/day, as in the western population.
BKM120 in combination with trastuzumab is currently investigated in a phase Ib/II 
[CBKM120X2107] study in patients with HER2-positive MBC who acquired trastuzumab 
resistance. The phase Ib part of the study has been presented (Saura et al 2011). In this study 
trastuzumab is given at fixed dose of 2 mg/kg/week (with a 4 mg/kg/week loading dose). In 
the dose escalation phase, 17 patients with MBC have been enrolled at the cut-off date of 
September 30th, 2011: 5 patients at 50 mg/day and 12 patients at 100 mg/day. The 
recommended phase 2 dose for BKM120 was declared at 100 mg/day. The median age was 47 
years (range 28 -70). Most of the patients have been heavily treated (range of prior 
chemotherapy lines 1-8). With the completion of escalation phase, BKM120 in combination 
with trastuzumab has shown an acceptable safety profile. Grade 3 adverse events reported 
with a suspected relationship to BKM120 were asthenia, ALT increase, hypersensitivity 
hyperglycemia, mood altered, affective disorder, photosensitivity reaction and rash in 1-2 
patients each. No drug related G4 toxicity has been observed so far. The trial is currently 
recruiting the phase II part.
Details on liver toxicity, mood alterations, pneumonitis and hyperglycemia as side effects of 
BKM120 are presented below.
Please refer to [BKM120 Investigator’s Brochure] for more detailed information on specifics 
of clinical safety and tolerability of BKM120.

Novartis
Confidential
Page 36
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Liver Toxicity
Approximately 25 to 45% of patients treated with single agent BKM120 reported liver 
toxicity (all grades, regardless of study drug relationship, 100 mg/d dose) based on a search of 
multiple MedDRA event terms (e.g. SMQ preferred terms). The incidence of grade 3 and 4 
events was approximately 10 to 30%. Liver function test (LFT) alterations observed during 
ongoing and completed studies have been mostly transaminase enzyme increases (ALT and/or 
AST). Data suggest a slightly higher rate of grade 3 and 4 liver enzyme elevations in Japanese 
patients (44%) in the [CBKM120X1101] study, however, the number of patients treated at 
100 mg in this study was limited (n=9). Transaminase elevations typically occur during the 
first 6 to 8 weeks of treatment start.
Although transaminase increases are relatively common, only a few of the patients had other 
simultaneous observations related to impaired liver function (e.g. bilirubin increase or clinical 
symptoms).
Based on these findings, conservative inclusion criteria and guidelines to monitor and follow 
patients with LFT alterations (including dose and schedule modifications) have been 
implemented. Please refer to the respective inclusion/exclusion criteria and Section 5 in this 
protocol for more detailed guidelines.
A recent liver safety review across Novartis-sponsored trials with BKM120 identified several 
potentially drug-induced liver toxicity (DILI) cases (e.g. AST/ALT >3.0 x ULN and 
TBL >2.0 x ULN at any time during the treatment, regardless of causality. Upon medical 
review, most of these cases occurred in the context of disease progression in terminally ill, 
advanced cancer patients and/or were confounded by other causes. However, six of these DILI 
candidates were consistent with Hy’s law criteria (e.g. AST/ALT >3.0x ULN and 
TBL >2.0xULN in the absence of cholestasis and other explanatory causes) with probable 
causal relationship to study treatment. Five of these cases were enrolled in study 
[CBKM120F2302] in combination with fulvestrant, and one in combination with the 
investigational drug LDE225 (sonidegib). All patients have recovered upon treatment 
discontinuation except one patient for whom no data is available since the patient refused to 
return for safety follow-up.
Mood alteration
Recently, a number of publications demonstrated that the modulation of AKT/GSK3 signaling 
pathway by neurotransmitters is important for the regulation of behavior (Beaulieu et al 2009). 
Preclinical studies conducted in rats to investigate the effect of BKM120 on different 
neurotransmitters have shown that repeated administration of BKM120 resulted in an 
enhanced decrease in glutamate, dopamine, serotonin and epinephrine as well as in an 
enhanced increase in GABA and HIAA.
Reversible mild to moderate mood disorders observed at 100 mg/day, regardless of study drug 
relationship, in ongoing BKM120 studies are summarized in Table 1-2.

Novartis
Confidential
Page 37
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table 1-2
Numbers of patients with mood disorders occurred at 100 mg/day in 
ongoing BKM120 studies
Study Number
(N= patient treated with 100 mg/d BKM120)
All grades
Grade3/4
CBKM120X2101 (N = 55)
11 (20%)
2 (3%)
CBKM120X1101 (N = 9)
4 ( 44%)
0 (0%)
CBKM120C2201 (N = 50)
6 (12%)
0 (0%)
CBKM120X2107 (N = 12)
7 (58%)
2 (16.7%)
CBEZ235A2118 (N = 6, BKM120 treated only)
0 ( 0 %)
0 ( 0%)
These adverse events are currently under investigation. Nevertheless, until a more complete 
understanding of this AE is compiled and in order to lower the risk, protocol guidelines 
disqualify patients with an active and/or history of major psychiatric disorder. In addition, 
throughout the trial patients must be closely monitored using self-rating questionnaires (i.e. 
PHQ-9 and GAD-7), when required a psychiatrist should be consulted and the use of standard 
available medication should be considered as per investigator’s discretion. Detailed 
instructions are provided in Section 7.
Across the ongoing studies of BKM120, 4 patients experienced other psychiatric toxicities 
related to BKM120: confusional state in 3 patients (grade 3 in 1 patient) and mental status 
change in 1 patient (grade 3). With regards to the confusional state, in one case it has been 
considered as a symptom related to mood disorders, cholangitis and brain metastases, and in 
the remaining two cases, the confusional state occurred in a context of infection and 
gastrointestinal disorders. In two out of the three cases, the event improved/resolved after 
study drug interruption. Further information is being collected for the latest reported case.
Lung Toxicity/Pneumonitis
Lung changes compatible with pneumonitis have not been observed in the preclinical setting. 
Among the current studies, lung toxicity has been observed in 2 patients and reported as 
pneumonitis, including a fatal outcome reported in one patient in a complex clinical context, 
combining progression of lung lesions and aspergillosis infection. The currently available data 
do not enable a clear assessment about the causal relationship of pneumonitis with BKM120 
treatment. Newly appearing or significant changes in pulmonary symptoms (which cannot be 
explained by the underlying disease), should be carefully followed with appropriate 
management as per institutional guidelines and the guidelines provided in the protocol.
Hyperglycemia events
The PI3K/Akt pathway plays a significant role in regulating glucose metabolism, particularly 
by regulating glucose transport into adipocytes and muscle tissue. Therefore, hyperglycemia 
is considered as an “on target” effect of BKM120. Regular monitoring of insulin C-peptide is 
implemented in BKM120 protocols to evaluate this pharmacodynamics effect. Transient 
increases of plasma glucose levels have been reported commonly in patients treated with 
BKM120. Hyperglycemia observed at 100 mg/day, regardless of study drug relationship, in 
ongoing BKM120 studies are summarized in Table 1-3.

Novartis
Confidential
Page 38
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table 1-3
Number of patients with hyperglycemia occurred at 100 mg/day in 
ongoing BKM studies
Study Number
(N= patient treated with 100 mg/d BKM120)
All grades
Grade3/4
CBKM120X2101 (N = 55)
17 (30.9%)
2 (3.6%)
CBKM120X1101 (N = 9)
2 (22.2%)
1 (11.1%)
CBKM120C2201 (N = 50)
31 (62.0%)
12 (24.0%)
CBKM120X2107 (N = 12)
4 (33.3%)
2 (16.7%)
CBEZ235A2118 (N = 6, BKM120 treated only)
2 (33.3%)
1 (16.7%)
The highest rate of hyperglycemia (62.0%) was reported in [CBKM120C2201], a phase II 
study conducted in patients with advanced endometrial carcinoma, as this was the only study 
among those listed allowing the enrollment of patients with controlled diabetes mellitus. 
However, so far, there were only two patients that experienced a grade 4 hyperglycemia, and
they both were treated at the highest dose level (150mg/day) in [CBKM120X2101] study.
Detailed guidelines to monitor and manage patients who develop hyperglycemia are provided 
in Table 6-3. Specifically, with regards to appropriate concomitant medication, considering 
that in vitro studies have shown that BKM120 may inhibit insulin-stimulated glucose uptake, 
the first recommended approach is to use oral anti-diabetics (e.g. metformin) who increases 
muscle and fat glucose uptake. The addition of insulin can be considered based on the 
guidelines of American Diabetes Association included as reference in the current protocol.
1.2.1.2.2 Human pharmacokinetic and metabolism data
Preliminary clinical pharmacokinetic data of BKM120 after single and multiple daily dosing
is available from the first-in-human trial [CBKM120X2101]. BKM120 was administered as a 
capsule (doses ranging between 12.5 and 150 mg) and full pharmacokinetic profiles were 
collected on Day 1, Day 8 and Day 28 of Cycle 1.
BKM120 was rapidly absorbed, with the median time to reach the peak plasma concentration 
(Tmax) ranging from 1.0 to 1.75 hours following administration. Tmax was independent of 
dose and was not altered after multiple oral doses. Variability in systemic drug exposure was 
moderate at all dose levels. At 100 mg the variability in systemic drug exposure and Cmax 
(CV %) at steady-state was moderate, about 36% and 25%, respectively.
During once daily dosing, plasma BKM120 concentrations were found to accumulate in 
reaching steady-state. After one week of oral daily dosing (day 8), both Cmax and AUC0-24h 
were approximately 3-fold higher than after a single dose (day 1). The mean accumulation 
ratio (Racc) of BKM120 at 100 mg was 2.7 and 3.3 on days 8 and 28, respectively, indicating 
the absence of significant drug accumulation after day 8.
The decay in BKM120 plasma concentration over time was bi-exponential, with an apparent 
long terminal half-life. The mean T1/2,acc (effective half-life, obtained from drug 
accumulation) calculated from exposure data at day 28 ranged between 38 and 49 hours 
across all dose levels. T1/2,acc was found to be independent of dose. Based on the effective 
half-life, steady state BKM120 plasma levels can be expected to be reached after 1 week of 
daily dosing.

Novartis
Confidential
Page 39
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Furthermore the preliminary PK data within the Japanese population [CBKM120X1101]
show no significant differences in Cmax or AUC0-24h with the Caucasian population 
[CBKM120X2101]. A preliminary population PK analysis, including data from studies 
[CBKM120X2101] and [CBKM120X1101] confirmed those findings (Novartis internal data).
1.2.1.2.3 Clinical efficacy data
BKM120 has not been tested in patients with NHL to date. The following information comes 
from the Novartis sponsored clinical trials for solid tumors.
Sixty six patients were evaluable for response in study [CBKM120X2101] where all patients 
in the expansion cohort were required to have mutated and/or amplified PIK3CA and/or 
mutated PTEN or null/low PTEN protein expression: partial tumor responses (PR) were 
observed in 3 patients, one of which was a RECIST v1.0 confirmed PR in a patient with triple 
negative breast cancer and the other 2 not confirmed (1 patient with metastatic breast cancer 
and 1 patient with parotid carcinoma) (Graña et al 2011).
The first patient was a 
 with poorly differentiated ductal metastatic breast 
cancer assessed as triple negative (ER-, PgR-, HER2-), PI3KCA wild type, PTEN IHC 
positive. Since 
 received many previous anticancer agents (cyclophosphamide, 
doxorubicin, gemcitabine, docetaxel, paclitaxel, vinorelbine, capecitabine, etoposide, 
anastrazole). As progressive disease developed (bulky lymph node involvement and local 
breast relapse), 
 was enrolled 
 in the Phase I study of BKM120 in the 
100 mg/day cohort. A metabolic response (
 decrease in SUV) was observed after 2 cycles, 
followed by a RECIST partial response (
 tumor shrinkage) after 4 cycles. This patient 
continues to receive treatment beyond 32 cycles.
The second patient was a 
 with moderately differentiated ductal metastatic 
breast cancer, assessed as ER positive, HER2 negative, PI3KCA mutated (E545K & H1047Y), 
PTEN IHC positive. 
 had been previously treated with several antineoplastic agents. When 
 received BKM120 at 100 mg/day 
, 
 had measurable metastases in the 
brain, lung and liver. At the second radiological assessment after receiving 4 cycles of 
BKM120 treatment, a 
 reduction of the sum of the lesions was recorded. The TTP for this 
patient was 24 weeks.
The third patient was a 
 with grade 4 parotid gland ductal carcinoma, 
PI3KCA wild type, PTEN IHC positive. 
had been previously treated with doxorubicin and 
adriamycin. After disease progression was observed on this regimen 
 was enrolled in the 
100mg/day cohort 
 in the [CBKM120X2101] study. At the first radiological 
assessment after receiving 2 cycles of BKM120 treatment, a 
 reduction of the sum of the 
lesions was recorded. The TTP for this patient was 16 weeks.
As of the data cut-off 4-Jul-2011, preliminary analysis shows forty-five percent of patients (30 
of 66 evaluable) had stable disease as best response, with 20 patients (30%) with a disease 
stabilization of 3 months or longer. A trend towards better activity (long-term stabilizations) 
has been observed at the higher dose cohorts, also expressed in metabolic FDG-PET response. 
However, considering the impact of a PI3K inhibitor on glucose metabolism, further data 
needs to be acquired to understand whether the current FDG-PET assessment data can be used 
as a predictive factor for efficacy.

Novartis
Confidential
Page 40
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
With regards to pharmacodynamic markers observed in study [CBKM120X2101], down 
regulation of pS6 in skin by 30-80% was demonstrated in 28 out of the 38 evaluable patients 
at 100 and 150 mg/d and more than 25% FDG-PET signal decrease in patients at doses greater 
than the MTD.
With regards to the PI3K pathway activation, of the two responders described above, one had 
a tumor with the PIK3CA mutation. Moreover, 18 patients had a stable disease lasting for 16 
weeks or longer, including 8 patients who had tumors with an activated PI3K pathway. These 
data are promising and continued exploration of the activity of BKM120 in patients with 
activated PI3K pathway is warranted.
Pharmacokinetic experience
Preliminary PK data showed that at the low dose of 40 mg on both days 8 and 22 of treatment, 
the PK of BKM120 in this study was consistent with that seen following single agent 
administration of BKM120. At the 80 mg dose, observed profiles on days 8 and 22 were 
slightly lower than expected (less than 10%). At the other 2 dose levels (60 mg and 100 mg) 
almost all of the profiles lie in the lower half of the expected distribution indicating a large 
reduction (around 30%) in exposure to BKM120 compared to expectations. Hypotheses 
explaining this observation are being evaluated. These include: a possible impact of H2 
antagonist administration as premedication for paclitaxel, which could limit BKM120 
solubility (i.e., BKM120 exhibits pH-dependent solubility, with a significant increase in 
solubility at low pH) or more likely an interaction between this and the extremely rapid 
absorption kinetics of BKM120 (half-life of 10 minutes) suggesting a limited window for 
absorption in the upper part of the duodenum. To limit the potential impact of H2 antagonists, 
in this study BKM120 will be administered at least one hour before H2 antagonists (or proton 
pump inhibitor, antacid, etc.) administration.
2
Rationale
2.1
Study rationale and purpose
The PI3K/Akt/mTOR pathway has become an important focus for cancer therapeutics.
BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor and has been studied 
extensively in non-clinical models and is currently being evaluated in clinical trials for several 
oncology indications other than NHL to date (see details in Section 1.2).
As already stated in the previous sections, inhibitors of the PI3K/mTOR/Akt pathway, 
including BKM120, may be therapeutically effective in NHL patients based on the 
observations from both pre-clinical and early phase clinical trials with either selective or non-
selective inhibitors of the PI3K/mTOR/Akt pathway. As pan class I PI3K inhibitors 
demonstrate evidence of efficacy in solid tumor patients and since there are several p110 
isoforms detected in B cell NHLs, this presents an intriguing opportunity for further 
evaluation of BKM120. Therefore, there is a strong rationale to support this study of BKM120 
for the selected types of B-cell NHL.
The purpose of this study is to explore therapeutic efficacy of BKM120 in three selected types 
of NHL, including DLBCL, MCL and FL, and the safety/tolerability of patients.

Novartis
Confidential
Page 41
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
2.2
Rationale for the study design
An open-label, multi-center, single arm phase II study has been selected to explore the 
efficacy and safety of BKM120 in patients with three histologically different 
relapsed/refractory non-Hodgkin’s lymphomas, including diffuse large B-cell lymphoma,
mantle cell lymphoma and follicular lymphoma.
No clear data exist on the effect of molecular alteration and data with PI3K/mTOR inhibitor 
do not currently support the notion of a specific target population. Thus, enrollment of 
patients with activated as well as non-activated PI3K pathway is considered appropriate.
In the absence of a comparator arm and robust historical data, ORR is considered an 
appropriate primary endpoint to objectively measure anti-tumor activity.
A single arm study will be performed due to the lack of approved agents as well as the small 
patient population.
The protocol specific assessments, treatment and follow-up are consistent with the standard 
procedures applied in this disease setting.
2.3
Rationale for dose and regimen selection
As described in details in Section 1.2.1.2.1, BKM120 100 mg once daily has been established 
as the MTD/RP2D in two single agent trials ([CBKM120X2101] and [CBKM120X1101]) and 
one combination trial ([CBKM120X2107] with trastuzumab).
Accordingly, BKM120 will be dosed at 100 mg/day.
2.4
Rationale for choice of combination drugs
Not applicable.
2.5
Rationale for choice of comparators drugs
Not applicable.
3
Objectives and endpoints
Objectives and related endpoints are described in Table 3-1 below.

Novartis
Confidential
Page 42
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table 3-1
Objectives and related endpoints
Objective
Endpoint
Analysis
Primary
- To determine the efficacy of BKM120 in patients with 
relapsed/refractory Non-Hodgkin Lymphoma in the three 
different histological subgroups (cohorts)
Overall Response rate (ORR) is defined as the proportion of patients 
with a best overall response of CR or PR according to Cheson criteria 
(Cheson et al 2007).
Refer to Section 10.4
Secondary
- To evaluate the safety and tolerability in the three different 
histological subgroups
Frequency and severity of adverse events; other safety data as 
considered appropriate
Refer to Section 10.5
- To assess progression free survival in the three different 
histological subgroups
Progression Free Survival (PFS) is defined as the time from the date of 
treatment start to the date of the first documented progressive disease 
(PD) or death due to any cause per local investigator.
- To assess the duration of response in the three different 
histological subgroups
Duration of Response is defined as the time from the date of first 
occurrence of CR or PR to the date of the first documented progressive 
disease (PD) or death due to lymphoma.
- To assess overall survival in the three different histological 
subgroups
Overall Survival (OS) is defined as the time from treatment start to the 
date of death due to any cause.

Novartis
Confidential
Page 43
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
4
Study design
4.1
Description of study design
This is a multi-center, open label, single arm phase II study in patients with relapsed and 
refractory Non-Hodgkin Lymphoma including 3 histological subgroups (cohorts): mantle cell 
lymphoma (MCL), follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). A 
study design overview is given in Figure 4-1.
Figure 4-1
Study Design Overview
Note: Maximum number of patients per cohort will be capped at N = 28 patients, in case of over 
enrollment.
Screening
Patient must provide a signed Informed Consent Form (ICF) prior to any study specific 
screening evaluations. Eligibility will be determined according to the inclusion/exclusion 
criteria as detailed in Section 5. A list of procedures to be performed at screening is 
summarized in Table 7-1. Patients must meet all eligibility criteria to be considered for 
enrollment in the study.
Treatment and monitoring
Treatment will be organized into cycles of 28 days in all cohorts and patients will receive 
daily BKM120 from Day 1 in Cycle 1, and continue until disease progression, intolerable 
toxicity or withdrawal of consent, or until other criteria for discontinuation are met, whichever 
comes first.
Patients will return to the clinic for regular safety and efficacy assessment as outlined in Table 
7-1. At each office visit, remaining study drug should be accounted for to allow assessment of 
patient treatment adherence.
Study treatment duration is determined independently for each cohort. Response to treatment 
will be determined locally according to Cheson criteria (Cheson et al 2007) every 8 weeks 
until disease progression or until 6 months after the last patient in that cohort has started the 
study treatment, whichever comes first. All patients benefiting from treatment at the time of 

Novartis
Confidential
Page 44
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
final analysis will be permitted to continue study drug at investigator’s discretion until disease 
progression, intolerable toxicity or withdrawal of consent.
An end of treatment visit will occur within 7 days following discontinuation of BKM120.
Safety follow-up
After discontinuation of study treatment, patients will be followed for safety (AEs and/or 
SAEs) for at least 30 days.
Efficacy follow-up
Patients who discontinue from BKM120 for other reasons than disease progression, lost to 
follow up, death, or withdrawal of consent will continue to have tumor assessments every 8 
weeks in each cohort until disease progression, start of new anticancer therapy, lost to follow 
up, death, withdrawal of consent or until 6 months after the last patient in that cohort has 
started the study treatment, whichever comes first. All new anticancer therapies given after 
the last dose of the study drug will be recorded on Case Report Forms (CRFs) designed to 
capture antineoplastic therapies since discontinuation from the study.
Survival follow-up
All patients will be followed for survival outcome after they discontinue from study treatment 
and tumor evaluations (efficacy follow-up). Survival follow-up assessments in each cohort 
will be performed once every 3 months by either office visits or telephone calls until death, 
lost to follow-up, withdrawal of consent or until 6 months after the last patient in that cohort 
has started the study treatment, whichever comes first.
4.2
Timing of interim analyses and design adaptations
Not applicable.
4.3
Definition of completion of the study
The study will end when the treatment period, safety follow-up, efficacy follow-up and 
survival follow up have ended for all patients as described above, or when a decision is made 
to terminate the study early.
The main efficacy and safety analysis for each cohort will be performed when all patients 
included in the corresponding cohort experienced disease progression, discontinued early, or 6 
months after the last patient has started the first cycle of treatment, whichever comes first. 
This is also the time of completion of study treatment for that cohort. An update of the 
analyses will be conducted after all enrolled patients have completed the study.
4.4
Early study termination
The study can be terminated at any time for any reason by Novartis. Should this be necessary, 
the patients remaining in the study should be seen as soon as possible and the same 
assessments should be performed as described in Section 7 for a prematurely withdrawn 
patient. The investigator may be informed of additional procedures to be followed in order to 
ensure that adequate consideration is given to the protection of the patient’s interests. The 

Novartis
Confidential
Page 45
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
investigator will be responsible for informing IRBs and/or ECs of the early termination of the 
trial.
5
Population
5.1
Patient population
The population consists of adult patients with relapsed and refractory mantle cell lymphoma, 
follicular lymphoma and diffuse large B-cell lymphoma.
The investigator or designee must ensure that only patients who meet all the following 
inclusion and none of the exclusion criteria are offered treatment in the study.
5.2
Inclusion criteria
Patients eligible for inclusion in this study have to meet all of the following criteria:
1. Patient has provided a signed study Informed Consent Form prior to any screening 
procedure
2. Patient is ≥ 18 years of age on the day of consenting to the study
3. Patient has a histologically confirmed diagnosis of mantle cell lymphoma, follicular 
lymphoma, or diffuse large B cell lymphoma
4. Patient has relapsed or refractory disease and received at least one prior therapy
5. Patient with diffuse large B cell lymphoma has received or is ineligible for autologous or 
allogeneic stem cell transplant. This does not apply to patients with mantle cell lymphoma 
and follicular lymphoma
6. Patient has at least one measurable nodal lesion (≥2 cm) according to Cheson criteria
(Cheson et al 2007). In case where the patient has no measurable nodal lesions ≥2 cm in 
the long axis at baseline, then the patient must have at least one measurable extra-nodal 
lesion
7. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2
8. Patient has adequate bone marrow and organ function shown by:

Absolute neutrophil count (ANC) ≥ 1.0 x 109/L

Platelets ≥ 75 x 109/L (no platelet transfusion within past 14 days)

Hemoglobin (Hgb) ≥ 9.0 g/dL (no RBC transfusion within past 14 days)

International Normalized Ratio (INR) ≤ 1.5

Potassium, calcium (corrected for albumin), magnesium within normal limits for the 
institution

Serum Creatinine ≤ 1.5 x ULN

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal 
range (or ≤3.0 x ULN if liver metastases are present)

Serum bilirubin ≤ULN(or ≤ 1.5 x ULN if liver metastases are present; or total 
bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well 
documented Gilbert Syndrome which is defined as presence of several episodes of 
unconjugated hyperbilirubinemia with normal results from CBC count (including 

Novartis
Confidential
Page 46
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
normal reticulocyte count and blood smear), normal liver function test results, and 
absence of other contributing disease processes at the time of diagnosis. )

Fasting plasma glucose (FPG) ≤ 120 mg/dL or ≤ 6.7 mmol/L
9. Patient is able to swallow and retain oral medication
5.3
Exclusion criteria
Patients eligible for this study must not meet any of the following criteria:
1. Patient has received previous treatment with PI3K inhibitors
2. Patient has evidence of graft versus host disease (GVHD)
3. Patient has active or history of central nervous system (CNS) disease
4. Patient has a concurrent malignancy or has a malignancy within 3 years of study 
enrollment (with the exception of adequately treated basal or squamous cell carcinoma or 
non-melanomatous skin cancer)
5. Patient has a score ≥ 12 on the PHQ-9 questionnaire
6. Patient selects a response of “1, 2 or 3” to question number 9 on the PHQ-9 questionnaire 
regarding potential for suicidal thoughts or ideation (independent of the response to 
question 9 or the total score of the PHQ-9)
7. Patient has a GAD-7 mood scale score ≥ 15
8. Patient has a medically documented history of or active major depressive episode, bipolar 
disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal 
attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or 
patients with active severe personality disorders (defined according to DSM- IV). For 
patients with psychotropic treatments ongoing at baseline, the dose and the schedule 
should not be modified within the previous 6 weeks prior to start of study drug.
9. Patient has ≥ CTCAE grade 3 anxiety
10. Patient is concurrently using other approved or investigational antineoplastic agent
11. Patient has received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6 weeks for 
nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug or who 
have not recovered from side effects of such therapy
12. Patient has received pelvic and/or para-aortic radiotherapy ≤ 28 days prior to enrollment in 
this study or has not recovered from side effects of such therapy at the time of initiation of 
screening procedures
13. Patient has had major surgery within 28 days prior to starting study drug or has not 
recovered from major side effects of the surgery
14. Patient has poorly controlled diabetes mellitus (HbA1c > 8 %) at baseline
15. Patient has active cardiac disease including any of the following:

Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated 
acquisition (MUGA) scan or echocardiogram (ECHO)

QTc > 480 msec on screening ECG (using the QTcF formula)

Angina pectoris that requires the use of anti-anginal medication

Ventricular arrhythmias except for benign premature ventricular contractions

Novartis
Confidential
Page 47
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with 
medication

Conduction abnormality requiring a pacemaker

Valvular disease with documented compromise in cardiac function

Symptomatic pericarditis
16. Patient has a history of cardiac dysfunction including any of the following;

Myocardial infarction within the last 6 months, documented by persistent elevated 
cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF 
function

History of documented congestive heart failure (New York Heart Association 
functional classification III-IV)

Documented cardiomyopathy
17. Patient is currently receiving treatment with QT prolonging medication known to have a 
risk to induce Torsades de Pointes, and the treatment cannot be discontinued or switched 
to a different medication prior to starting study drug
18. Patient has impairment of gastrointestinal (GI) function or GI disease that may 
significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled 
nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
19. Patient is currently receiving increasing or chronic treatment (> 5 days) with 
corticosteroids or another immunosuppressive agent, as chronic administration of 
corticosteroids (> 5 days) can induce CYP3A4. The following uses of corticosteroids are 
permitted: single dose, topical applications (e.g., rash), inhaled sprays (e.g., obstructive 
airways diseases), eye drops or local injections (e.g., intra-articular).
20. Patient has other concurrent severe and/or uncontrolled medical condition that would, in 
the investigator’s judgment contraindicate his/her participation in the clinical study (e.g. 
chronic pancreatitis, active chronic hepatitis, immunocompromised, chronic pulmonary 
disease including dyspnea at rest or interstitial lung disease, uncontrolled hypertension etc.)
21. Patient has a history of non-compliance to medical regimen or inability to grant consent.
22. Patient is currently being treated with drugs known to be moderate or strong inhibitors or 
inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a 
different medication prior to starting study drug. Patients must have discontinued strong 
inducers for at least one week and must have discontinued strong inhibitors before the 
start of treatment. Note: the oral anti-diabetic drugs troglitazone and pioglitazone are 
CYP3A inducers. Refer to Table 14-1 in Appendix 1.
23. Patient is currently receiving warfarin or other coumarin derived anti-coagulant for 
prophylaxis. Therapy with heparin, low molecular weight heparin (LMWH), or 
fondaparinux is allowed.
24. Patient has a known history of HIV (testing not mandatory) infection
25. Patient has acute viral hepatitis or a history of chronic or active HBV or HCV infection, 
(typically defined by elevated AST/ALT (persistent or intermittent), high HBV DNA level, 
HBsAg positive, or high HCV RNA level (testing not mandatory, refer to 
Section 7.2.2.5.8)

Novartis
Confidential
Page 48
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
26. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female 
after conception and until the termination of gestation, confirmed by a positive serum hCG 
laboratory test (> 5 mIU/mL)
27. Patient who does not apply highly effective contraception during the study and through the 
duration as defined below after the final dose of study treatment
Female Patients

Women of child-bearing potential, defined as all women physiologically capable of 
becoming pregnant, must use highly effective contraception during the study and 
through 4 weeks after the final dose of study treatment
Highly effective contraception is defined as either:

Total abstinence: When this is in line with the preferred and usual lifestyle of the 
subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception].

Sterilization: have had surgical bilateral oophorectomy (with or without hysterectomy) 
or tubal ligation at least six weeks before taking study treatment. In case of 
oophorectomy alone, only when the reproductive status of the woman has been 
confirmed by follow up hormone level assessment

Male partner sterilization (with the appropriate post-vasectomy documentation of the 
absence of sperm in the ejaculate). [For female study subjects, the vasectomized male 
partner should be the sole partner for that patient]

Use a combination of the following:
a. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
b. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
Note: Hormonal contraception methods (e.g. oral, injected, implanted) are not 
allowed as it cannot be ruled out that BKM120 decreases the effectiveness of 
hormonal contraceptives.

Women are considered post-menopausal and not of child bearing potential if any 
of the following conditions is fulfilled:

Prior bilateral oophorectomy (with or without hysterectomy) or tubal ligation at 
least six weeks ago

Age ≥60

Age < 60 and amenorrhea for 12 or more months (in the absence of 
chemotherapy), and FSH and estradiol in the postmenopausal range (serum 
FSH > 40 mIU/mL and estradiol <20 pg/mL or according to the postmenopausal 
range definition for the laboratory involved).
Male Patients

Fertile males, defined as all males physiologically capable of conceiving offspring 
must use a highly effective contraception during dosing of the study agent -
contraception through 16 weeks after final dose of study therapy and should not father 
a child in this period. Female partner of male study subject: highly effective 

Novartis
Confidential
Page 49
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
contraception during dosing of the study agent - contraception through 16 weeks after 
final dose of study therapy
28. Patient who has a known hypersensitivity to any of the excipients of BKM120
6
Treatment
6.1
Study treatment
The investigational or study drug to be used in the course of this trial is BKM120. Novartis 
Drug Supply Management or its designee will provide BKM120 as 10-mg, and 50-mg hard 
gelatin capsules as individual patient supply, packaged in bottles. BKM120 will be dosed on a 
flat scale of mg/day and not be adjusted to body weight or body surface area. The investigator 
needs to instruct the patient to take the study drug as per the protocol. All dosages prescribed 
and dispensed to the patient and all dose changes during the study must be recorded in the 
Dosage Administration Record eCRF.
6.1.1
Dosing regimen
BKM120 100 mg will be administered orally once daily on a continuous dosing schedule. A 
complete treatment cycle is defined as 28 days of once daily continuous treatment with 
BKM120.
Table 6-1
Dose and treatment schedule
Study treatments
Pharmaceutical form and 
route of administration
Dose
Frequency and/or 
Regimen
BKM120
Oral gelatin capsules
100 mg
Daily (28 day cycles)
6.1.1.1
BKM120 Administration
BKM120 will be administered on a continuous once daily dosing schedule. There will be no 
breaks between dosing cycles.
The following general guidelines should be followed for BKM120 administration:

Patients should be instructed to take the dose of BKM120 once daily in the morning, at 
approximately the same time each day.

BKM120 can be taken with or without food.

BKM120 should be taken with a glass of water. Patients should swallow the capsules as a 
whole and not chew them.

To limit the potential impact of H2 antagonists, in this study BKM120 will be 
administered at least one hour before or 10 hours after H2 antagonists (or proton pump 
inhibitor, antacid, etc.) administration.

If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed 
before the next scheduled dose. The occurrence and frequency of any vomiting during a 
treatment cycle must be noted in the adverse events section of the eCRF.

If the patient forgets to take her dose before 18:00 (6:00 PM), then the dose should be 
withheld that day and BKM120 should be restarted the following day.

Novartis
Confidential
Page 50
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

Patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit 
juice, grapefruit hybrids, pummelos, starfruits and cranberry juice from 7 days prior to the 
first dose of study drug and during the entire study treatment period due to potential 
CYP3A interaction. Regular orange (Citrus X sinensis) juice is allowed.

Patients must avoid concomitant intake of strong and moderate CYP3A inhibitors and 
inducers. Detailed information on potential drug interactions and a list of prohibited 
concomitant CYP3A interfering medications is provided in Table 14-1 in Appendix 1.
6.1.2
Ancillary treatments
For more information about handling diarrhea, rash, hyperglycemia and pneumonitis see
Section 6.3.
6.1.3
Rescue medication
Not applicable.
6.1.4
Guidelines for continuation of treatment
In general, patients will be treated until disease progression or unacceptable toxicity. 
Guidance for continuation of study treatment in case of toxicity (e.g. dose delay and/or 
modification) is provided in Section 6.3.
6.1.5
Treatment duration
Patient will be treated until disease progression, death, unacceptable toxicity or other 
discontinuation criteria are met. One cycle equals 28 days.
6.2
Dose escalation guidelines
Not applicable.
6.3
Dose modification
6.3.1
Dose modification and dose delay
For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are 
permitted in order to allow the patient to continue the study treatment. Any changes in 
BKM120 administration must be recorded on the eCRF.
BKM120 dose modification guidelines are described in Section 6.3.2.1. Any planned variance 
from these guidelines in the view of the patient safety must be previously discussed with the 
sponsor unless there is an urgent need for action.
All dose modifications, interruptions or discontinuations must be based on the worst 
preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03). 
Once a dose has been reduced during a treatment cycle, re-escalation will not be permitted 
during any subsequent cycle.
If the administration of BKM120 is interrupted for reasons other than toxicity, then treatment 
with the study drug may be resumed at the same dose. The same applies if the patient 

Novartis
Confidential
Page 51
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
experienced an unacceptable toxicity not specifically described in Table 6-3 or Section 6.3.2, 
provided this toxicity resolved to ≤ CTCAE grade 1, unless otherwise specified.
6.3.2
Treatment interruption and treatment discontinuation
If the study drug is being held due to toxicity, scheduled visits and all assessments should 
continue to be performed (with the exception of the dosing of the held study drug), as 
described in Table 7-1. Additional exams may be required as outlined in Table 6-3, or as 
medically indicated.
If treatment with the study drug is held for ≥28 days due to toxicity, then study drug must be 
permanently discontinued. Patients who permanently discontinue the study drug should have 
weekly follow-up for 30 days after discontinuation of all study treatment or resolution of the 
AE to ≤ grade 1, whichever occurs first, that includes all study assessments appropriate to 
monitor the event.
6.3.2.1
Criteria for BKM120 dose modifications
For each patient, a maximum of 2 dose reductions (as outlined in Table 6-2) will be allowed. 
Patients requiring an additional dose reduction will be discontinued from treatment with
BKM120.
Table 6-2
Dose reduction steps for BKM120
BKM120 dose levels and dose reductions*
Starting dose level – 0
100 mg/day
Dose level – 1
80 mg/day
Dose level – 2
60 mg/day
*Dose reduction should be based on the worst preceding toxicity
Guidelines for dose modification and dose interruption for toxicities suspected to be related to
BKM120 are described in Table 6-3.
After treatment is resumed at a lower dose:

If the same toxicity recurs with the same severity, then the next treatment re-initiation 
must resume at a lower dose irrespective of duration.

These stipulations do not apply to hyperglycemia, as specific rules are stated in Table 6-3.

Novartis
Confidential
Page 52
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table 6-3
Criteria for interruption and re-initiation of BKM120 treatment
These changes must be recorded on the Dosage Administration Record CRF
Dose Modifications for BKM120
Worst toxicity (CTCAE 4.03 Grade)**
Dose Modifications for BKM120
HEMATOLOGICAL
Neutropenia (ANC)
Grade 1 (ANC < LLN - 1.5 x 109/L)
Grade 2 (ANC < 1.5 - 1.0 x 109/L)
Maintain dose level
Grade 3 (ANC < 1.0 - 0.5 x 109/L)
Grade 4 (ANC < 0.5 x 109/L)
Omit dose until resolved to ≤ Grade 1, then:
-- If resolved in ≤ 7 days, then maintain dose level
-- If resolved in > 7 days, then 1 dose level
Febrile neutropenia 
(ANC < 1.0 x 109/L, with a single
temperature of ≥ 38.3 °C or a sustained 
temperature of ≥ 38 °C for more than one 
hour )
Omit dose until resolved, then 1 dose level
Thrombocytopenia
Grade 1 (PLT < LLN - 75 x 109/L)
Grade 2 (PLT < 75 - 50 x 109/L)
Maintain dose level
Grade 3 (PLT < 50-25 x 109/L)
Omit dose until resolved to ≤ Grade 1, then:
-- If resolved in ≤ 7 days, then maintain dose level
-- If resolved in > 7 days, then 1 dose level
Grade 4 (PLT < 25 x 109/L)
Omit dose until resolved to ≤ Grade 1, then 1 dose level
RENAL
Serum creatinine 
< 2 x ULN 
Maintain dose level 
2 – 3 x ULN 
Omit dose until resolved to ≤ grade 1, then:
-- If resolved in ≤ 7 days, then maintain dose level
-- If resolved in > 7 days, then 1 dose level
Grade 3 (> 3.0 – 6.0 x ULN)
Permanently discontinue patient from BKM120
Grade 4 ( > 6.0 x ULN)
Permanently discontinue patient from BKM120
HEPATIC
Bilirubin
(*for patients with Gilbert Syndrome these dose modifications apply to changes in direct bilirubin only)
will be fractionated if elevated
Grade 1 (> ULN - 1.5 x ULN)
Maintain dose level with LFTs* monitored as per protocol
Grade 2 (> 1.5 - 3.0 x ULN) with ALT or 
AST ≤ 3.0 x ULN
Omit dose until resolved to ≤ Grade 1, then:
-- If resolved in ≤ 7 days, then maintain dose level
-- If resolved in > 7 days, then 1 dose level
Grade 3 (> 3.0 - 10.0 x ULN) with ALT or 
AST ≤ 3.0 x ULN
Omit dose until resolved to ≤ Grade 1, then:
-- If resolved in ≤ 7 days, 1 dose level
-- If resolved in 7 days discontinue patient from BKM120
Grade 4 (> 10.0 x ULN)
Permanently discontinue patient from BKM120

Novartis
Confidential
Page 53
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity (CTCAE 4.03 Grade)**
Dose Modifications for BKM120
AST or ALT
AST or ALT without bilirubin elevation > 2ULN
Note: confounding factors and/or alternative causes for increased transaminases like concomitant medications, 
infection, hepato-biliary disorder, obstruction, liver metastasis, etc. should be excluded before dose 
interruption/reduction
Same grade as baseline (i.e. Grade 0 or 
Grade 1 (> ULN – 3.0 x ULN) if presence 
of liver metastasis)
Maintain dose level with LFTs* monitored per protocol
Increase from baseline Grade 0 to > 1.5 
ULN or from baseline Grade 1 to Grade 2
Can continue treatment at 1 dose level
Increase of two grades from baseline 
(from baseline Grade 0 to Grade 2 or from 
baseline Grade 1 to Grade 3)
Omit dose until resolved to Grade 1 or less, then 1 dose level**
If no recovery in ≤ 28 days, discontinue permanently BKM120
Grade 4 (> 20.0 x ULN) 
Discontinue BKM120 permanently
AST or ALT and concurrent Bilirubin
AST or ALT > 3.0 x ULN and total 
bilirubin > 2.0 x ULN
Permanently discontinue BKM120
*(LFTs include albumin, ALT, AST, total bilirubin (fractionated if total bilirubin > 2.0 x ULN), alkaline phosphatase 
(fractionated if alkaline phosphatase is grade 2 or higher) and GGT)
** In case of recurring Grade 3 or higher toxicity after re-challenge, patients should be permanently discontinued
*** All patients with ALT or AST >3.0x ULN and total bilirubin > 2.0x ULN in the absence of cholestasis must 
immediately be withdrawn from BKM120 and every attempt should be made to carry out the liver event follow-up 
assessments as described below in Section 6.3.2.2 and Section 7.2.2.5.8).
Hepatic toxicity monitoring (*for patients with Gilbert Syndrome: total and direct bilirubin must be monitored, 
intensified monitoring applies to changes in direct bilirubin only; the monitoring includes the following LFTs: 
albumin, ALT, AST, total bilirubin (fractionated if total bilirubin > 2.0 x ULN), alkaline phosphatase (fractionated if 
alkaline phosphatase is grade 2 or higher) and GGT):
- Cycle 1 and 2: every other week (if visit schedule allows a more frequent monitoring this should be considered) 
or more frequently if clinically indicated especially for patients with borderline acceptable AST/ ALT, or bilirubin* 
values
- Cycle 3 and onward: monthly or more frequently if clinically indicated
In case of any occurrence of ALT/AST, orbilirubin* increase ≥ grade 2 the liver function tests must be monitored 
weekly or more frequently if clinically indicated until resolved to ≤ grade 1
In case of any occurrence of ALT/ AST or bilirubin* increase ≥ grade 3 the liver function tests must be monitored 
weekly or more frequently if clinically indicated until resolved to ≤grade 1; hereafter the monitoring should be 
continued every other week or more frequently if clinically indicated until the end of treatment with study 
medication
Patients who discontinued study treatment should be monitored weekly, including LFTs* or more frequently if 
clinically indicated until resolved to ≤ grade 1 or stabilization (no CTCAE grade change over 4 weeks).

Novartis
Confidential
Page 54
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity (CTCAE 4.03 Grade)**
Dose Modifications for BKM120
ENDOCRINE/METABOLIC
Fasting Plasma Glucose (FPG)
Grade 1 (> ULN - 160 mg/dL) [> ULN - 8.9 
mmol/L]
Maintain dose level, check FPG every week
- initiate or intensify medication with appropriate anti-diabetic 
treatment as per investigator’s discretion
- instruct patient to follow dietary guidelines according to local and/or 
institutional standards for management of diabetes mellitus (such as 
those provided by the American Diabetes Association) during the 
study
- consider use of oral anti-hyperglycemic therapy such as metformin 
(or intensify existing medications) 
-check FPG at least weekly for 8 weeks, then continue checking at 
least every 2 weeks
Grade 2 (>160 - 250 mg/dL) [> 8.9 - 13.9 
mmol/L]
- If signs or symptoms of hyperglycemia (for example, mental status 
changes, excessive thirst, polyuria), omit BKM120 immediately and 
manage as for Grade 3 hyperglycemia (below)
- If asymptomatic, maintain dose and re-check FPG within 24 hours. 
If grade worsens or improves then follow specific grade 
recommendations. If FPG remains at Grade 2:
-- maintain dose level and monitor FPG at least weekly until FPG 
resolves to ≤ Grade 1
-- initiate or intensify medication with appropriate anti-diabetic 
treatment such as metformin; consider adding a second oral agent if 
no improvement after several days.
--- instruct patient to follow dietary guidelines according to local 
and/or institutional standards for management of diabetes mellitus 
(such as those provided by the American Diabetes Association) 
during the study
- If FPG does not resolve to ≤ Grade 1 within 14 days after 
initiation/intensifying of appropriate anti-diabetic treatment, reduce 
BKM120 by 1 dose level
-Continue with anti-diabetic treatment and check FPG at least 
weekly for 8 weeks, then continue checking at least every 2 weeks.
Grade 3 (> 250 - 500 mg/dL) [> 13.9 -
27.8 mmol/L]
- Immediately omit BKM120, initiate or intensify medication with 
appropriate anti-diabetic treatment, re-check FPG within 24 hours. If 
grade worsens or improves then follow specific grade 
recommendations. If FPG remains at Grade 3:
-- administer intravenous hydration and intervention for 
electrolyte/ketoacidosis/hyperosmolar disturbances as clinically 
appropriate
-- continue to omit BKM120
-- monitor FPG at least twice weekly until FPG resolves to ≤Grade 1
-- If FPG resolves to ≤ Grade 1 in 7 days or less, then re-start 
BKM120 and 1 dose level
-- If FPG remains greater than Grade 1 severity for more than 7 
days, then discontinue patient from BKM120

Novartis
Confidential
Page 55
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity (CTCAE 4.03 Grade)**
Dose Modifications for BKM120
-- initiate or continue anti-diabetic treatment as appropriate
--- instruct patient to follow dietary guidelines according to local
and/or institutional standards for management of diabetes mellitus 
(such as those provided by the American Diabetes Association) 
during the study
--- consider use of oral anti-hyperglycemic therapy such as 
metformin
-- check FPG at least weekly for 8 weeks, then continue checking at 
least every 2 weeks
For non-fasting plasma glucose >250-500 mg/dL (> 13.9 - 27.8 
mmol/L) accompanied by signs/symptoms of hyperglycemia (for 
example, mental status changes, excessive thirst, polyuria), or 
presence of blood or urine ketones, omit BKM120 and following 
guidance for management of Grade 3 fasting plasma glucose (FPG)
Grade 4 (> 500 mg/dL) [≥ 27.8 mmol/L]
- immediately omit BKM120, initiate or intensify medication with 
appropriate anti-diabetic treatment, re-check within 24 hours. If 
grade improves then follow specific grade recommendations. If FPG 
is confirmed at Grade 4:
-- administer intravenous hydration and intervention for 
electrolyte/ketoacidosis/hyperosmolar disturbances as clinically 
appropriate
-- discontinue patient from BKM120
-- instruct patient to follow dietary guidelines according to local 
and/or institutional standards for management of diabetes mellitus 
(such as those provided by the American Diabetes Association) 
during the study
-- consider use of oral anti-hyperglycemic therapy such as metformin
-- check FPG at least weekly for 8 weeks, then continue checking at 
least every 2 weeks if clinically indicated
For non-fasting plasma glucose >500 mg/dL (> 27.8 mmol/L) 
accompanied by signs/symptoms of hyperglycemia (for example, 
mental status changes, excessive thirst, polyuria), or presence of 
blood or urine ketones, discontinue BKM120 and following guidance 
for management of Grade 4 fasting plasma glucose (FPG).
CARDIAC
Cardiac - Left Ventricular systolic dysfunction
Asymptomatic, 
resting ejection fraction 40-50%;
or 10-20% drop from baseline
Maintain dose level, and continue BKM120 with caution
Repeat LVEF within 4 weeks or as clinically appropriate
Symptomatic, 
responsive to intervention, 
ejection fraction 20-39%
or > 20% drop from baseline
- Omit BKM120 until resolved* (as defined below), then 1 dose 
level
- LVEF measurement to be repeated, if not resolved* within28 days, 
permanently discontinue patient from BKM120 treatment
Refractory or poorly controlled,
ejection fraction < 20%
- Permanently discontinue patient from BKM120
*the event is considered resolved when the patient is asymptomatic, has a resting ejection fraction ≥ 40% and 
≤20% decrease from baseline.

Novartis
Confidential
Page 56
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity (CTCAE 4.03 Grade)**
Dose Modifications for BKM120
Cardiac – QTc prolongation
QTcF > 500 ms (≥ Grade 3) 
or > 60 ms change from baseline 
on at least two separate ECGs
First Occurrence:
- omit BKM120
- Perform an analysis of serum potassium and magnesium, and if 
below lower limit of normal, correct with supplements to within 
normal limits. Concomitant medication usage must be reviewed.
- Perform a repeat ECG within one hour of the first QTcF of > 500 
ms or >60ms from baseline
- If QTcF remains > 500 ms or >60ms from baseline, repeat ECG as 
clinically indicated, but at least once a day until the QTcF returns to 
< 480 ms. Seek cardiologist input.
- Once QTcF prolongation has resolved, BKM120 may be restarted 
at a one lower dose level
Second Occurrence:
- Permanently discontinue patient from BKM120
Other Cardiac Events
Grade 1 or 2
Maintain dose level
Grade 3
Omit dose until resolved to ≤ Grade 1, then 1 dose level
Grade 4
Permanently discontinue patient from BKM120
OTHER
Mood alteration
* Note: For all grades, if question 9 on the PHQ-9 has a positive response (as indicated by selecting "1", "2", or 
"3"), omit study drug and refer patient for psychiatric consult regardless of the total questionnaire score or CTCAE 
grading to confirm if study drug should be interrupted or permanently discontinued.
Grade 1*
●
Maintain dose level
Consider psychiatric consultation at the investigator’s discretion and 
introduce appropriate psychotropic management except in presence 
of suicidal ideation where dose must be interrupted and psychiatric 
consultation is required to provide optimal management
Grade 2*
●
Omit dose until resolved to ≤ Grade 1 or baseline status
●
Consider psychiatric consultation at the investigator’s discretion 
and introduce appropriate optimal psychotropic management except 
in presence of suicidal ideation where dose must be interrupted and 
psychiatric consultation is required to provide optimal management
●
First event: if the condition resolved to Grade ≤ 1 or to baseline 
status, continue psychotropic treatment and reinitiate study drug at 
the same dose level
●
Second and further events: if the condition resolved to Grade ≤ 1 
or to baseline status, continue psychotropic treatment and reinitiate 
study drug ↓ 1 dose level
Grade 3*
●
Omit dose until resolved to ≤ Grade 1 or baseline status
●
Psychiatric consultation is required
Introduce appropriate psychotropic management
●
If the condition resolved to Grade ≤ 1 or to baseline status, 
continue psychotropic treatment and reinitiate study drug ↓ 1 dose 
level

Novartis
Confidential
Page 57
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity (CTCAE 4.03 Grade)**
Dose Modifications for BKM120
Grade 4*
●
Permanently discontinue patient from BKM120
●
Psychiatric consultation is required.
Introduce appropriate psychotropic management
* A timely interview with the patient after the questionnaire completion is recommended. For all grades, if question 
9 on the PHQ-9 has a positive response (as indicated by selecting “1”, “2”, or “3”) and/or the patient presents with 
suicidal ideation, interrupt study drug and refer patient for psychiatric consultation regardless of the total 
questionnaire score or CTCAE grading for optimal management and to confirm if study drug should be interrupted 
or permanently discontinued. If the patient does not respond to question 9 on the PHQ-9 or to the whole 
questionnaire, then the investigator must assess if the patient has suicidal ideation. If the investigator identifies 
suicidal ideation, then study drug must be interrupted and the patient referred for psychiatric consultation for 
assessment.
Rash
Grade 1
Maintain dose level. Consider to initiate appropriate skin toxicity 
therapy (such as antihistamines, topical corticosteroids) 
Grade 2
First occurrence: Omit dose until resolved to grade ≤ 1 then:
●
If resolved in ≤ 2 weeks, maintain dose level.
●
If resolved in more than 2 weeks, 1 dose level.
Second occurrence: 1 dose level.
Initiate/intensify appropriate skin toxicity therapy (such as 
antihistamines, topical corticosteroids)
Grade 3
First occurrence: Omit does until resolved to CTCAE Grade ≤ Grade 
1, then re-start at ↓ dose level.
Second occurrence: permanently discontinue patient from
BKM120/placebo. If skin rash is readily manageable, re-introduction
at a reduced dose level might be considered at the discretion of the
investigator.
According to the investigators discretion, a paired skin biopsy could 
be obtained (from both an affected and an unaffected skin area for 
local histopathology assessment) if clinical appropriate.
Grade 4
Permanently discontinue patient from BKM120
According to the investigators discretion, a paired skin biopsy could 
be obtained (from both an affected and an unaffected skin area for 
local histopathology assessment) if clinical appropriate.
Fatigue (asthenia)
Grade 1 or 2
Maintain dose level
Grade 3
Omit dose until resolved to ≤ Grade 1, then:
- If resolved in ≤ 7 days, maintain dose level
- If resolved in 7 days, 1 dose level
Grade 4
Permanently discontinue patient from BKM120
Pneumonitis
please see Section 6.3.2.1.2
Other non- hematological adverse events
Grade 1 or 2
Maintain dose level
Grade 3
Omit dose until resolved to ≤ Grade 1, then 1 dose level
Grade 4
Permanently discontinue patient from BKM120
Note: Omit dose for ≥ Grade 3 vomiting or Grade 3 nausea only if 
the vomiting or nausea cannot be controlled with optimal antiemetic

Novartis
Confidential
Page 58
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Dose Modifications for BKM120
Worst toxicity (CTCAE 4.03 Grade)**
Dose Modifications for BKM120
Stomatitis/Oral mucositis
Grade 1 / Tolerable Grade 2
Maintain dose level.
Non-alcoholic or salt water mouth wash (see also Section 6.3.2.1.3)
Intolerable Grade 2 or Grade 3
First occurrence: hold until resolved to grade ≤ G1 and 1 dose 
level (if stomatitis is readily manageable with optimal management, 
re-introduction at the same level might be considered at the 
discretion of the investigator).
Second occurrence: hold until resolved to grade ≤ G1 and 1 dose 
level.
Grade 4
Permanently discontinue patient from BKM120
** Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
6.3.2.1.1 Additional follow-up for selected toxicities
6.3.2.1.2 Management of Pneumonitis in patients receiving BKM120
All patients participating in clinical trials with BKM120 will be routinely asked about and 
observed for the occurrence of adverse events which could include new or changed 
pulmonary symptoms (consistent with lung abnormalities). CT scans and pulmonary function 
tests should be done, as clinically indicated, or if there are symptoms that indicate that the 
patient has developed Pneumonitis. In case of a documented Pneumonitis, the guidelines 
(including dose modifications) in Table 6-4 should be followed. Consultation with a 
pulmonologist is highly recommended for any Pneumonitis case during the study treatment.
Table 6-4
Management of Pneumonitis
Worst Grade 
Pneumonitis
Required Investigations
Management of 
Pneumonitis
BKM120 Dose Adjustment
Grade 1
CT scans with lung windows. Repeat 
at least every 8 weeks until return to 
within normal limits.
No specific 
therapy is 
required
Administer 100% of BKM120 dose.
Grade 2
CT scan with lung windows. Consider 
pulmonary function testing includes: 
spirometry, DLCO, and room air O2 
saturation at rest. Repeat at least 
every 8 weeks until return to within 
normal limits. Consider a 
bronchoscopy with biopsy and / or 
BAL.
Symptomatic 
only. Consider 
corticosteroids if 
symptoms are 
troublesome.
Reduce BKM120 dose by 1 dose 
level (see Table 6-3) until recovery 
to < Grade 1. Study treatment may 
also be interrupted if symptoms are 
troublesome. Patients will 
discontinue study treatment if they 
fail to recover to < Grade 1 within 
28 days.
Grade 3
CT scan with lung windows and 
pulmonary function testing includes: 
spirometry, DLCO, and room air O2 
saturation at rest. Repeat at least 
every 6 weeks until return to within 
normal limits. Bronchoscopy with 
biopsy and / or BAL is recommended.
Consider 
corticosteroids if 
infective origin is 
ruled out. Taper 
as medically 
indicated.
Hold treatment with BKM120 until 
recovery to < Grade 1. May restart 
study treatment within 28 days at a 
reduced dose (by one level) if 
evidence of clinical benefit.

Novartis
Confidential
Page 59
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Worst Grade 
Pneumonitis
Required Investigations
Management of 
Pneumonitis
BKM120 Dose Adjustment
Grade 4
CT scan with lung windows and 
required pulmonary function testing, if 
possible, includes: spirometry, DLCO, 
and room air O2 saturation at rest. 
Repeat at least every 6 weeks until 
return to within normal limits. 
Bronchoscopy with biopsy and / or 
BAL is recommended if possible.
Consider 
corticosteroids if 
infective origin is 
ruled out. Taper 
as medically 
indicated.
Discontinue treatment with 
BKM120.
6.3.2.1.3 Guidelines for the treatment of study drug induced stomatitis/oral mucositis
General guidance and management include patient awareness and early intervention. 
Evaluation for herpes virus or fungal infection should be considered.
Patients should be informed about the possibility of developing mouth ulcers/ oral mucositis 
and instructed to report promptly any signs or symptoms to their physician,
Patients should be educated about good oral hygiene, instructed to avoid spicy/acidic/salty 
foods, and should follow the following guidelines:

For mild toxicity (grade 1), use conservative measures such as non-alcoholic mouth wash 
or salt water (0.9%) mouth wash several times a day until resolution.

For more severe toxicity (grade 2 in which case patients have pain but are able to maintain 
adequate oral alimentation, or grade 3 in which case patients cannot maintain adequate 
oral alimentation), the suggested treatments are topical analgesic mouth treatments (i.e., 
local anesthetics such as benzocaine, butyl aminobenzoate, tetracaine hydrochloride, 
menthol, or phenol) with or without topical corticosteroids, such as triamcinolone oral 
paste 0.1% (Kenalog in Orabase®).

Agents containing alcohol, hydrogen peroxide, iodine, and thyme derivatives may tend to 
worsen mouth ulcers. It is preferable to avoid these agents.
Antifungal agents should be avoided unless a fungal infection is diagnosed as they may 
interfere with BKM120 metabolism (see Section 6.3).
6.3.2.1.4 Guidelines for the treatment of study drug induced diarrhea
The investigator should consider/investigate potential concomitant medication, food or 
comorbidity driven causes of diarrhea (including infectious causes) and remedy these causes 
if possible (e.g. discontinuation of concomitant medication, dietary modification, treatment of 
comorbidity).
The patient should be monitored for signs of dehydration and instructed to take preventive 
measures against dehydration as soon as diarrhea occurs. Concomitant medication for the 
treatment of diarrhea should be considered, as per local practice and best investigator’s 
judgment and may consist for example, as per “the recommended guidelines for the treatment 
of cancer treatment-induced diarrhea” (Benson et al 2004), of loperamide given at a standard 
dose (e.g. initial administration of 4mg, then 2mg every 4 hours, maximum of 16 mg/day), 
along with oral hydration and dietetic measures could be considered for grade 1-2 diarrhea. 
More severe diarrhea should be treated appropriately according to investigator discretion, 
including for example IV fluids.

Novartis
Confidential
Page 60
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Dose adaptations of BKM120 in case of treatment related diarrhea should follow the 
guidelines presented above for other non-hematological adverse events.
6.3.2.1.5 Guidelines for the treatment of study drug induced psychiatric disorders
Psychiatric adverse events will be closely monitored and evaluated at each planned visit until 
recovery to Grade ≤ 1 or baseline status. The grading of psychiatric adverse events/mood 
alterations must be based on the clinical interpretation of severity according to the NCI-
CTCAE (v 4.03) guidelines.
For patients who experience new or worsening of existing psychiatric AEs of Grade ≥1, 
psychiatric consultation should be considered as described in Table 6-3.
Patient self-reported mood questionnaires (GAD-7 and PHQ-9) will be used for screening and 
during the study treatment phase to aid the investigator in identifying new or worsening of 
events. For additional information regarding safety assessments based on patient self-reported 
mood questionnaires, please refer to Section 7.2.2.8.
If question 9 in the PHQ-9 has a positive response (as indicated by selecting "1", "2", or "3"), 
or patient exhibits suicidal idealation, interrupt treatment with study drug and refer the patient 
for psychiatric consultation for optimal management regardless of the total questionnaire 
score or CTCAE grading and to confirm if study drug should be interrupted or permanently 
discontinued. In this specific case, the psychiatric advice can overrule the patient’s PHQ-9 
self-assessment.
During the study, subjects will be monitored at regular scheduled visits (eg, Day 1 of each 
cycle and at the End of Treatment visit) by the investigator/site staff through personal 
interaction and the two self-reported questionnaires. Additional assessments may be done 
according to the clinical judgment of the investigator if desired.
6.3.2.1.6 Guidelines for the treatment of study drug induced skin toxicity
Close monitoring of potential skin reactions will be performed at each planned visit and will 
be reported as adverse event.
Although preclinical experiments demonstrated that BKM120 has no potential phototoxic 
effect, it is recommended to caution patients to avoid sun exposure during treatment with 
BKM120, especially when they already have experienced rash or other skin toxicities. 
Patients should be advised to take measures to protect themselves from direct exposure to 
sunlight, including the wearing of sunglasses as well as the use of hats, long-sleeve shirts and
long pants when outdoors.
6.3.2.2 Management of hepatotoxicity (ALT and/or AST >3.0x ULN and total 
bilirubin >2.0x ULN) in patients receiving BKM120
Criteria for interruption and re-initiation of BKM120 treatment in case of the occurrence of 
AST, ALT or bilirubin increase are detailed in Section 6.3, Dose Modification (Table 6-3).
Patients with clinically significant liver test abnormalities should perform liver-directed 
medical history, physical examination and other tests as medically indicated to assess 
potential relationship with study treatment and rule out other underlying causes (e.g. disease

Novartis
Confidential
Page 61
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
progression/obstruction, infection/hepatitis or other liver diseases, sepsis, metabolic diseases 
including diabetes, concomitant medications including herbals, alcohol, drug-drug interaction, 
cardiovascular disease/ischemia, other organ injuries, etc.). Any pre-existing liver conditions 
or risk factors should be reported in the respective medical history and concomitant 
medication CRF pages (if not done already).
All patients with ALT or AST >3.0 x ULN and total bilirubin > 2.0 x ULN in the absence of 
cholestasis (elevation of ALP in patients without bone metastasis or if bone metastasis are 
present elevation of 5’-nucleotidase and ALP liver fraction) must be immediately withdrawn 
from BKM120, and every attempt should be made to carry out locally the liver event follow-
up assessments as described below:

Inform the sponsor about the event immediately after its occurrence by reporting the event 
immediately in the clinical database if it meets the criteria for an AE or SAE.

Evaluate if associated with the appearance or worsening of clinical symptoms of hepatitis
or hypersensitivity such as fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash or eosinophilia, or other organ involvement.

Obtain fractionated bilirubin, serum Alkaline Phosphatase (ALP), creatine phosphokinase 
(CPK), lactate dehydrogenase (LDH), and blood count with differential to assess 
eosinophilia.

Perform liver imaging (ultrasound, magnetic resonance, or computerized tomography) to 
evaluate liver disease including metastasis or new lesions, obstruction/compression, etc.

Perform viral hepatitis and other serology tests:

Hepatitis C (HCV) serology and viral RNA, Hepatitis B (HBV) serology and viral 
DNA, Hepatitis A (HAV) Immunoglobulin M (IgM) and HAV total

Hepatitis E (HEV) serology: IgM and IgG, viral RNA

Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Epstein-Barr viral (EBV) 
serology

Verify and record the use of concomitant medications, acetaminophen, herbal remedies, 
and other over the counter medications, or putative hepatotoxins, on the concomitant 
medications report form.

Consultation with a specialist(s) or a hepatologist(s) is recommended.

Liver biopsy as clinically indicated to assess pathological change and degree of potential 
liver injury

LFTs should be followed-up weekly until resolve to ≤ grade 1, baseline or stabilization 
(no CTCAE grade change over 4 weeks) and outcome documented on the respective AE 
and lab chemistry pages.
6.4
Concomitant medications
In general, the use of any concomitant medication/therapies deemed necessary for the care of 
the patient is permitted (see Section 6.4.1), except as specifically prohibited (see Section 
6.4.2).
All medications (excluding study treatment and prior antineoplastic treatments), procedures 
and significant non-drug therapies (including physical therapy and blood transfusions) 

Novartis
Confidential
Page 62
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
administered within 28 days prior to the administration of BKM120 through 30 days after the 
last dose of study treatment will be recorded in the Concomitant Medications/Significant Non-
Drug Therapies eCRF page. Medications include not only physician prescribed medications, 
but also all over-the counter medications, herbal medications (prohibited, see Section 6.4.2.8) 
and food or vitamin supplements. The investigator should instruct the patient to notify the 
investigational site about any new medications she takes after the start of the study drug.
The patient must be told to notify the investigational site about any new medications he/she 
takes after the start of the study drug. All medications (other than study drug) and significant 
non-drug therapies (including physical therapy and blood transfusions) administered during 
the study must be listed on the Concomitant Medications/Significant Non-Drug Therapies 
eCRF page.
6.4.1
Permitted concomitant therapy
6.4.1.1
Corticosteroids
Chronic dosing of corticosteroids such as dexamethasone and prednisone is known to induce 
CYP3A enzymes, thereby increasing the risk of reducing BKM120 drug exposure to sub-
therapeutic levels. Systemic corticosteroid treatment must not be given during the study, 
except for:

topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye 
drops or local injections (e.g., intra-articular);

a short duration (< 5 days) of systemic corticosteroids ≤ to the anti-inflammatory potency 
of 4 mg dexamethasone (e.g. for chronic obstructive pulmonary disease, or as an 
antiemetic);
6.4.1.2
Drugs that are metabolized by CYP450 enzymes
In vitro metabolism studies performed to examine the reversible and metabolism-dependent 
inhibition of CYPP450 enzymes showed that BKM120 is a weak, reversible inhibitor of 
CYP3A4/5, CYP2C8, CYP2C9 and CPY2C19. Note that with the data available, it is not 
possible to confirm whether such interactions will occur in patients. Therefore, investigators, 
at their discretion, may administer concomitant medications known to be metabolized by 
CYP3A4/5, CYP2C8, CYP2C9 and CYP2C19. Patients receiving such medications must be 
monitored for potentiation of toxicity due to any individual concomitant medications, and 
may require dose titration or reduction of the drug substrate.
Refer to Table 14-2 in Appendix 2 for a list of CYP3A and CYP2C substrates to be used with 
caution. Particularly, caution is advised when BKM120 is co-administered with drugs that are 
sensitive substrates and/or have a narrow therapeutic index (e.g., SSRI).
Concomitant treatment of BKM120 with weak inducers of CYP3A4 is permitted, however, 
duration of concomitant treatment should be kept as short as possible (e.g., less than 1 week), 
or fully avoided whenever possible. Note that coadministration of BKM120 with strong and 
moderate inducers is prohibited (refer to Section 6.4.2.7).

Novartis
Confidential
Page 63
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
6.4.1.3
Non-enzyme Inducing Anti-epileptic drugs
Non-enzyme inducing anti-epileptic medication (Non-EIAED) is allowed, except for those 
listed in Table 14-1 in Appendix 1.
6.4.1.4
Palliative radiotherapy
Local radiotherapy for analgesic purposes or for lytic lesions at risk of fracture may be carried 
out if required. Whenever possible, these patients should have a tumor assessment of the 
lesion(s) before receiving the radiotherapy in order to rule out progression of disease. No dose 
modification of study treatment is needed during radiotherapy.
6.4.1.5
Drugs with a conditional or possible risk to induce Torsades de 
Pointes
If a patient, after enrollment in the study, requires the concomitant use of any QT prolonging 
medication with a possible or conditional risk for Torsades de Pointes included in Table 14-4
of Appendix 4, then investigators, at their discretion, may co-administer such medications. 
Patients receiving such medications must however be closely monitored.
6.4.1.6
Gastric protection agents
BKM120 is characterized by a pH-dependent solubility. Medicinal products that alter the pH 
of the upper Gastro-Intestinal (GI) tract may alter the solubility of BKM120 and hence its 
bioavailability. These agents include, but are not limited to, proton-pump inhibitors (e.g., 
omeprazole), H2-antagonists (e.g., ranitidine) and antacids. BKM120 should be dosed in a 
staggered manner at least 1 hour before or 10 hours after dosing with medicinal products that 
may alter the pH of the upper GI tract.
6.4.1.7
Allopurinol and rasburicase
Allopurinol or rasburicase may be used at the physician’s discretion in DLBCL patients at risk 
for tumor lysis syndrome.
6.4.2
Prohibited concomitant therapy
Prohibited concomitant therapy should be stopped at least 5 half-lives or 7 days whichever is 
the longest before start of study treatment (C1D1) and must not be used while the patient is on 
study.
6.4.2.1
Other anticancer therapy
Anticancer therapy (chemotherapy, biologic or radiation therapy, and surgery) other than the 
study treatments must not be given to patients while the patient is enrolled in the treatment 
portion of the trial. If such agents are required for a patient then the patient must be 
permanently discontinued from the treatment portion of the study.
6.4.2.2
Other investigational therapies
Other investigational therapies must not be used while the patient is on the study.

Novartis
Confidential
Page 64
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
6.4.2.3
Hematopoietic growth factors
Prophylactic use of hematopoietic growth factors (e.g. erythropoietins, granulocyte colony-
stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF)) 
are not permitted. However, in the event of an emergency (e.g. acute myelosuppression with 
infection), a patient may be given hematopoietic growth factors according to the investigator’s 
judgment, and the sponsor should be notified as soon as possible. Subsequent secondary 
prevention use is permitted at investigator’s discretion.
Patients who begin erythropoietin or darbepoetin therapy before randomization, may continue 
this treatment at the discretion of the investigator.
6.4.2.4
Warfarin and coumarin derivatives
Therapeutic doses of warfarin sodium or any other coumarin-derivative anticoagulants are not 
permitted.
BKM120 is a weak inhibitor of CYP2C8 and 2C9, the major metabolizing enzyme of 
warfarin. Despite the fact that the inhibitory signal was weak, an increase of 40-50% of 
warfarin exposure is possible and for a drug like warfarin, this might be clinically relevant.
6.4.2.5
Enzyme-inducing anti-epileptic drug (EIAED)
Use of enzyme-inducing anti-epileptic drug (EIAED) is not permitted. Refer to Table 14-1 for 
a list of prohibited EIAED.
If a patient is currently taking EIAED, they must have discontinued the EIAED therapy for at 
least two weeks prior to starting study drug.
If a patient is previously on a non-EIAED and needs to permanently change the 
anticonvulsant agent, but cannot change to another non-EIAED, the patient will be taken off 
BKM120.
6.4.2.6
Drugs with a known risk for Torsades de Pointes
If a patient requires the concomitant use of any medication included in Table 14-3 in 
Appendix 3 entitled “List of Prohibited QT prolonging drugs” (i.e., drugs that are generally 
accepted by the Qtdrugs.org Advisory Board of the Arizona CERT to have a risk of causing 
Torsade de Pointes), study treatment must be delayed. Note that Table 14-3 lists drugs with a 
known risk for Torsades de Pointes (TdP) as well as sensitive CYP3A substrates (with narrow 
TI) with a possible or conditional risk for TdP. Study treatment administration must be 
interrupted as long as the patient requires therapy with the QT prolonging agent.
Please also refer to http://crediblemeds.org/ for a comprehensive list of agents that prolong the 
QT interval.
6.4.2.7
Moderate and strong CYP3A inhibitors and inducers
In vitro metabolism studies suggest that oxidative metabolism of BKM120 is predominantly 
mediated by CYP3A4 and UGT1A4. Coadministration of BKM120 with strong and moderate 
CYP3A4 inhibitors and inducers is predicted to respectively increase or decrease the systemic 
exposure to BKM120.

Novartis
Confidential
Page 65
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Please refer to Table 14-1 in Appendix 1 for a list of prohibited drugs. Please note that this list 
may not be comprehensive.
6.4.2.8
Herbal medications
Herbal preparations/medications are not allowed throughout the study, as a potential drug-
drug interaction is always possible. These herbal medications include, but are not limited to: 
St. John’s wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), 
yohimbe, saw palmetto, and ginseng.
Patients should stop using these herbal medications at least 7 days prior to first dose of study 
treatment.
6.4.2.9
Hormonal contraception
Hormonal contraceptives may be affected by cytochrome P450 interactions, and are therefore 
not considered effective for this study, since induction of CYP3A4 may not be excluded in 
patients receiving BKM120.
6.5
Patient numbering, treatment assignment or randomization
6.5.1
Patient numbering
Each patient is identified in the study by a Subject Number (Subject No.), that is assigned 
when the patient is first enrolled for screening and is retained as the primary identifier for the 
patient throughout his/her entire participation in the trial. The Subject No. consists of the 
Center Number (Center No.) (as assigned by Novartis to the investigative site) with a 
sequential patient number suffixed to it, so that each subject is numbered uniquely across the 
entire database. Upon signing the informed consent form, the patient is assigned to the next 
sequential Subject No. available at the site.
Once assigned, the Subject No. must not be reused for any other subject and the Subject No. 
for that individual must not be changed, even if the patient is re-screened.
Re-screening is permitted for patients as long as all screening procedures are performed 
within the specific time window. Any re-screened patient must retain the same Subject No.
Re-screening of patients is only allowed once per patient.
If the patient fails to be assigned to treatment for any reason, the reason will be entered into 
the Screening log eCRF page.
6.5.2
Treatment assignment or randomization
Not applicable.
6.5.3
Treatment blinding
This is an open-label study.

Novartis
Confidential
Page 66
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
6.6
Study drug supply
6.6.1
Study drug preparation and dispensation
Study medication will be dispensed by an authorized person at the investigator’s site. 
Investigator staff will add the patient number on the label. Immediately before dispensing the 
package to the patient, investigator staff will detach the outer part of the label from the 
packaging and affix it to the source document (Drug Label Form) for that patient’s unique 
patient number.
Patients will be provided with an adequate supply of study drug for self-administration at 
home, including instructions for administration, until at least their next scheduled study visit. 
Patients will receive BKM120 on an outpatient basis. The investigator shall provide the 
patient with instructions for BKM120 administration according to the protocol.
All dosages prescribed to the patient and all dose changes during the study must be recorded 
on the Dosage Administration Record CRF.
6.6.2
Study drug packaging and labeling
BKM120 will be supplied as 10 mg and 50 mg hard gelatin capsules, packaged in bottles, and 
will be given orally on a flat scale of mg/day. The capsules are packaged in HDPE bottles 
with a plastic child resistant closure.
Medication labels will comply with the legal requirements of each country and printed in the 
local language for each specific country. The storage conditions for study drug will be 
described on the medication label.
Immediately before dispensing the study drug to the patient, the investigator or his/her 
designee will detach the outer part of the label from the packaging and affix it to the source 
document containing that patient’s unique patient number.
Table 6-5
Packaging and labeling
Study treatments
Packaging
Labeling (and dosing frequency)
BKM120
Capsules in bottle
10 mg
50 mg
Labeled as “BKM120”
Once daily dosing
6.6.3
Drug supply and storage
Study treatments must be received by designated personnel at the study site, handled and 
stored safely and properly, and kept in a secured location to which only the investigator and 
designated site personnel have access. Upon receipt, the study treatment should be stored 
according to the instructions specified on the drug labels and in the [Investigator’s Brochure]. 
These instructions should also be made clear to the patient for storage and self-administration 
of BKM120 at home.

Novartis
Confidential
Page 67
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
6.6.4
Study drug compliance and accountability
6.6.4.1
Study drug compliance
Compliance will be assessed and verified by the investigator and/or study personnel at each 
patient visit by counting the number of BKM120 capsules consumed between visits and 
information provided by the patient and/or caregiver will be captured in the Drug 
Accountability Form. This information must be captured in the source document at each 
patient visit.
Any overdose must be recorded in the dosage administration record of the eCRF. An overdose 
is defined as any dose greater than the daily dose level at which the patient is being treated. If 
the subject has taken a higher dose than stated in the protocol, then the patient should also be 
monitored for potential adverse reactions. In case of an overdose that needs to be treated, the 
investigator should use his or her clinical judgment for the management of this overdose and 
apply adequate supportive care and follow up until recovery.
6.6.4.2
Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study treatment in a drug accountability log. Drug accountability will be noted by the field 
monitor during site visits and at the completion of the study. Patients will be asked to return 
all unused study treatment and packaging on a regular basis, at the end of the study or at the 
time of study treatment discontinuation.
At study close-out, and, as appropriate during the course of the study, the investigator will 
return all used and unused study treatment, packaging, drug labels, and a copy of the 
completed drug accountability log to the Novartis monitor or to the Novartis address provided 
in the investigator folder at each site.
6.6.4.3
Handling of other study treatment
Not applicable.
6.6.5
Disposal and destruction
The study drug supply can be destroyed at the local Novartis facility, Drug Supply group or 
third party, as appropriate. Study drug destruction at the investigational site will only be 
permitted if authorized by Novartis in a prior agreement and if permitted by local regulations.

Novartis
Confidential
Page 68
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
7
Visit schedule and assessments
7.1
Study flow and visit schedule
Table 7-1 lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be supported in the patient’s source 
documentation. The table indicates which assessments produce data to be entered into the 
database (D) or remain in source documents only (S) (“Category” column).
All visits can take place 3 days before or 3 days after the specified study visit (total window of 
7 days) except for the time window for the end of treatment and safety follow-up visit which 
is +7 days.

Novartis
Confidential
Page 69
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table 7-1
Visit evaluation schedule
Category
Referenc
e to 
Section
Screening
Cycl
e 1
(28 
days
)
Cycl
e 1
Cycl
e 1
Cycl
e 1
Cycl
e 2
(28 
days
)
Cycl
e 3
(28 
days
)
Subsequen
t cycles
(28 days)
End of 
study 
treatmen
t (EOT)
Safety 
follow
-up
Efficac
y 
follow-
up (FU)
Completio
n of Study
(end of 
Efficacy 
FU)
Overall 
Surviva
l 
follow-
up
Visit Number
1
2
601
602
603
3
4
5
777
501
778
Day of cycle
-28 
to-
1
1
2
3
4
1
1
1
EOT + 
30
(+7)
days
Obtain Informed 
Consent
D
4.1 & 11.3
X
Patient history
Demography
D
7.1.2.3
X
Inclusion/exclusio
n criteria
D
5.2 & 5.3
X
Relevant medical 
history/current 
medical 
conditions
D
7.1.2.3
X
Diagnosis and 
extent of cancer
D
7.1.2.3
X
Prior 
antineoplastic 
therapy
D
7.1.2.3
X
Prior/concomitant 
medications
D
7.1.2.3 &
6.4
X
Continuous
Antineoplastic 
therapies since 
discontinuation of 
study treatment
D
7.1.5 & 
7.1.6.3
X
X
X
X

Novartis
Confidential
Page 70
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Category
Referenc
e to 
Section
Screening
Cycl
e 1
(28 
days
)
Cycl
e 1
Cycl
e 1
Cycl
e 1
Cycl
e 2
(28 
days
)
Cycl
e 3
(28 
days
)
Subsequen
t cycles
(28 days)
End of 
study 
treatmen
t (EOT)
Safety 
follow
-up
Efficac
y 
follow-
up (FU)
Completio
n of Study
(end of 
Efficacy 
FU)
Overall 
Surviva
l 
follow-
up
Visit Number
1
2
601
602
603
3
4
5
777
501
778
Day of cycle
-28 
to-
1
1
2
3
4
1
1
1
EOT + 
30
(+7)
days
Physical 
examination
S
7.2.2.1
X
X*
X
X
X
X
ECOG 
Performance 
status
D
7.2.2.4
X
X*
X
X
X
X
Height
D
7.2.2.3
X
Weight
D
7.2.2.3
X
X*
X
X
X
X
Vital signs
D
7.2.2.2
X
X*
X
X
X
X
PHQ-9 Patient 
self-rating mood 
scale
D
7.2.2.8
X
X*
X
X
X
X
GAD7 Patient 
self-rating mood 
scale
D
7.2.2.8
X
X*
X
X
X
X
Laboratory assessments
Hematology
D
7.2.2.5.1
X
X*
X
X
X
X
Biochemistry (full)
D
7.2.2.5.2
X
X*
X
X
X
X
Hepatotoxicity 
follow-up 
testing/procedure
s
D
6.3.2.2
As clinically indicated

Novartis
Confidential
Page 71
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Category
Referenc
e to 
Section
Screening
Cycl
e 1
(28 
days
)
Cycl
e 1
Cycl
e 1
Cycl
e 1
Cycl
e 2
(28 
days
)
Cycl
e 3
(28 
days
)
Subsequen
t cycles
(28 days)
End of 
study 
treatmen
t (EOT)
Safety 
follow
-up
Efficac
y 
follow-
up (FU)
Completio
n of Study
(end of 
Efficacy 
FU)
Overall 
Surviva
l 
follow-
up
Visit Number
1
2
601
602
603
3
4
5
777
501
778
Day of cycle
-28 
to-
1
1
2
3
4
1
1
1
EOT + 
30
(+7)
days
DLBCL arm only: 
Chemistry specific
to tumor lysis 
syndrome
D
7.2.2.5.2
X
X
X
Lipid profile
D
7.2.2.5.4
X
X*
X
X (every 2nd
cycle)
X
Fasting plasma 
glucose
D
7.2.2.5.2
X
X*
X
X
X
X
HbA1c
D
7.2.2.5.5
X
X*
X
X (every 2nd
cycle)
X
Coagulation
D
7.2.2.5.3
X
X*
As clinically indicated
C-peptide
D
7.2.2.5.5
X
X*
X
X (every 2nd
cycle)
X
Pregnancy test 
(serum)
D
7.2.2.5.7
X
X*
X
X
X
X
Imaging/Other assessments
Tumor evaluation
D
7.2.1.2
X
X
X (every 2nd
cycle)
X
X
X
Bone Marrow 
biopsy
D
7.2.1.3
Only at time of complete response
ECG
D
7.2.2.7.1
X
X*
X
X
X
X
Cardiac imaging 
(MUGA/ECHO)
D
7.2.2.7.2
X
As clinically indicated

Novartis
Confidential
Page 72
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Category
Referenc
e to 
Section
Screening
Cycl
e 1
(28 
days
)
Cycl
e 1
Cycl
e 1
Cycl
e 1
Cycl
e 2
(28 
days
)
Cycl
e 3
(28 
days
)
Subsequen
t cycles
(28 days)
End of 
study 
treatmen
t (EOT)
Safety 
follow
-up
Efficac
y 
follow-
up (FU)
Completio
n of Study
(end of 
Efficacy 
FU)
Overall 
Surviva
l 
follow-
up
Visit Number
1
2
601
602
603
3
4
5
777
501
778
Day of cycle
-28 
to-
1
1
2
3
4
1
1
1
EOT + 
30
(+7)
days
Safety
Adverse events
D
7.2.2
X
Continuous
BKM120 kit 
dispensation
S
6.6.1
X
X
X
X
Drug 
administration
D
6.1.1.1
Continuous
Screening Log
D
7.1.2
X
End of Treatment
D
7.1.5
X

Novartis
Confidential
Page 73
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Category
Referenc
e to 
Section
Screening
Cycl
e 1
(28 
days
)
Cycl
e 1
Cycl
e 1
Cycl
e 1
Cycl
e 2
(28 
days
)
Cycl
e 3
(28 
days
)
Subsequen
t cycles
(28 days)
End of 
study 
treatmen
t (EOT)
Safety 
follow
-up
Efficac
y 
follow-
up (FU)
Completio
n of Study
(end of 
Efficacy 
FU)
Overall 
Surviva
l 
follow-
up
Visit Number
1
2
601
602
603
3
4
5
777
501
778
Day of cycle
-28 
to-
1
1
2
3
4
1
1
1
EOT + 
30
(+7)
days
Study Evaluation 
Completion
D
7.1.6
X
Survival 
information
D
7.1.6.3
X
* Does not need to be repeated if done within 7 days before cycle 1 day 1

Novartis
Confidential
Page 74
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
7.1.1
Molecular pre-screening
Not applicable.
7.1.2
Screening
After signing the main study ICF (S-ICF) for the study, the remaining screening assessments 
will be done generally within 7 to 28 days prior to start of treatment (see Table 7-1).
Please note that the screening period must not exceed 28 days.
7.1.2.1
Eligibility screening
Following registration for screening, patient eligibility will be checked once all screening 
procedures are completed. The investigator will complete the Screening Log and
Inclusion/Exclusion criteria eCRF pages.
7.1.2.2
Information to be collected on screening failures
Patients who sign an informed consent but fail to be started on treatment for any reason will 
be considered a screen failure. The reason for not being started on treatment will be entered on 
the Screening Log eCRF Page. The following CRFs must be completed for screen failure 
patients:

Screening failure log (including reason for not being started on treatment)

Demography
7.1.2.3
Patient demographics and other baseline characteristics
Data will be collected on patient characteristics including demographic information (age, 
gender, race) and other background or relevant medical history, including history of disease 
and current disease status, staging (Table 7-2), bone marrow involvement, sites of disease, 
prior anticancer therapies, prior medications/significant non-drug therapies and any other 
assessments that are done for the purpose of determining eligibility for inclusion in the study 
(i.e., ECOG Performance Status, complete physical examination (including neurological 
assessment, tumor assessment and B symptoms Table 7-2), vital signs, hematology, blood 
chemistries including coagulation studies and a serum lipid profile, pregnancy test only 
required for women of childbearing potential, 12-lead ECG). Furthermore the following 
assessments will be performed to assess the eligibility of the patient:

Viral hepatitis serology [e.g. HAAb, HBsAg, HBsAb HBcAb, HCV RNA or HDV RNA
(where needed), HEAb, CMVAb, EBcAb] and other tests (see Section 6.3.2.2 and
Section 7.2.2.5.8)

Novartis
Confidential
Page 75
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table 7-2
Ann Arbor staging classification1
Stage Area of involvement
I Single lymph node group
II Multiple lymph node groups on the same side of the diaphragm
III Multiple lymph node groups on both sides of the diaphragm
IV Multiple extranodal sites or lymph nodes and extranodal disease
X Bulk disease > 10 cm
E Extranodal extension or single isolated site of extranodal disease
Class A patients who experience no B symptoms
Class B patients experience unexplained fever of ≥ 38°C; unexplained, recurrent drenching night sweats; or 
unexplained loss of >10% body weight within the previous 6 months
1 Cotswolds modification of Ann Arbor staging system adapted from 2007 NCCI guidelines for non-Hodgkin’s 
lymphoma
7.1.3
Run-in period
Not applicable.
7.1.4
Treatment period
Patients will receive study treatment BKM120 daily as a 28 day cycle until disease 
progression, unacceptable toxicity or until other discontinuation criteria are met, whichever 
come first.
Following initiation of study treatment (Cycle 1 Day 1), the patient should visit the site every 
cycle; see Table 7-1. Permitted visit windows for assessments within the treatment period and
at efficacy follow-up visits: +/- 3 days of the protocol required date.
Information on drug exposure will be collected on the Dosage Administration Record eCRF. 
Concomitant medications/significant non-drug therapies prior to start (≤ 28 days) and after 
start of study treatment will be recorded on the appropriate eCRFs.
Compliance will be assessed by the investigator and/or study personnel at each visit using box 
counts and information provided by the caregiver. This information should be captured in the 
source document at each visit (Please also refer to Section 6.6.4).
7.1.5
End of treatment visit including study completion and premature 
withdrawal
Patients will continue study treatment until disease progression or until any of the study’s 
discontinuation criteria (Section 7.1.5.1) are met.
Patients who discontinue study treatment should be scheduled for an End-of-Treatment visit
as early as for patient’s convenience, but it should occur within 7 days from treatment 
discontinuation, at which time all of the assessments listed for the EOT visit will be 
performed. For details of assessments, refer to Table 7-1.
An End of Treatment eCRF page should be completed, giving the date and reason for 
discontinuation of study treatment.

Novartis
Confidential
Page 76
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
If a study withdrawal occurs, or if the patient fails to return for visits, the investigator must 
determine the primary reason for a patient’s premature withdrawal from the study and record 
this information on the End of Treatment eCRF page.
Patients who discontinue study treatment for reasons other than disease progression will enter 
the efficacy follow-up period until disease progression or initiation of a new antineoplastic 
therapy and should not be considered withdrawn from the study.
7.1.5.1
Criteria for premature patient withdrawal
Patients may voluntarily withdraw from the study or be dropped from it at the discretion of 
the investigator at any time. Patients may be withdrawn from the study if any of the following 
occur:

Unacceptable toxicities

Protocol deviation

Lost to follow-up

Pregnancy

Discovery of patient ineligibility

Errors in treatment compliance

Administrative problems

Death
In addition to the general study treatment withdrawal criteria, the following study specific 
criteria will also require premature study treatment discontinuation:

Study treatment modifications that result in discontinuation.

Interruption of BKM120 treatment for more than 28 days

Use of prohibited medication.

Start of any other anti-neoplastic therapy
If a study treatment withdrawal occurs, or if the patient fails to return for visits, the 
investigator must determine the primary reason for a patient’s premature withdrawal from 
study treatment and record this information on the End of Treatment CRF page. In case of 
withdrawal from study treatment, the patient needs to indicate on the informed consent form 
whether she is willing to continue with subsequent follow-up procedures.
7.1.5.2
Replacement policy
Not applicable.
7.1.6
Follow up period
All patients must be followed for safety for at least 30 days after the last dose of study 
treatment.
Patients lost to follow up should be recorded as such on the CRF. For patients who are lost to 
follow-up, the investigator should show "due diligence" by documenting in the source 

Novartis
Confidential
Page 77
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
documents steps taken to contact the patient, e.g., dates of telephone calls, registered letters, 
etc.
7.1.6.1
Safety follow up
All patients will be followed for adverse events and serious adverse events for at least 30 days 
following the last dose of BKM120. At the end of this period (between day 30 and day 37
after last dose), the investigator should contact the patient to inquire about any AE 
observed/concomitant medication taken during this period. This could be done via either an 
office visit or a phone contact.
Patients whose treatment is interrupted or permanently discontinued due to an adverse event 
or abnormal laboratory value must be followed until resolution or stabilization of the event, 
whichever comes first. In case the patient has any abnormal lab values at end of treatment that 
are considered clinically significant by the investigator, the patient needs to come to the site 
for repeat blood analysis until resolution or stabilization including at least a site visit with 
respective analyses 30-37 days after end of treatment.
If patients refuse to return for safety evaluation visits or are unable to do so, every effort 
should be made to contact them by telephone to determine their status. Attempts to contact the 
patient should be documented in the source documents (e.g., dates of telephone calls, 
registered letters, etc.).
All new anti-cancer therapies given after the last dose of the study drug will be recorded on 
eCRFs designed to capture anti-neoplastic therapies administered after discontinuation of 
study treatment.
7.1.6.2
Efficacy follow up
Patients who discontinue study treatment for reasons other than disease progression, death 
start of new anti-neoplastic therapies, lost to follow-up, or withdrawal of consent to efficacy 
follow-up will continue to have radiological tumor assessments every 8 weeks (± 7 days) until 
6 months after last patient in the same cohort has started the study treatment, or until disease 
progression , start of a new antineoplastic therapy, death, lost to follow-up, withdrawn consent 
to efficacy follow-up, whichever comes first.
At the time the patient discontinues the efficacy follow-up period, the Study Evaluation 
Completion page should be completed. In case the patient starts a new antineoplastic therapy, 
this will be recorded on the Antineoplastic therapies since discontinuation of study treatment 
CRF page.
7.1.6.3
Survival follow up
All patients who discontinue study treatment and are no longer followed radiologically will be 
contacted for survival information every 12 weeks (± 7 days) from the time of the End of 
Treatment (EoT) visit or, where applicable, from the last visit in the efficacy follow-up period 
until death. Further, patients who refuse to return for scheduled visits or are unable to do so 
should be asked to consent for survival follow-up. If applicable, the date of death should be 
captured on the End of Treatment page, Study Evaluation Completion, or Survival Follow Up
(whichever is applicable) page in the eCRF.

Novartis
Confidential
Page 78
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
The survival follow-up period will continue for 6 months after the last patient in the same 
cohort has started the study treatment, or until all patients in the same cohort have 
discontinued efficacy follow up, whichever comes first.
7.2
Assessment types
7.2.1
Efficacy assessments
The primary efficacy endpoint is the overall response rate, as defined in Section 10.4.1. 
Secondary efficacy endpoints are duration of response, progression-free survival and overall 
survival as defined in Section 10.5.2.
Response will be evaluated, using modified criteria for malignant lymphoma (adapted from 
Cheson et al 1999 and Cheson et al 2007). PET scan will not be used in this study, as it is not 
yet widely accepted by clinicians and regulatory agencies for assessing response to treatment 
of NHLs, and it may not be available in all of the participating centers. Otherwise, response 
criteria will generally follow the CT scan recommendations in the later publication (Cheson et 
al 2007). Further clarification on these criteria has been published by (Cheson 2007b). MRI 
will be allowed only in those cases when CT scan cannot be performed. For complete details, 
refer to Appendix 5.
Clinical evaluation and tumor assessments will be performed periodically, as is indicated in 
Table 7-1, based on physical examination, radiological evaluation and core bone marrow 
biopsy (only to confirm complete responses in patients with bone marrow tumor involvement 
prior to study treatment). Tumor assessments will be performed every 2 cycles (every 8 weeks 
±7 days). Clinical suspicion of disease progression at any time will require a physical 
examination and radiological confirmation to be performed promptly, rather than waiting for
the next scheduled tumor assessment. In case of an unscheduled or delayed tumor assessment
for any reason, subsequent tumor assessments must be performed according to the originally
planned schedule from baseline.
7.2.1.1
Physical examination
Tumor assessment by physical examination and evaluation of disease related B symptoms 
(unexplained fever of ≥ 38°C; unexplained, recurrent drenching night sweats; or unexplained 
loss of >10% body weight within the previous 6 months) will be performed and recorded 
following the schedule for radiological tumor assessments.
7.2.1.2
Radiological tumor assessment
At screening, all patients must have a CT scan with contrast of the Chest/Abdomen and Pelvis. 
The same type of CT scan used at screening must be used for all subsequent assessments. 
MRI with contrast will be allowed only in those cases when CT scan cannot be performed and 
will be used at baseline and all subsequent assessments in these patients. No modality change 
would be allowed during the study. Only in exceptional cases when during the study a patient 
develops intolerance to the CT scan contrast medium, a CT scan without contrast will be 
acceptable to avoid modality change. At screening, tumor assessments should preferably be 
performed ≤ 7 days prior to the first dose of BKM120, however tumor assessments ≤ 28 days 
prior to first dose of study drug will be acceptable.

Novartis
Confidential
Page 79
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
CT Scans of the Chest/Abdomen and Pelvis will be performed following completion of every 
2 cycles. It may also be performed as clinically indicated. For visit schedule refer to 
Table 7-1. Any patient who has been discontinued from treatment with BKM120 for any 
reason other than death or loss to follow-up (i.e., documented disease progression by the 
investigator, an AE or SAE, administrative reason, withdrawal of consent from treatment, etc.) 
will continue to have tumor assessments as per their current schedule until the initiation of a 
new anticancer therapy. The response CRFs are expected to continue being completed in a 
timely fashion. The investigator or his/her designee will collect information on a new 
anticancer therapy, given after the last dose of study drug, and record the information on the 
appropriate eCRF. All patients should have at least one site of measurable nodal disease > 2.0 
cm in the longest transverse diameter and clearly measurable in at least two perpendicular 
dimensions, as determined by CT scan (MRI is allowed only if CT scan cannot be performed). 
Complete guidance for selecting index lesions is provided in Appendix 5. Index lesions will 
be measured and recorded at baseline and during the course of the study. They should be 
selected on the basis of their size and suitability for accurate repeat measurements. Skin 
lesions, if the area is ≥ 2 cm in at least one diameter, must be histologically conformed for 
lymphoma involvement (the site must document the histological confirmation (yes or no) to 
the corresponding CRF) and photographed (color photography using digital camera) 
(optional).
A sum of the product of diameters (SPD) for lesions measured prior to study treatment will be 
calculated and reported at baseline.
Conventional CT and MRI should be performed with contiguous cuts of 7.5 mm or less in 
slice thickness. Spiral CT should be performed using a 5 mm or less contiguous 
reconstruction algorithm (this specification applies to tumors of the chest, abdomen and 
pelvis).
If a very small lesion can not be reliably measured because of its size, it is recommended to 
enter the minimum lesion size (i.e., 5 mm for spiral CT). In other cases where the lesion 
cannot be reliably measured for reasons other than its size (i.e., borders of the lesion are 
confounded by neighboring anatomical structures), no measurement should be entered and the 
lesion cannot be evaluated.
Any measurable extranodal lesions (organs other than lymph nodes) that resolves from 
baseline (disappear completely) must be assigned a size of 0 mm when documenting on the 
corresponding eCRFs. An extranodal lesion must be ≥ 1 cm x 1 cm to be considered 
measurable. Refer to Appendix 5 for complete reporting guidelines.
7.2.1.3
Bone marrow assessment
Information on the patient bone marrow involvement prior to study entry must be present in 
his/her source documents. Prior tumor bone marrow involvement should be entered on the 
corresponding eCRF.
Core bone marrow biopsy is required to confirm Complete Responses (at the first occurrence 
of radiological and clinical evidence of CR) in patients with bone marrow tumor involvement 
prior to study treatment who achieve Complete Response based on clinical and radiological 
evidence. The biopsy sample on which this determination is made must be adequate (with a 

Novartis
Confidential
Page 80
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
goal of > 20 mm unilateral core). Bone marrow biopsy should be obtained no later than at the 
next visit immediately following clinical and radiological evidence of CR (i.e. < 28 days ± 7 
days from the date of the radiological assessment, on which the CR is based on).
7.2.2
Safety and tolerability assessments
Safety assessments will be monitored by assessing all adverse events, concomitant 
medications, and the regular monitoring of laboratory tests (including glucose monitoring), 
physical examinations, weight, vital signs, as well as collecting of the adverse events at every 
visit. For details on AE collection and reporting, refer to Section 8.
7.2.2.1
Physical examination
The clinical examination comprises a total body examination that should include general 
appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, 
back, lymph-nodes, and extremities, vascular and neurological. If indicated; rectal, external 
genitalia, breast and pelvis exams will be performed.
Clinical examinations will be performed on the scheduled day, even if study medication is 
being withheld. More frequent examinations may be performed at the investigator’s discretion 
and/or if medically indicated.
Evaluation of ocular signs and symptoms is recommended as part of the physical examination 
throughout the study. In case a patient develops symptoms such as tearing, ocular redness, 
pain, photophobia or altered vision, the possibility of a drug-induced effect should be 
considered. To ensure appropriate diagnosis and management, and to avoid potential 
complications, referral to an ophthalmologist may be required.
Information about the physical examination must be present in the source documentation at 
the study site. Significant findings those were present prior to the signing of informed consent 
must be included in the Relevant Medical History/Current Medical Conditions page on the 
patient’s eCRF. Significant new findings that begin or worsen after informed consent must be 
recorded on the Adverse Event page of the patient’s eCRF.
7.2.2.2
Vital signs
Vital signs assessments include body temperature, sitting blood pressure, and sitting pulse. 
Vital signs should be assessed on the scheduled day even if study treatment is being withheld. 
More frequent examinations may be performed at the investigator’s discretion, if medically 
indicated. If the vital signs are determined during screening ≤ 7 days before the first dose of 
study treatment, it does not need to be repeated on Day 1 of Cycle 1.
7.2.2.3
Height and weight
Weight will be performed at screening, on Day 1 Cycle 1, on Day 1 of every subsequent 
treatment Cycle, as clinically indicated and at the End of treatment. Height will be measured 
and recorded at screening only. If weight is determined during screening ≤ 7 days before the 
first dose of study treatment, it does not need to be repeated on Day 1 of Cycle 1.

Novartis
Confidential
Page 81
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
7.2.2.4
Performance status
The baseline ECOG performance status will be assessed and recorded at screening, on Day 1 
Cycle 1, on Day 1 of every subsequent treatment Cycle, and at the End of Treatment. If the 
ECOG performance status is determined during screening ≤ 7 days before the first dose of 
study treatment, it does not need to be repeated on Day 1 of Cycle 1.
The ECOG scale and criteria allows patients to be classified, based on evaluation of patient’s 
disease progression, how the disease affects the daily living abilities of the patient, and allows 
the determination of appropriate treatment and prognosis. The definition of scores in relation 
to the performance status is given in Table 7-3.
Table 7-3
ECOG performance scale
Grade
ECOG
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light housework, office work.
2
Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more 
than 50% of waking hours.
3
Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.
4
Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
5
Death
As published by (Oken et al 1982). Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair.
7.2.2.5
Laboratory evaluations
The standard clinical laboratory analyses described below are to be performed by the study 
site’s local laboratories according to the Visit Schedule, outlined in Table 7-1. Novartis will 
be provided with a copy of the laboratory certification and tabulation of the normal ranges for 
each parameter required at study start and should be kept apprised of any updates on an 
ongoing basis. In addition, if at any time a patient has laboratory parameters obtained from a 
different outside laboratory, Novartis must be provided with a copy of the certification and a 
tabulation of the normal ranges for that laboratory.
The investigator is responsible for reviewing all laboratory reports for patients in the study 
and evaluating any abnormalities for clinical significance. At any time during the study, 
abnormal laboratory parameters that are clinically relevant (e.g., require dose modification 
and/or interruption of study drug, lead to clinical symptoms or signs, or require therapeutic 
intervention), whether specifically requested in the protocol or not, must be recorded on the 
Adverse events CRF.
Laboratory data will be summarized using the Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.03.
Local laboratory tests will be collected and analyzed on the scheduled day, even if study 
medication is being held. More frequent examinations may be performed at the investigator’s 
discretion if medically indicated; those results should be recorded on the Unscheduled Visit 
CRF.

Novartis
Confidential
Page 82
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Laboratory assessments performed as part of the screening evaluations and within 7 days of 
the first dose of study drug, will not be required to be repeated on Day1 of Cycle 1.
In the event of grade 2, grade 3 or grade 4 hematological toxicities that require study drug 
dose modifications or interruptions, hematological tests must be repeated until recovery to the 
baseline value or grade 1.
Hepatotoxicity follow-up testing will be performed when needed (refer to Section 6.3.2.2).
Table 7-4
Clinical laboratory parameters collection plan
Test Category
Test Name
*Viral hepatitis serologic 
tests and other tests for 
hepatotoxicity follow-up *
HAAb, HBsAg, HBsAb HBcAb, HCV RNA or HDV RNA (where needed), HEAb, 
CMVAb, EBcAb, ALP, CPK, LDH, WBC (eosinophilia), and others.
* Hepatotoxicity follow-up testing/procedures will be performed locally (refer to Section 6.3.2.2 and 
Section 7.2.2.5.8).
7.2.2.5.1 Hematology
Hematology includes the following parameters: complete blood count consisting of a white 
blood cell (WBC) count with differential (total neutrophils [including bands], lymphocytes, 
monocytes, eosinophils, basophils), hemoglobin (Hgb), and platelet counts.
Hematological tests will be performed at screening, on Cycle 1 Day 1 (prior to administration 
of the study drug) and repeated on Day 1 of every subsequent treatment Cycle and at the End 
of Treatment. Hematology test may also be performed as medically necessary.
7.2.2.5.2 Clinical chemistry
Clinical chemistry includes the following parameters:

Potassium, sodium, calcium, magnesium, chloride, inorganic phosphorus

ALT/SGPT, AST/SGOT, alkaline phosphatase, total bilirubin, direct bilirubin, LDH, 
Gamma GT

Serum creatinine, urea or blood urea nitrogen (BUN), lipase, albumin, uric acid

Fasting plasma glucose (fasting is defined as no caloric intake for at least 8 hrs).
Clinical chemistry will be performed at screening, on Cycle 1 Day 1 (prior to administration 
of study drug), repeated on Day 1 of every subsequent treatment cycle and at End of 
Treatment. Chemistry tests may also be performed as clinically indicated. Patients with 
diffuse large B-cell lymphoma will require additional evaluations of the following parameters 
on days 2, 3 and 4 in the first treatment cycle to monitor for TLS:

Uric acid, potassium, sodium, calcium, inorganic phosphorus and serum creatinine
7.2.2.5.3 Coagulation
The coagulation profile includes partial thromboplastin time (PTT) and either prothrombin 
time (PT) or International normalized ratio (INR).
Coagulation profile will be performed at screening, on Cycle 1 Day 1 (prior to administration 
of study drug) and as clinically indicated.

Novartis
Confidential
Page 83
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
7.2.2.5.4 Lipid panel
The patient must be fasting when blood is drawn for lipid panel. Lipid panel includes total-, 
LDL- and HDL-cholesterol and triglycerides.
Lipid panel will be performed at screening, on Cycle 1 Day 1 (prior to administration of study 
drug, on Day 1 of Cycle 3, every 2nd cycle thereafter (i.e. Day 1 of Cycle 5, Day 1 of Cycle 7, 
etc.) and at End of Treatment.
7.2.2.5.5 C-peptide and HbA1c
The patient must be fasting when blood is drawn for C-peptide and HbA1c analysis. Analysis 
should be performed prior to BKM120 administration.
C-peptide and HbA1c testing will be performed at screening, on Cycle 1 Day 1 (prior to 
administration of study drug), on Day 1 of Cycle 3, every 2nd cycle thereafter (i.e. Day 1 of 
Cycle 5, Day 1 of Cycle 7, etc.) and at End of Treatment.
7.2.2.5.6 Urinalysis
Not applicable.
7.2.2.5.7 Pregnancy and assessments of fertility
Pregnancy tests are indicated for all females of childbearing potential. Serum tests are 
required at screening, on Cycle 1 Day 1 (prior to administration of study drug) and repeated 
on Day 1 of every subsequent treatment cycle and at End of Treatment. Additional serum 
pregnancy tests should be performed as soon as indicated in case the patient is suspected to be 
pregnant.
In case of pregnancy, the patient must immediately be withdrawn from study treatment. Each 
pregnancy in a patient on study drug must be reported to the sponsor within 24 hours of 
learning of its occurrence. See Section 8.4 for detailed reporting and follow up procedures.
Note: Women are considered post-menopausal and not of child bearing potential if any of the 
following conditions is fulfilled:

Prior surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at 
least six weeks ago.

Age ≥60

Age < 60 and amenorrhea for 12 or more months (in the absence of chemotherapy), and 
FSH and estradiol in the postmenopausal range (serum FSH > 40 mIU/mL and estradiol 
<20 pg/mL or according to the postmenopausal range definition for the laboratory 
involved).

Novartis
Confidential
Page 84
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
7.2.2.5.8 Viral hepatitis serology and other tests for hepatotoxicity follow-up
Viral hepatitis serologic tests are performed confirm patient’s eligibility when needed per 
clinical judgment and specific patient’s clinical circumstances.
During study treatment, viral hepatitis serologic and other tests will be performed as per the 
guidelines of management of hepatotoxicity (ALT or AST >3.0x ULN and total bilirubin > 
2.0x ULN) in patients receiving BKM120, refer to Section 6.3.2.2 for details.
Viral hepatitis serology includes the following:

Hepatitis A IgM antibody and hepatitis A serology total

Hepatitis B surface antigen, Hepatitis B Core Antibody (IgM) and viral DNA

Hepatitis C serology and viral RNA

Hepatitis D RNA (where needed)

Hepatitis E IgM and IgG antibody and viral RNA
Obtain fractionated bilirubin, serum Alkaline Phosphatase (ALP), creatine phosphokinase 
(CPK), lactate dehydrogenase (LDH), and blood count with differential to assess eosinophilia.
Additional viral serology tests may include:

Cytomegalovirus IgM antibody

Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain heterophile 
antibody or monospot testing)

Herpes Simplex Virus
7.2.2.6
Radiological examinations
Not applicable.
7.2.2.7
Cardiac assessments
7.2.2.7.1 Electrocardiogram (ECG)
The study requires standard 12-lead digital ECG as indicated in Table 7-1. Pre-dose ECGs 
must be performed prior to any study drug administration on the respective days.
Single ECG should generally be done prior to any blood draws.
ECGs will be performed at screening, on Cycle 1 Day 1 (prior to administration of study 
drug), repeated on Day 1 of every subsequent treatment cycle and at End of Treatment. ECGs 
may be repeated more frequently at the investigator’s discretion if signs and symptoms of 
cardio-toxicity exist. If an ECG is performed for screening ≤ 7 days before the first dose of 
study treatment, it does not need to be repeated on Day 1 of Cycle 1.
Clinically significant findings must be discussed with the sponsor prior to enrolling the patient 
in the study. New or worsened clinically significant findings occurring after informed consent 
must be recorded on the Adverse Events CRF page.

Novartis
Confidential
Page 85
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
7.2.2.7.2 Cardiac imaging - MUGA (multiple gated acquisition) scan or 
echocardiogram
MUGA (multiple gated acquisitions) scan or echocardiogram (ECHO) will be used to assess 
LVEF at screening.
LVEF assessment may be performed as clinically indicated at the investigator’s discretion if 
there are signs or symptoms of cardiotoxicity. In case of clinically significant abnormalities, 
they should be reported on the Adverse Events CRF.
7.2.2.8
Patient self-rating mood questionnaire
The Patient Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7) will 
be collected to screen patients for study eligibility and to aid in the identification and severity 
assessment of potential mood alterations. The PHQ-9 and GAD-7 are validated (Kroenke et al 
2001, Spitzer et al 2006, Spitzer et al 1999), patient self-administered questionnaires 
developed for use in clinical practices.
The GAD-7 (Table 7-6) is a one-dimensional questionnaire consisting of 7 questions. 
Similarly to the PHQ-9, in the GAD-7, patients are asked to indicate how often, over the past 
2 weeks, they have been bothered by each of the seven core symptoms of generalized anxiety 
disorder as referenced in the DSM IV. Response options are ‘‘not at all,’’ ‘‘several days,’’ 
‘‘more than half the days,’’ and ‘‘nearly every day,’’ scored as 0, 1, 2, and 3, respectively. 
The sum of all seven questions calculate the total GAD-7 score. Therefore, GAD-7 scores 
range from 0 to 21.
The PHQ-9 (Table 7-7) consists of 9 questions that assess anhedonia, depressed mood, sleep, 
energy, appetite, guilt and worthlessness, concentration, feeling slowed down or restlessness, 
and suicidal thoughts. For each of these questions, patients are asked to rate how much over 
the past 2 weeks they have been bothered by the symptom. Scoring of the PHQ-9 is based on 
a Likert-type scale from 0 to 3 (0 indicates not at all; 1, several days; 2, more than half the 
days; 3, nearly every day). The sum of all nine questions is used to determine a total PHQ-9 
score ranging from 0 to 27.
The patient must complete two different mood questionnaires, (PHQ-9 and GAD-7) at 
Screening, Cycle 1 Day 1, and Day 1 of each subsequent cycle in addition to the EOT visit. If 
the questionnaires are completed as part of screening ≤ 7 days before the first dose of study 
treatment, they do not need to be repeated on Day 1 of Cycle 1. Sites should instruct patients 
to complete the mood questionnaires prior to administration of any study-related treatment or 
clinical assessments or procedure. Additional assessments may be done according to the 
clinical judgment of the investigator.
All questionnaires should be administered in the patient’s local language at the beginning of 
the study visit prior to any interaction with the study investigator including any tests, 
treatments or receipt of results from any tests to avoid biasing the patient’s perspective. This 
is to avoid potentially biasing patients or their responses to study questionnaires.
Patients should be given sufficient space and time to complete all study questionnaires and all 
administered questionnaires should be reviewed for completeness. If missing responses are 
noted, patients should be encouraged to complete any missing responses. Attempts should be 

Novartis
Confidential
Page 86
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
made to collect responses to all questionnaires for all patients, including from those who 
discontinue prior to the study evaluation completion visit, however, if patients refuse to 
complete questionnaires, this should be documented in study source records.
Completed questionnaires, including both responses to the questions and any unsolicited 
comments written by the patient, must be reviewed and assessed by the investigator before the 
clinical examination for responses which may indicate potential AEs or SAEs. This review 
should be documented in study source records.
If an AE or SAE is confirmed then the physician should record the event as instructed in 
Section 8 of this protocol. Investigators should not encourage the patients to change responses 
reported in questionnaires.
The severity classification table described in Table 7-5 for the PHQ-9 and GAD-7 will be 
used in this study to increase the sensitivity of identifying potential anxiety and/or depression 
disorders. During the study, questionnaire scores and corresponding severity classification can 
be used to aid the investigator in identifying new or worsening of events. Importantly, grading 
must be based on the clinical interpretation of severity according to the NCI-CTCAE (v 4.03).
Table 7-5
Classification of severity based on mood questionnaire scores
PHQ-9 (depression)
GAD-7 (anxiety)
Score
Severity
Score
Severity
0-4
None
0-4
None
5-9
Mild
5-9
Mild
10-19
Moderate
10-14
Moderate
20-27
Severe
≥ 15
Severe
At Screening, a patient may be judged by the investigator or a psychiatrist to be ineligible 
based on medical mental health history as listed in the exclusion criteria. Alternatively, 
patients who score ≥ 12 on the PHQ-9 or ≥ 15 on the GAD-7 mood scale, respectively, or 
select a positive response of ‘1, 2, or 3’ to question number 9 regarding suicidal thoughts or 
ideation will be excluded from the study.
A timely interview with the patient after the questionnaire completion is recommended.
During the treatment phase, patients who indicate a positive response by selecting ‘1, 2, or 3’ 
to question number 9 in the PHQ-9 and/or present with suicidal ideation must interrupt
treatment with study drug and must be referred for psychiatric consultation for appropriate 
psychotropic management regardless of the total questionnaire score or CTCAE grading and 
to confirm if study drug should be interrupted or permanently discontinued. In this specific 
case, the psychiatric advice can overrule the patient PHQ-9 self-assessment. If question 9 on 
the PHQ-9 was not answered, or the whole questionnaire was not answered, the investigator 
must assess the patient for suicidal ideation. If the investigator identifies suicidal ideation, 
then study drug must be interrupted and the patient referred for psychiatric consultation for 
assessment.
Investigators must not encourage the patients to change responses reported in questionnaires. 
Guidelines on how to instruct the patient to complete the questionnaires as well as how to 
determine the scores will be provided with each instrument. Dosing modification guidelines 

Novartis
Confidential
Page 87
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
for BKM120 are provided in Table 6-3. For additional information on AE reporting, please 
refer to Section 8.1.
Table 7-6
GAD-7 anxiety scale
Over the last 2 weeks, how often have you 
been bothered by the following problems?
(Use “✔” to indicate your answer”
Not at 
all
Several 
days
More than
half the 
days
Nearly 
every 
day
1. Feeling nervous, anxious or on edge
0
1
2
3
2. Not being able to stop or control worrying
0
1
2
3
3. Worrying too much about different things
0
1
2
3
4. Trouble relaxing
0
1
2
3
5. Being so restless that it is hard to sit still
0
1
2
3
6. Becoming easily annoyed or irritable
0
1
2
3
7. Feeling afraid as if something awful might 
happen
0
1
2
3
Column totals:
+
+
+
= Total Score
Table 7-7
PHQ-9 depression scale
Over the last 2 weeks, how often have you been 
bothered by any of the following problems?
(Use “✔” to indicate your answer”
Not at 
all
Several 
days
More 
than half 
the days
Nearly 
every
day
1. Little interest or pleasure in doing things
0
1
2
3
2. Feeling down, depressed, or hopeless.
0
1
2
3
3. Trouble falling or staying asleep, or sleeping too 
much
0
1
2
3
4. Feeling tired or having little energy.
0
1
2
3
5. Poor appetite or overeating
0
1
2
3
6. Feeling bad about yourself - or that you are a failure 
or have let yourself or your family down
0
1
2
3
7. Trouble concentrating on things, such as reading the 
newspaper or watching television.
0
1
2
3
8. Moving or speaking so slowly that other people could 
have noticed? Or the opposite - being so fidgety or 
restless that you have been moving around a lot more 
than usual
0
1
2
3
9. Thoughts that you would be better off dead or of 
hurting yourself in some way
0
1
2
3
Column totals:
+
+
+
= Total Score _____
If you checked off any problems, how difficult have these problems made it for you to do your work, take care of 
things at home, or get along with other people?
Not difficult
at all
Somewhat
difficult
Very
Difficult
Extremely
Difficult

Novartis
Confidential
Page 88
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

Novartis
Confidential
Page 89
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

Novartis
Confidential
Page 90
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
7.2.4
Other assessments
No additional tests will be performed on patients entered into this study.
8
Safety monitoring and reporting
8.1
Adverse events
8.1.1
Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient’s signed 
informed consent has been obtained. Abnormal laboratory values or test results occurring 
after informed consent constitute adverse events only if they induce clinical signs or 
symptoms, are considered clinically significant, require therapy (e.g., hematologic 
abnormality that requires transfusion or hematological stem cell support), or require changes 
in study medication(s).

Novartis
Confidential
Page 91
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events CRF. Conditions that were already present at the time of informed consent should be 
recorded in the Medical History CRF. Adverse event monitoring should be continued for at 
least 30 days following the last dose of study treatment. Adverse events (including lab 
abnormalities that constitute AEs) should be described using a diagnosis whenever possible, 
rather than individual underlying signs and symptoms. When a clear diagnosis cannot be 
identified, each sign or symptom should be reported as a separate Adverse Event.
Adverse events will be assessed according to the Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the 
severity of mild, moderate, severe, and life-threatening, corresponding to grades 1 - 4, will be 
used. CTCAE grade 5 (death) will not be used in this study; rather, information about deaths 
will be collected through the EOT/SEC/Survival Information eCRF pages.
The occurrence of adverse events should be sought by non-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study. Adverse events also may be detected when they are volunteered by the patient 
(subject) during the screening process or between visits, or through physical examination, 
laboratory test, or other assessments. As far as possible, each adverse event should be 
evaluated to determine:
1. The severity grade (CTCAE grade 1-4)
2. Its duration (Start and end dates)
3. Its relationship to the study treatment (Reasonable possibility that AE is related: No, Yes)
or
Its relationship to the study treatment (Reasonable possibility that AE is related: No,
Yes, investigational treatment, Yes, the study treatment (non-investigational), Yes, both 
and/or indistinguishable)
4. Action taken with respect to study or investigational treatment (none, dose adjusted, 
temporarily interrupted, permanently discontinued, unknown, not applicable)
5. Whether medication or therapy taken (no concomitant medication/non-drug therapy, 
concomitant medication/non-drug therapy)
6. Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
7. Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
All adverse events should be treated appropriately. If a concomitant medication or non-drug 
therapy is given, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently, if 
necessary) of any changes in severity, the suspected relationship to the study treatment, the 
interventions required to treat it, and the outcome.
Progression of malignancy (including fatal outcomes), if documented by use of appropriate 
method (Cheson criteria), should not be reported as a serious adverse event.
Adverse events separate from the progression of malignancy (example, deep vein thrombosis 
at the time of progression or hemoptysis concurrent with finding of disease progression) will 

Novartis
Confidential
Page 92
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.2
Laboratory test abnormalities
8.1.2.1
Definitions and reporting
Laboratory abnormalities that constitute an Adverse event in their own right (are considered 
clinically significant, induce clinical signs or symptoms, require concomitant therapy or 
require changes in study treatment), should be recorded on the Adverse Events CRF. 
Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia 
instead of low hemoglobin). Laboratory abnormalities that meet the criteria for Adverse 
Events should be followed until they have returned to normal or an adequate explanation of 
the abnormality is found. When an abnormal laboratory or test result corresponds to a 
sign/symptom of an already reported adverse event, it is not necessary to separately record the 
lab/test result as an additional event.
Laboratory abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A grade 3 or 4 event (severe) as per CTCAE does not 
automatically indicate a SAE unless it meets the definition of serious as defined below and/or 
as per investigator’s discretion. A dose hold or medication for the lab abnormality may be 
required by the protocol in which case the lab abnormality would still, by definition, be an 
adverse event and must be reported as such.
8.2
Serious adverse events
8.2.1
Definitions

Serious adverse event (SAE) is defined as one of the following:

Is fatal or life-threatening

Results in persistent or significant disability/incapacity

Constitutes a congenital anomaly/birth defect

Is medically significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above

Requires inpatient hospitalization or prolongation of existing hospitalization,

Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:

Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition

Elective or pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent

Social reasons and respite care in the absence of any deterioration in the patient’s 
general condition

Note that treatment on an emergency outpatient basis that does not result in hospital 
admission and involves an event not fulfilling any of the definitions of a SAE given above 
is not a serious adverse event

Novartis
Confidential
Page 93
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Protocol specific SAE: any Hy’s law case of drug-induced liver toxicity should be reported as 
an SAE, even when assessed non-serious by the investigator. These reports will always be 
assessed as medically significant by Novartis in the absence of any other seriousness criteria.

Protocol exempt SAEs: Progression of malignancy (including fatal outcomes), if 
documented by use of appropriate method (Cheson criteria), should not be reported as a 
serious adverse event.
8.2.2
Reporting
To ensure patient safety, every SAE, regardless of suspected causality, occurring after the 
patient has provided informed consent and until at least 30 days after the patient has stopped 
study treatment must be reported to Novartis within 24 hours of learning of its occurrence. 
Any SAEs experienced after this 30 days period should only be reported to Novartis if the 
investigator suspects a causal relationship to the study treatment. Recurrent episodes, 
complications, or progression of the initial SAE must be reported as follow-up to the original 
episode within 24 hours of the investigator receiving the follow-up information. An SAE 
occurring at a different time interval or otherwise considered completely unrelated to a 
previously reported one should be reported separately as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study treatment (if there is more than one study treatment), complete the SAE Report 
Form in English, and send the completed, signed form by fax within 24 hours Novartis.
The telephone and telefax number of the contact persons in the local department of Drug 
Safety and Epidemiology (DS&E), specific to the site, are listed in the investigator folder 
provided to each site. The original copy of the SAE Report Form and the fax confirmation 
sheet must be kept with the case report form documentation at the study site.
Follow-up information is sent to the same contact(s) to whom the original SAE Report Form 
was sent, using a new SAE Report Form stating that this is a follow-up to the previously 
reported SAE and giving the date of the original report. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow-up to that event regardless of 
when it occurs. The follow-up information should describe whether the event has resolved or 
continues, if and how it was treated, whether the blind was broken or not, and whether the 
patient continued or withdrew from study participation.
If the SAE is not previously documented in the [Investigator’s Brochure] or Package Insert 
(new occurrence) and is thought to be related to the Novartis study treatment, an oncology 
Novartis Drug Safety and Epidemiology (DS&E) department associate may urgently require 
further information from the investigator for Health Authority reporting. Novartis may need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse 
Reactions (SUSARs) will be collected and reported to the competent authorities and relevant 
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in participating countries.

Novartis
Confidential
Page 94
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
8.3
Emergency unblinding of treatment assignment
Not applicable.
8.4
Pregnancies
To ensure patient safety, each pregnancy occurring while the patient is on study treatment 
must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary termination, 
details of the birth, and the presence or absence of any birth defects, congenital abnormalities, 
or maternal and/or newborn complications.
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by the 
investigator to the oncology Novartis Drug Safety and Epidemiology Department (DS&E). 
Pregnancy follow-up should be recorded on the same form and should include an assessment 
of the possible relationship to the Novartis study treatment of any pregnancy outcome. Any 
SAE experienced during pregnancy must be reported on the SAE Report Form.
Pregnancy outcomes must be collected for the female partners of any males who took study
drug in this study. Consent to report information regarding these pregnancy outcomes should 
be obtained from the female partner.
8.5
Warnings and precautions
No evidence available at the time of the approval of this study protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided 
[Investigator’s Brochure]. Additional safety information collected between IB updates will be 
communicated in the form of Investigator Notifications. This information will be included in 
the patient informed consent and should be discussed with the patient during the study as 
needed.
8.6
Data Monitoring Committee
Not applicable.
8.7
Steering Committee
The Steering Committee will be established comprising investigators participating in the trial, 
i.e. not being Novartis representatives from the Clinical Trial Team.
The Steering Committee will ensure transparent management of the study according to the 
protocol through recommending and approving modifications as circumstances require. The 
Steering Committee will review protocol amendments as appropriate. Together with the 
clinical trial team, the Steering Committee will also develop recommendations for 
publications of study results including authorship rules. The details of the role of the Steering 
Committee will be defined in a Steering Committee charter.

Novartis
Confidential
Page 95
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
9
Data collection and management
9.1
Data confidentiality
Information about study subjects will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:

What protected health information (PHI) will be collected from subjects in this study

Who will have access to that information and why

Who will use or disclose that information

The rights of a research subject to revoke their authorization for use of their PHI.
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) 
at the end of their scheduled study period.
The data collection system for this study uses built-in security features to encrypt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually assigned 
user identification codes and passwords, made available only to authorized personnel who 
have completed prerequisite training.
Prior to entering key sensitive personally identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify that this data is allowed to be collected. If 
the site indicates that country rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the subject satisfies protocol age requirements 
and to enable appropriate age-related normal ranges to be used in assessing laboratory test 
results.
9.2
Site monitoring
Before study initiation, at a site initiation visit or at an investigator’s meeting, Novartis 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study, the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study, consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed copy is given to the patient).

Novartis
Confidential
Page 96
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency with the CRF entries. Novartis monitoring standards require full verification 
for the presence of informed consent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency of the source data with the 
CRFs are performed according to the study-specific monitoring plan.
9.3
Data collection
This study will be using Electronic Data Capture (EDC), the designated investigator staff will 
enter the data required by the protocol into the Electronic Case Report Forms (eCRF). The 
eCRFs have been built using fully validated secure web-enabled software that conforms to 21 
CFR Part 11 requirements, Investigator site staff will not be given access to the EDC system 
until they have been trained. Automatic validation programs check for data discrepancies in 
the eCRFs and, allow modification or verification of the entered data by the investigator staff.
The Principal Investigator is responsible for assuring that the data entered into eCRF is 
complete, accurate, and that entry and updates are performed in a timely manner.
9.4
Database management and quality control
Novartis personnel (or designated CRO) will review the data entered by investigational staff 
for completeness and accuracy. Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly to queries and to make any necessary changes to the data.
Concomitant treatments entered into the database will be coded using the WHO Drug 
Reference List, which employs the Anatomical Therapeutic Chemical classification system. 
Medical history/current medical conditions and adverse events will be coded using the 
Medical dictionary for regulatory activities (MedDRA) terminology.
Biomarker samples and/or data will be processed centrally and the results will be sent 
electronically to Novartis (or a designated CRO).
After database lock, the investigator will receive a CD-ROM or paper copies of the patient 
data for archiving at the investigational site.
10
Statistical methods and data analysis
The trial will include at least N = 66 subjects, i.e. N = 22 patients in each of the three
histologically defined cohorts: mantle cell lymphoma, follicular lymphoma and diffuse large 
B-cell lymphoma. Maximum number of patients per cohort will be capped at N = 28 patients, 
in case of over enrollment. The final analysis for each cohort will be performed when all 
included patient in a cohort have finished their 6 month assessment or discontinued early.
The data will be summarized with respect to demographic and baseline characteristics, 
efficacy observations and measurements, and safety observations and measurements. 
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented.

Novartis
Confidential
Page 97
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
If not specified otherwise, all statistical tests will use a significance level of 5% and 95% 
confidence intervals will be calculated.
10.1
Analysis sets
10.1.1
Full Analysis Set
The Full Analysis Set (FAS) comprises all included patients who received at least one dose of 
study treatment. As a consequence, the FAS excludes screened patients who were not 
administered study treatment but were intended to be treated.
10.1.2
Safety Set
The Safety Set includes all patients who received at least one dose of study medication and 
who have at least one post baseline safety assessment.
Note: The statement that a patient had no adverse events (on the Adverse Event CRF page) 
constitutes a safety assessment.
10.1.3
Per Protocol Set
The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who received at 
least one dose of the study treatment and who have no major protocol deviations.
Oncology standards for major protocol deviations potentially leading to exclusion from the 
PPS are:

type of indication different from those required by the clinical study protocol (CSP) (e.g. 
incorrect histology/cytology, not refractory, not metastatic, different grade of cancer, etc.),

if prior therapy does not match with CSP requirements in terms of number and types of 
previous therapy regimens,

missing or incomplete documentation of stage of disease (as required in the CSP),

if ECOG performance status at least 2 categories worse than protocol-defined inclusion 
criteria,

another anti-neoplastic therapy administered after start of study treatment and prior to first 
tumor assessment.
All protocol deviations leading to exclusion from the PPS will be detailed in the report and 
analysis plan (RAP) and validation analysis plan (VAP).
10.1.4
Dose-determining analysis set
Not applicable.
10.1.5
Pharmacokinetic analysis set
Not applicable.

Novartis
Confidential
Page 98
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
10.2
Patient demographics/other baseline characteristics
Demographic and other baseline data including disease characteristics will be summarized 
descriptively by cohort for the FAS. Categorical data will be presented as frequencies and 
percentages. For continuous data, mean, standard deviation, median, 25th and 75th percentiles, 
minimum, and maximum will be presented.
10.3
Treatments (study treatment, concomitant therapies, compliance)
The actual dose and duration in days of BKM120 as well as the dose intensity (computed as 
the ratio of actual dose received and actual duration) and the relative dose intensity (computed 
as the ratio of dose intensity and planned dose received/planned duration), will be listed and 
summarized by means of descriptive statistics in the FAS by cohort. Dose reductions, 
interruptions/delays and increases (including the reasons for these) will be listed and 
summarized by cohort.
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study treatment will be summarized for the safety set by cohort.
10.4
Primary objective
The primary objective of the trial is to determine the efficacy of BKM120 in patients with 
relapsed/refractory Non-Hodgkin Lymphoma in the three histological subgroups (cohorts): 
mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma.
10.4.1
Variable
Overall response rate (ORR) is defined as the proportion of patients with a best overall 
response of CR or PR according to Cheson criteria (Cheson et al 2007).
The ORR is the number of patients in a cohort who experience either complete response (CR) 
or partial response (PR) during their follow-up after treatment start divided by the total
number of patients included in the corresponding cohort. Patients for whom the best response 
after treatment start is missing, ‘UNK’ or ‘PD’ will be considered as non-responders and will 
be counted in the denominator for the estimation of the ORR.
10.4.2
Statistical hypothesis, model, and method of analysis
The analysis for each cohort will be based on an exact binomial test comparing the ORR to 
the reference level of 10% (null hypothesis) in the FAS. The test for each cohort will use a 
significance level of 5%. The ORR will be presented together with an exact 95% Clopper-
Pearson confidence interval.
10.4.3
Handling of missing values/censoring/discontinuations
For the primary analysis of the ORR, patients without any efficacy assessment after treatment 
start will be counted as failures for the FAS analysis. These patients will be excluded from the 
PPS analysis.

Novartis
Confidential
Page 99
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
10.4.4
Supportive analyses
The primary analysis will be repeated on the PPS instead of the FAS.
10.5
Secondary objectives
10.5.1
Key secondary objective(s)
Not applicable.
10.5.2
Other secondary efficacy objectives
Progression-free survival
Progression-free survival (PFS) is defined as the time from the date of treatment start to the 
date of the first documented progressive disease (PD) or death due to any cause. If a patient is 
not known to have progressed or died at the date of the analysis cut-off of the corresponding 
cohort or when he/she receives any further anti-cancer therapy, PFS is censored at the time of 
the last tumor assessment before the cut-off date and before the anti-cancer therapy date. PFS 
will be based on the investigator’s assessment.
PFS will be described using Kaplan-Meier curves with appropriate summary statistics.
Duration of response
Duration of response is defined as the time from the date of first occurrence of CR or PR to 
the date of the first documented progressive disease (PD) or death due to lymphoma. If a 
patient is not known to have progressed or died at the date of the analysis cut-off for the 
corresponding cohort, or when he/she receives any further anti-cancer therapy, duration of 
response is censored at the time of the last tumor assessment before the cut-off date and 
before the anti-cancer therapy date.
Duration of response will be described using Kaplan-Meier curves with appropriate summary 
statistics.
Overall survival
Overall survival (OS) is defined as the time from treatment start to the date of death due to 
any cause. Patients not known to have died will be censored at the date of their last available 
assessment or at the analysis cut-off date whichever comes earlier.
OS will be described using Kaplan-Meier curves with appropriate summary statistics.
10.5.3
Safety objectives
10.5.3.1 Analysis set and grouping for the analyses
For all safety analyses, the safety set will be used. All listings and tables will be presented by 
cohort.
The overall observation period will be divided into three mutually exclusive segments:

Novartis
Confidential
Page 100
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
1. pre-treatment period: from day of patient’s informed consent to the day before first dose 
of study medication
2. on-treatment period: from day of first dose of study medication to 30 days after last dose 
of study medication
3. post-treatment period: starting at day 31 after last dose of study medication.
If dates are incomplete in a way that clear assignment to pre-, on-, post-treatment period 
cannot be made, then the respective data will be assigned to the on-treatment period.
10.5.3.2 Adverse events (AEs)
Summary tables for adverse events (AEs) have to include only AEs that started or worsened 
during the on-treatment period, the treatment-emergent AEs. However, all safety data 
(including those from the pre and post-treatment periods) will be listed and those collected 
during the pre-treatment and post-treatment period are to be flagged.
The incidence of treatment-emergent adverse events (new or worsening from baseline) will be 
summarized by system organ class and or preferred term, severity (based on CTCAE grades), 
type of adverse event, relation to study treatment by cohort. Deaths reportable as SAEs and 
non-fatal serious adverse events will be listed by patient and tabulated by type of adverse 
event and cohort.
Specific safety event categories (SEC) will be considered. Such categories consist of one or 
more well-defined safety events which are similar in nature and for which there is a specific 
clinical interest in connection with the study treatment.
For each specified SEC, number and percentage of patients with at least one event part of the 
SEC will be reported.
10.5.3.3 Laboratory abnormalities
For laboratory tests covered by the Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.03 (see NCI 2009), the study’s biostatistical and reporting team will grade 
laboratory data accordingly. For laboratory tests covered by CTCAE, a grade 0 will be 
assigned for all non-missing values not graded as 1 or higher. Grade 5 will not be used.
In cases (e.g. white blood cell differentials) the lower limits of normal ranges used in CTCAE 
definition have to be replaced by a clinical meaningful limit expressed in absolute counts.
For laboratory tests where grades are not defined by CTCAE, results will be graded by the 
low/normal/high classifications based on laboratory normal ranges.
The following by-treatment summaries will be generated separately for hematology, 
biochemistry and urinary laboratory tests:

frequency table for newly occurring on-treatment grades 3 or 4 (see below for details)

shift tables using CTCAE grades to compare baseline to the worst on-treatment value

for laboratory tests where CTCAE grades are not defined, shift tables using the 
low/normal/high/(low and high) classification to compare baseline to the worst on-
treatment value.

Novartis
Confidential
Page 101
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

listing of all laboratory data with values flagged to show the corresponding CTCAE 
grades and the classifications relative to the laboratory normal ranges.
In addition to the above mentioned tables and listings, other exploratory analyses, for example 
figures plotting time course of raw or change in laboratory tests over time or box plots might 
be specified in the MAP and/or RAP.
10.5.3.4 Other safety data
ECG

shift table baseline to worst on-treatment result for overall assessments

listing of ECG evaluations for all patients with at least one abnormality.
Vital signs
Definitions of notably abnormal results have to be part of the CDP, MAP, CSP and RAP.

shift table baseline to worst on-treatment result

table with descriptive statistics at baseline, one or several post-baseline time points and 
change from baseline to this/these post-baseline time points.
Data from other tests will be listed, notable values flagged, and any other information 
collected will be listed as appropriate. Any statistical tests performed to explore the data will 
be used only to highlight any interesting comparisons that may warrant further consideration.
Mood scales
Mood assessment includes two self-reported mood questionnaires, the GAD-7 Anxiety scale 
and PHQ-9 Depression scale. Shift tables comparing the baseline severity score to worst post-
baseline severity score for each questionnaire will be provided.
10.5.3.5 Supportive analyses for secondary objectives
Not applicable.
10.5.3.6 Tolerability
Not applicable.
10.5.4
Pharmacokinetics
Not applicable.

Novartis
Confidential
Page 102
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

Novartis
Confidential
Page 103
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
10.7
Interim analysis
Not applicable.
10.8
Sample size calculation
The analysis for each cohort will be based on an exact binomial test comparing the ORR to 
the reference level of 10% (null hypothesis). The test for each cohort will use a significance 
level of 5%. Sample size is determined in order to detect a true ORR of 35% with a 
probability of at least 80%. N=22 patients have to be included in each cohort in order to 
ensure this condition. A significant test result is achieved when at least 6 responses are 
observed among the 22 patients corresponding to a minimal observed ORR of 27.3%.
Maximum number of patients per cohort will capped at N = 28 patients, in case of over 
enrollment. The following table provides the minimum number of responses (k) to be 
observed along with the corresponding number of patients enrolled (N) to achieve significant 
test result with corresponding power and observed ORR:

Novartis
Confidential
Page 104
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table 10-1
Rejection criteria and power for different sample sizes
N
k
Power
(%)
Observed
ORR (%)
22
6
83.7
27.3
23
6
86.9
26.1
24
7
78.9
29.2
25
7
82.7
28.0
26
7
85.8
26.9
27
7
88.5
25.9
28
7
90.8
25.0
10.9
Power for analysis of key secondary variables
Not applicable.
11
Ethical considerations and administrative procedures
11.1
Regulatory and ethical compliance
This clinical study was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2
Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properly constituted Institutional Review Board/Independent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study start. A signed and dated statement that the 
protocol and informed consent have been approved by the IRB/IEC/REB must be given to 
Novartis before study initiation. Prior to study start, the investigator is required to sign a 
protocol signature page confirming his/her agreement to conduct the study in accordance with 
these documents and all of the instructions and procedures found in this protocol and to give 
access to all relevant data and records to Novartis monitors, auditors, Novartis Clinical 
Quality Assurance representatives, designated agents of Novartis, IRBs/IECs/REBs and 
regulatory authorities as required.
11.3
Informed consent procedures
Eligible patients may only be included in the study after providing written (witnessed, where 
required by law or regulation), IRB/IEC/REB-approved informed consent or, if incapable of 
doing so, after such consent has been provided by a legally acceptable representative of the 
patient. In cases where the patient’s representative gives consent, the patient should be 
informed about the study to the extent possible given his/her understanding. If the patient is 
capable of doing so, he/she should indicate assent by personally signing and dating the written 
informed consent document or a separate assent form. Informed consent must be obtained 
before conducting any study-specific procedures (i.e. all of the procedures described in the 
protocol). The process of obtaining informed consent should be documented in the patient 

Novartis
Confidential
Page 105
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
source documents. The date when a subject’s Informed Consent was actually obtained will be 
captured in their CRFs.
Novartis will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study and complies with the ICH GCP 
guideline and regulatory requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by Novartis before submission to the IRB/IEC/REB, and a copy of the 
approved version must be provided to the Novartis monitor after IRB/IEC/REB approval.
Women of child bearing potential should be informed that taking the study medication may 
involve unknown risks to the fetus if pregnancy were to occur during the study and agree that 
in order to participate in the study they must adhere to the contraception requirement for the 
duration of the study. If there is any question that the patient will not reliably comply, they 
should not be entered in the study.
11.4
Discontinuation of the study
Novartis reserves the right to discontinue this study under the conditions specified in the 
clinical study agreement. Specific conditions for terminating the study are outlined in 
Section 4.
11.5
Publication of study protocol and results
Novartis assures that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov. In addition, upon study completion and 
finalization of the study report the results of this study will be either submitted for publication 
and/or posted in a publicly accessible database of clinical study results.
11.6
Study documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protection of confidentiality of subjects. As part of participating in a 
Novartis-sponsored study, each site will permit authorized representatives of the sponsor(s) 
and regulatory agencies to examine (and when required by applicable law, to copy) clinical 
records for the purposes of quality assurance reviews, audits and evaluation of the study 
safety and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, hospital 
records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries or 
evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copies or transcriptions certified after verification as being accurate and complete, 
microfiches, photographic negatives, microfilm or magnetic media, x-rays, and subject files 
and records kept at the pharmacy, at the laboratories, and medico-technical departments 
involved in the clinical trial.

Novartis
Confidential
Page 106
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study case report form (CRF) is the primary data collection 
instrument for the study. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported 
on the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF 
should be dated, initialed, and explained (if necessary) and should not obscure the original 
entry. For electronic CRFs an audit trail will be maintained by the system. The investigator 
should retain records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
applicable regulations and/or guidelines. The investigator/institution should take measures to 
prevent accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.7
Confidentiality of study documents and patient records
The investigator must ensure anonymity of the patients; patients must not be identified by 
names in any documents submitted to Novartis. Signed informed consent forms and patient 
enrollment log must be kept strictly confidential to enable patient identification at the site.
11.8
Audits and inspections
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9
Financial disclosures
Financial disclosures should be provided by study personnel who are directly involved in the 
treatment or evaluation of patients at the site - prior to study start.
12
Protocol adherence
Investigators ascertain they will apply due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact Novartis or its agents, if any, monitoring the 
study to request approval of a protocol deviation, as no authorized deviations are permitted. If 
the investigator feels a protocol deviation would improve the conduct of the study this must 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
Novartis and approved by the IRB/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.

Novartis
Confidential
Page 107
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
12.1
Amendments to the protocol
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. 
Only amendments that are required for patient safety may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safety 
of any patient included in this study, even if this action represents a deviation from the 
protocol. In such cases, Novartis should be notified of this action and the IRB/IEC at the study 
site should be informed according to local regulations (e.g. UK requires the notification of 
urgent safety measures within 3 days) but not later than 10 working days.

Novartis
Confidential
Page 108
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
13
References (available upon request)
Abubaker J Bavi PP, Al-Harbi S et al. PIK3CA mutations are mutually exclusive with PTEN 
loss in diffuse large B-cell lymphoma. Leukemia 2007; 21: 2368-2370
American Cancer Society (2012) SEER fact sheet Non-Hodgkin Lymphoma Available from: 
http://seer.cancer.gov/statfacts/html/nhl.html
Armitage JO (1993) Treatment of non-Hodgkin’s lymphoma. N Engl J Med. 238: 1023-1030
Baohua Y, Xiaoyan Z, Tiecheng Z et al (2008). Mutations of the PIK3CA gene in diffuse 
large B cell lymphoma. Diagn Mol Pathol; 17: 159-165
Beaulieu J-M, Gainetdinov RR, Caron MG (2009) AKT/GSK3 signaling in the action of 
psychotropic drugs. Annual Review of Pharmacology and Toxicology 49; 327-347
Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral 
pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012; 282-
290.
Benson AB 3rd, Ajani JA, Catalano RB, et al (2004). Recommended guidelines for the 
treatment of cancer treatment-induced diarrhea. J Clin Oncol; 22(14):2918-26.
Busaidy N, Farooki A, Dowlati A, et al. (2012) Management of metabolic effects associated 
with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30 (23):2919-28
Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to 
standardize response criteria for non-Hodgkin’s lymphoma. J Clin Oncol; 17(4):1244-1253.
Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant 
lymphoma. J Clin Oncol; 25(5):579-86.
Cheson BD (2007b) The International Harmonization Project for response criteria in 
lymphoma clinical trials. Hematol Oncol Clin North Am; 21(5):841-54.
Cheson BD (2011) New agents in follicular lymphoma. Best Practice & Research Clinical 
Haematology. 24: 305–312
Chiorean EG, Mahadevan D, Harris WB, et al. Phase I evaluation of SF1126, a vascular 
targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. 
ASCO Meeting Abstracts 2009: 2558. (Abstr.)
Chow L, Baker S (2006) PTEN function in normal and neoplastic growth. Cancer Lett. 
241(2):184-96. Epub 2006 Jan 18.
Cully M, You H, Levine AJ, et al (2006) Beyond PTEN mutations: the PI3K pathway as an 
integrator of multiple inputs during tumorigenesis. Nat Rev Cancer; 6(3):184-92.
Dal Col J, Zancai P, Terrin L, et al (2008). Distinct functional significance of Akt and mTOR 
constitutive activation in mantle cell lymphoma. Blood; 111: 5142-5151.
Doi T, Ando Y, Bando H, et al (2011) Phase I dose-escalation study of BKM120, an oral 
panclass I PI3K inhibitor, in Japanese patients with advanced solid tumors. Molecular Cancer 
Therapeutics: Volume 10, Issue 11 (Supplement 1, Abstract B159).
Flinn IW, Byrd JC, Furman RR et al (2009). Evidence of Clinical Activity in a Phase 1 Study 
of CAL-101, An Oral P110{Delta} Isoform-Selective Inhibitor of Phosphatidylinositol 3-

Novartis
Confidential
Page 109
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies. Blood (ASH Annual 
Meeting Abstracts) 114:922.
Fisher RI, Bernstein SH, Kahl BS et al (2006). Multicenter Phase II study of bortezomib in 
patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol; 24(30):4867-4874.
Graña-Suárez B, Burris HA, Ahnert JR, et al (2011) Oral Pan-Class I PI3 Kinase Inhibitor 
BKM120 Monotherapy in Patients With Advanced Solid Tumors: An Update on Safety and 
Efficacy. ASCO Annual Meeting; Poster.
Kahl B, Byrd JC, Flinn IW et al (2010) Clinical Safety and Activity In a Phase 1 Study of 
CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, In Patients 
with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood (ASH Annual Meeting 
Abstracts) 2010 116: Abstract 1777.
Katso R, Okkenhaug K, Ahmadi K, et al (2001) Cellular function of phosphoinositide 3-
kinases: implications for development, homeostasis, and cancer. Cell Dev Biol; 17:615-75.
Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity 
measure. J Gen Intern Med 2001;16:606-613.
Lannutti BJ, Meadows SA, Herman SEM, et al. CAL-101, a p110δ selective 
phophatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K 
signaling and cellular viability. Blood. 2011; 117(2): 591-594.
Liu, Cheng, Roberts & Zhao (2009). Targeting the phosphoinositide 3- kinase pathway in 
cancer; Nature review drug discovery; 8:627-644
Mahadvan D, Qi W, Stejskal A et al (2011) SF1126, a Pan-PI3K Inhibitor Has Superior 
Preclinical Activity to CAL-101 a PI3K Delta-Specific Inhibitor in Aggressive B-Cell Non-
Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 2011 118 (21): 1170
McCubrey JA, Steelman LS, Abrams SL, et al (2006) Roles of the RAF/MEK/ERK and 
PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme 
Regul. Jul 17.
Meadows SA, Kashishian A, Johnson D (2011) CAL-101 (GS-1101), a Specific Inhibitor of 
Phosphatidylinositol-3-Kinase-Delta (PI3K), Disrupts Signals From the Microenvironment, 
Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An 
Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL). 
Blood (ASH Annual Meeting Abstracts) 2011 118(21):1593.
National Cancer Institution (2012) Estimated new cases and deaths from non-Hodgkin 
lymphoma in the United States in 2012 http://cancer.gov/cancertopics/types/non-hodgkin
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) 
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin 
Oncology. 5: 649-55
Papadopoulos KP, Abrisqueta P, Chambers G et al(2011) A Phase I Dose Expansion Cohort 
Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An 
Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma. Blood (ASH Annual 
Meeting Abstracts) 2011 118: Abstract 1608

Novartis
Confidential
Page 110
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Reeder CB, Gornet MK, Habermann TM et al (2007) A Phase II Trial of the Oral mTOR 
Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).
Blood (ASH Annual Meeting Abstracts) 110: 121
Renner C, Zinzani P, Gressin R et al (2012) A multicenter phase II trial (SAKK 36/06) of 
single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell 
lymphoma. Haematologica 2012:Epub ahead of print.Rudelius M, Pittaluga S, Nishizuka S, et 
al. Constitutive activation of Aktcontributes to the pathogenesis and survival of mantle cell 
lymphoma. Blood. 2006; 108: 1668-1676.
Saura C, Bendell J, Jerusalem G, et al (2011). Phase I/II Study of BKM120 in Combination 
with Trastuzumab in Patients with HER2 Overexpressing Metastatic Breast Cancer Resistant 
to Trastuzumab-Containing Therapy; CTRC-AACR, San Antonio Breast Cancer Symposium, 
Poster.
Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, et al. 
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The 
University of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740-6
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized 
anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-1097.
Spitzer RL, Kroenke K, Williams JBW, for the Patient Health Questionnaire Primary Care 
Study Group. Validation and utility of a self-report version of PRIME-MD: the PHQ Primary 
Care Study. JAMA 1999;282:1737-1744
Uddin S Hussain AR, Siraj AK et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in 
diffuse large B-cell lymphoma survival. Blood 2006; 108: 4178-4186Von Hoff DD, LoRusso 
P, Demetri GD et al (2011). A phase I dose-escalation study to evaluate GDC-0941, a pan-
PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. 
ASCO Meeting Abstracts; 3052 (Abstr.)
Walsh, KJ, Fan S, Patel A et al (2009). PI3K inhibitors inhibit lymphoma growth by 
downregulation of myc-dependent proliferation. Blood. 2009; 114: 1697. (Abstr.)
Witzig TE, Geyer SM, Ghobrial I et al (2005) Phase II trial of single-agent temsirolimus 
(CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol; 23(23):5347-5356.
Witzig TE, Reeder CB, LaPlan BR et al (2011) A phase II trial of the oral mTOR inhibitor 
everolimus in relapsed aggressive lymphoma. Leukemia. 25: 341–347
Zha H, Raffeld M, Carboneau L et al (2004). Similarities of prosurvival signals in Bcl-2-
positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein 
microarray. Laboratory Investigation. 84: 235-244.
Zhou, Y, Jin L, Pittaluga S, et al (2010). PI3K, a selective inhibitor induces growth inhibition 
in mantle cell lymphoma. ASH Annual Meeting Abstracts. 116: 1812. (Abstr.)

Novartis
Confidential
Page 111
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14
Appendices
14.1
Appendix 1 - List of prohibited CYP3A inhibitors and inducers
Table 14-1
List of prohibited CYP3A inhibitors and inducers
Strong CYP3A 
inhibitors
Moderate CYP3A inhibitors
Strong CYP3A
inducers
Moderate CYP3A
inducers
clarithromycin
amprenavir
carbamazepine *
felbamate *
conivaptan
aprepitant
phenobarbital *
topiramate * (>200 mg/day)
indinavir
atazanavir
phenytoin *
oxcarbazepin *
itraconazole
cimetidine
fosphenytoin *
eslicarbazepin *
ketoconazole
ciprofloxacin
primidone *
rufinamide *
lopinavir
darunavir
avasimibe
bosentan
mibefradil
diltiazem
rifabutin
efavirenz
nefazodone
elvitegravir
rifampin
etravirine
nelfinavir
erythromycin
St. John's Wort
modafenil
posaconazole
fluconazole
nafcillin
ritonavir
grapefruit juice
ritonavir
saquinavir
schisandra sphenanthera
talviraline
telithromycin
tipranavir
tipranavir
troleandomycin
tofisopam
voriconazole
verapamil
* These drugs are Enzyme Inducing Anti-Epileptic drugs
This database of CYP inhibitors and inducers was compiled from the Indiana University School of Medicine’s 
“Clinically Relevant” Table, from the University of Washington’s Drug Interaction Database based on in vitro 
studies and from the FDA’s “Guidance for Industry, Drug Interaction Studies;” and from (Pursche 2008).

Novartis
Confidential
Page 112
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.2
Appendix 2 - List of CYP450 substrates to be used with caution
Table 14-2
List of CYP450 substrates to be used with caution
CYP2C8
CYP2C9
CYP2C19
CYP3A**
amodiaquine
celecoxib
amitriptyline
adinazolam
felodipine1
cerivastatin
diclofenac
citalopram
alfentanil1,2
fentanyl2
pioglitazone
flurbiprofen
clobazam
alpha-
dihydroergocryptine1
flunitrazepam
repaglinide
fluvastatin
clomipramine
alprazolam
fluticasone1
rosiglitazone
glibenclamide 
(glyburide)
clopidogrel
amlodipine
lovastatin1
torasemide
gliclazide
diazepam
aripiprazole
maraviroc1
troglitazone
glimepiride
fluoxetine
atorvastatin
midazolam1
glipizide
imipramine
brecanavir
nifedipine
indomethacin
lansoprazole
brotizolam1
nisoldipine
irbesartan
mephobarbital
budesonide1
nitrendipine
ketobemidone
moclobemide
buspirone1
perospirone1
lornoxicam
omeprazole
capravirine
quinine
losartan
pantoprazole
cerivastatin
sildenafil1
meloxicam
progesterone
chlorpheniramine
simvastatin1
naproxen
quazepam
cyclosporine2
sirolimus1,2
nateglinide
rabeprazole
darifenacin1
tolvaptan
piroxicam
sertraline
diazepam
trazodone
rosiglitazone
S-mephenytoin
diergotamine2
triazolam1
S-ibuprofen
ebastine1
sulfamethoxazole
eletriptan1
tenoxicam
eplerenone1
tolbutamide
ergotamine2
torasemide
estazolam
valdecoxib
everolimus1
This database of CYP substrates was compiled from the Indiana University School of Medicine’s “Clinically 
Relevant” Table, and from (Zhou 2009)
** CYP3A substrates were compiled from the Indiana University School of Medicine’s “Clinically Relevant” Table; 
and supplemented by the FDA’s “Guidance for Industry, Drug Interaction Studies” and the University of 
Washington’s Drug Interaction Database.
1 Sensitive substrates: Drugs whose plasma AUC values have been shown to increase 5-fold or higher when co-
administered with a potent inhibitor of the respective enzyme.
2 Substrates with narrow therapeutic index (NTI): Drugs whose exposure-response indicates that increases in their 
exposure levels by the concomitant use of potent inhibitors may lead to serious safety concerns (e.g., Torsades 
de Pointes).

Novartis
Confidential
Page 113
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.3
Appendix 3 - List of prohibited QT prolonging drugs
Table 14-3
List of prohibited QT prolonging drugs
Drug
QT risk(*)
Comment
Amiodarone
known risk for TdP
TdP risk regarded as low
Arsenic trioxide
known risk for TdP
Astemizole
known risk for TdP
CYP3A4 substrate with narrow therapeutic index.
Bepridil
known risk for TdP
Chloroquine
known risk for TdP
Chlorpromazine
known risk for TdP
Cisapride
known risk for TdP
CYP3A substrate with narrow therapeutic index.
Disopyramide
known risk for TdP
Dofetilide
known risk for TdP
Domperidone
known risk for TdP
Droperidol
known risk for TdP
Halofantrine
known risk for TdP
Haloperidol
known risk for TdP
When given intravenously or at higher-than-
recommended doses, risk of sudden death, QT 
prolongation and torsades increases.
Ibutilide
known risk for TdP
Levomethadyl
known risk for TdP
Sensitive CYP3A substrate
Mesoridazine
known risk for TdP
Methadone
known risk for TdP
Pentamidine
known risk for TdP
Pimozide
known risk for TdP
Sensitive CYP3A substrate with narrow therapeutic index
Probucol
known risk for TdP
Procainamide
known risk for TdP
Quetiapine
possible risk for TdP
Sensitive CYP3A substrate
Quinidine
known risk for TdP
Sensitive CYP3A substrate 
Sotalol
known risk for TdP
Sparfloxacin
known risk for TdP
Tacrolimus
possible risk for TdP
Sensitive CYP3A substrate with narrow therapeutic index
Terfenadine
Known risk for TdP
Sensitive CYP3A substrate with narrow therapeutic index
Thioridazine
Known risk for TdP
Vardenafil
possible risk for TdP
Sensitive CYP3A substrate
(*) Classification according to the QTdrugs.org Advisory Board of the Arizona CERT
Sensitive substrates: Drugs whose plasma AUC values have been shown to increase 5-fold or higher when co-
administered with a potent inhibitor of the respective enzyme.
Please also refer to http://crediblemeds.org/ for a comprehensive list of agents that prolong the QT interval

Novartis
Confidential
Page 114
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.4
Appendix 4 - List of QT prolonging drugs to be used with caution
Table 14-4
List of QT prolonging drugs to be used with caution
Drug
QT risk
Alfuzosin
possible risk for Torsades de Pointes
Amantadine
possible risk for Torsades de Pointes
Amitriptyline
conditional risk for Torsades de Pointes
Azithromycin
possible risk for Torsades de Pointes
Chloral hydrate
possible risk for Torsades de Pointes
Citalopram
conditional risk for Torsades de Pointes
Clomipramine
conditional risk for Torsades de Pointes
Clozapine
possible risk for Torsades de Pointes
Desipramine
conditional risk for Torsades de Pointes
Diphenhydramine
conditional risk for Torsades de Pointes
Dolasetron
possible risk for Torsades de Pointes
Doxepin
conditional risk for Torsades de Pointes
Dronedarone
possible risk for Torsades de Pointes
Felbamate
possible risk for Torsades de Pointes
Flecainide
possible risk for Torsades de Pointes
Fluoxetine
conditional risk for Torsades de Pointes
Foscarnet
possible risk for Torsades de Pointes
Fosphenytoin
possible risk for Torsades de Pointes
Galantamine
conditional risk for Torsades de Pointes
Gatifloxacin
possible risk for Torsades de Pointes
Gemifloxacin
possible risk for Torsades de Pointes
Granisetron
possible risk for Torsades de Pointes
Imipramine
conditional risk for Torsades de Pointes
Indapamide
possible risk for Torsades de Pointes
Isradipine
possible risk for Torsades de Pointes
Levofloxacin
possible risk for Torsades de Pointes
Lithium
possible risk for Torsades de Pointes
Mexiletine
conditional risk for Torsades de Pointes
Moexipril/HCTZ
possible risk for Torsades de Pointes
Moxifloxacin
possible risk for Torsades de Pointes
Nicardipine
possible risk for Torsades de Pointes
Nortriptyline
conditional risk for Torsades de Pointes
Octreotide
possible risk for Torsades de Pointes
Ofloxacin
possible risk for Torsades de Pointes
Ondansetron
possible risk for Torsades de Pointes
Oxytocin
possible risk for Torsades de Pointes
Paliperidone
possible risk for Torsades de Pointes
Paroxetine
conditional risk for Torsades de Pointes
Perflutren lipid microspheres
possible risk for Torsades de Pointes
Protriptyline
conditional risk for Torsades de Pointes

Novartis
Confidential
Page 115
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Drug
QT risk
Ranolazine
possible risk for Torsades de Pointes
Risperidone
possible risk for Torsades de Pointes
Roxithromycin*
possible risk for Torsades de Pointes
Sertindole
possible risk for Torsades de Pointes
Sertraline
conditional risk for Torsades de Pointes
Solifenacin
conditional risk for Torsades de Pointes
Tizanidine
possible risk for Torsades de Pointes
Trazodone
conditional risk for Torsades de Pointes
Trimethoprim-Sulfa
conditional risk for Torsades de Pointes
Trimipramine
conditional risk for Torsades de Pointes
Venlafaxine
possible risk for Torsades de Pointes
Ziprasidone
possible risk for Torsades de Pointes
(*) Classification according to the QTdrugs.org Advisory Board of the Arizona CERT
Please also refer to http://crediblemeds.org/ for a comprehensive list of agents that prolong the QT interval.

Novartis
Confidential
Page 116
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.5
Appendix 5 - Guideline for efficacy evaluation in lymphoma 
studies (based on Cheson response criteria)
14.5.1
Introduction
The purpose of this document is to provide the working definitions and rules necessary for a 
consistent and efficient analysis of efficacy in Oncology Lymphoma studies where Cheson 
response criteria apply.
This document is based on the International Working Group response criteria (Cheson et al 
1999), and the International Harmonization Project revised response criteria (Cheson et al 
2007b). Further clarification on these criteria has been published by (Cheson 2007a).
As Positron emission tomography (PET) is not yet widely accepted (Cheson 2009) for 
assessing response to treatment in lymphoma it is not considered for standard use in Novartis 
Oncology Lymphoma studies and therefore it is not considered in this document.
In general, this document is intended for studies where patients currently have measurable 
disease to be assessed, and therefore does not specifically address studies when the eligible 
patient population has no measurable disease (such as studies in patients who achieved 
complete response to first line treatment, or in post-transplantation settings). However, this 
guidance should be readily adaptable to these settings (see Appendix E).
As these are general guidelines, the following adjustments will apply to this trial:

Randomization is not applicable to the study since it is a non-randomized trial. All 
responses will be calculated from start of treatment.

If a lesion splits during the study, the sub-lesions will not be measured separately. Instead, 
such lesions which have split into sub-lesions will be measured as one lesion with all sub-
lesions contributing to the overall SPD.

Central Blinded Review of radiological response will not be used for this study. 
Responses will be assessed by the Investigator.
14.5.2
Definitions and criteria for normalization
14.5.2.1 Definitions
Throughout this document, the following definitions will apply (See also Appendix A).
Nodal vs extranodal lesion
A lesion is categorized based on the location as:

Nodal lesion,

Extranodal lesion, if it is located in organs other than lymph node or nodal mass, but 
including spleen and liver.

Novartis
Confidential
Page 117
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Measurability
Throughout this document, a lesion will be called measurable if it can be measured 
accurately in 2 perpendicular dimensions and:

For nodal lesion, if the long axis is > 15 mm, regardless of the length of the short axis,

For extranodal lesion, if the long and short axes are ≥ 10 mm.
Classification of lymph nodes
Lymph nodes are classified according to their size and/or relationship to the disease:

A lymph node meeting the measurability requirement above will constitute a measurable 
nodal lesion.

A lymph node not meeting the measurability requirement but with long axis > 15 mm (e.g. 
short axis can not be measured accurately) will constitute a non-measurable nodal lesion.

A lymph node not meeting the measurability criteria but with a size of 11 mm to 15 mm in 
the long axis and > 10 mm in the short axis will be checked for relationship to disease:

If it is thought to be disease related, it will constitute a non-measurable nodal lesion 
(referred to as “involved node” in Cheson et al 2007b).

If it is not thought to be disease related, it will constitute an abnormal lymph node 
but not a lesion.

All other lymph nodes will be considered normal and will not constitute nodal lesions.
14.5.2.2 Criteria for normalization of lesions
The normalization of lesions is defined as follow:

A measurable nodal lesion must become ≤ 15 mm in long axis to be considered 
normalized.

A non-measurable nodal lesion must decrease to ≤ 10 mm in the short axis and be ≤ 15 
mm in long axis to be considered normalized.

An extranodal lesion must disappear completely (assigned a size of 0 mm x 0 mm) to be 
considered normalized.
14.5.3
Efficacy assessments
14.5.3.1 Eligibility
Studies will be intended to include patients with measurable disease.
Patients should have at least one measurable nodal lesion greater than 20 mm in the long 
axis.
In cases where the patient has no measurable nodal lesions greater than 20 mm in the long 
axis at baseline, then the patient must have at least one measurable extranodal lesion.

Novartis
Confidential
Page 118
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.5.3.2 Methods of disease assessment
All radiological measurements should be taken in two perpendicular dimensions and recorded 
in metric notation, using a ruler or calipers.
All baseline evaluations should be performed as closely as possible to the randomization/start 
of treatment (preferably within 7 days) and never more than 3 weeks (21 days) before the 
randomization/start of treatment.
14.5.3.2.1
CT scan (or MRI)
For optimal evaluation of patients, the same methods of assessment and technique should be 
used to characterize each identified and reported lesion at baseline and during follow-up. 
Contrast-enhanced CT of chest, abdomen and pelvis should preferably be performed using a 
5mm slice thickness with a contiguous reconstruction algorithm. CT/MRI scan slice thickness 
should not exceed 8 mm cuts using a contiguous reconstruction algorithm. If at baseline a 
patient is known to be allergic to CT contrast or develops allergy during the trial, the 
following change in imaging modality will be accepted for follow up: a non-contrast CT of 
chest (MRI not recommended due to respiratory artifacts) plus contrast-enhanced MRI of 
abdomen and pelvis.
A change in methodology can be defined as either a change in contrast use (e.g. keeping the 
same technique, like CT, but switching from with to without contrast use or vice-versa, 
regardless of the justification for the change) or a change in technique (eg. from CT to MRI, 
or vice-versa), or a change in any other imaging modality. A change in methodology will 
result by default in a “Unknown” overall radiological response assessment. However, another 
overall radiological response than the Novartis calculated “Unknown” response may be 
accepted from the investigator or the central blinded reviewer if a definitive overall 
radiological response can be justified to be based on the available information.
In order to calculate the sum of the product of the diameters (SPD) of all index lesions (or 
extranodal lesions), their size must be entered throughout the study.
Actual lesion measurements should be entered on the corresponding CRFs. If, during the 
course of the study, either of the perpendicular diameters of a lesion can not be reliably 
measured because of its small size, it is recommended to enter the minimum limit of detection 
as the diameter size (e.g. 5 mm for spiral CT). In other cases when, during the course of the 
study, the diameter cannot be reliably measured for reasons other than its size (i.e. borders of 
the lesion are confounded by neighboring anatomical structures), no measurement should be 
entered and the lesion cannot be evaluated.
If lesions become confluent over time, it is recommended to measure them as one lesion, 
report the overall diameters to one of the lesions and assign 0 mm x 0 mm to each of the other 
previously measured lesions. If a lesion splits during the study, each sub-lesion should be 
measured separately for all subsequent assessments and all sub-lesions contribute to the SPD.

Novartis
Confidential
Page 119
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.5.3.2.2
Bone marrow assessment
Documentation of status of bone marrow involvement by lymphoma based on prior bone 
marrow biopsy or aspirate findings is required at baseline for all patients.
If no such documentation is available then a bone marrow biopsy or aspirate should be 
performed at baseline.
If bone marrow involvement is assessed by biopsy, the biopsy sample should have a goal of > 
20 mm unilateral core. If the biopsy sample is indeterminate by morphology 
(immunohistochemistry), then flow cytometry may be performed on bone marrow aspirate to 
confirm the findings.
14.5.3.2.3
Physical examination and assessment of B-symptoms
Skin lesions, if the size is ≥ 20 mm in at least one diameter, must be histologically confirmed 
for lymphoma involvement (the investigational site must document the histological 
confirmation (yes or no) on the corresponding CRF) and photographed including a ruler 
(color photography using digital camera). Tumor assessment will be performed and results 
will be recorded on the corresponding CRF at baseline and at the time of each radiological 
assessment.
B-symptoms are of importance in determining prognosis and should resolve completely in 
patients who have achieved complete response. B-symptoms in lymphoma patients are disease 
related clinical symptoms and are not caused by anticancer therapy (or drug toxicity).
B-symptoms are defined as follows:

Significant unexplained fever (≥ 38°C),

Unexplained, recurrent drenching night sweats

Unexplained loss of > 10% body weight within the previous 6 months,
as assessed and reported (present vs. absent) by the Investigator.
14.5.3.3 Documentation of disease
For the evaluation of disease at baseline and throughout the study, the following are recorded.
Index nodal lesions
Index nodal lesions are selected from the measurable nodal lesions. A minimum of one 
measurable index nodal lesion and maximum of six of the largest dominant nodal lesions 
should be documented at baseline and assessed throughout the study. If a patient has no 
measurable nodal disease at baseline, then it would be acceptable that no index nodal lesions 
be identified. Index nodal lesions should be from disparate regions of the body including 
mediastinal and retroperitoneal areas of disease whenever these sites are involved. Two 
perpendicular dimensions must be recorded on the corresponding CRF at each assessment of a 
measurable lesion selected to be an index lesion.

Novartis
Confidential
Page 120
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Non-index nodal lesions
All other nodal lesions (both measurable and non-measurable) are considered as non-index 
lesions.
Non-index lesions should be documented at baseline and assessed throughout the study. 
Measurements of these lesions are not required to be documented on the CRF. Their response 
status will be determined from investigator assessment as described in Section 14.5.3.4.2.
Spleen and liver (index and non-index) lesions
The spleen and liver will be assessed by CT scan (or MRI scan).
A maximum four of the largest dominant measurable nodules representing all involved 
anatomic locations should be selected as splenic and hepatic index lesions to be measured at 
baseline and followed up during the treatment. Two perpendicular dimensions will be 
recorded into the CRF at each assessment.
All other splenic or hepatic nodules (both measurable and non-measurable) are considered as 
non-index lesions. They should be documented at baseline and assessed throughout the study. 
Measurements of these lesions are not required to be documented on the CRF. Their response 
status will be determined from investigator assessment as described in Section 14.5.3.4.2.
Other extranodal (index and non-index) lesions
Organs other than lymph nodes, liver, spleen and bone marrow (such as breast and lung) can 
be occasionally involved by lymphoma. Determination of lymphoma involvement of these 
organs should be confirmed histologically.
If such organs are confirmed to be involved with measurable lesions, then index lesions 
should be selected from those organs. Up to four measurable lesions will be selected as index 
extranodal lesions from disparate regions (other than liver and spleen) at baseline and 
followed during the study.
Additional measurable lesions and all non-measurable extranodal disease will be documented 
at baseline and assessed throughout the study as non-index lesions. Other non-measurable 
disease, such as pleural effusion or bone lesions that are documented to be due to malignant 
disease, will be recorded at baseline as non-index lesions and followed during the study. 
Measurements of these lesions are not required to be documented on the CRF. Their response 
status will be determined from investigator assessment as described in Section 14.5.3.4.2.
Enlarged spleen or liver
The presence of enlarged spleen or liver before randomization/start of treatment on the basis 
of CT scan should be recorded on the corresponding CRF at baseline, and reassessed if the
patient has a radiological CR.
Bone marrow involvement
Status of bone marrow involvement by lymphoma before randomization/start of treatment 
will be collected (see Section 14.5.3.2.2).

Novartis
Confidential
Page 121
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
B-symptoms
B-symptoms (unexplained fever ≥ 38°C; unexplained, recurrent drenching night sweats; 
unexplained loss of > 10% body weight within the previous 6 months) will be recorded before 
randomization/start of treatment (baseline) and reevaluated if patients have achieved 
radiological CR as well as at the end of therapy.
14.5.3.4 Evaluation of radiological response
For the sake of simplicity, complete remission (as defined in Cheson et al 2007b) and 
complete response will both be referred to as complete response in this document.
To evaluate disease response to treatment, all index and non-index lesions will be followed 
and assessed throughout the study. At each assessment, response is evaluated separately for 
the index lesions (Table 14-7) and non-index lesions (Table 14-8) identified at baseline, then 
a combined overall radiological response is determined (Table 14-9).
14.5.3.4.1
Evaluation of index lesions (nodal and extranodal)
(a) When index nodal lesions are not in complete response
The response for index lesions is evaluated by calculating the Sum of the Products of 
Diameters (SPD) of all index lesions (see Table 14-5), except when there is a Complete 
Response for index nodal lesions (i.e. complete normalization of all index nodal lesions) (see 
Section b below).
Table 14-5
Radiological status based on SPD calculation for all index lesions
Response Criteria1
Evaluation of index lesions
Complete Response (CR)
See Table 14-7 below (not based on SPD calculation for all index lesions)
Partial Response (PR)
At least 50% decrease from baseline in the SPD of all index lesions
Stable Disease (SD)
Failure to attain the criteria needed for CR or PR and failure to fulfill the criteria 
for PD
Progressive Disease (PD)
At least a 50% increase from nadir2 in the SPD of all index lesions
1 At each assessment (if the index nodal lesions are not in CR status), the response status based on SPD 
calculation will be first assessed for meeting PD status criteria, then PR status and SD status.
2 Nadir is defined as the smallest sum of the product of the diameters of all index lesions recorded so far, at or 
after baseline.
(b) When index nodal lesions are in complete response
When there is a Complete Response for index nodal lesions (i.e. complete normalization of all 
index nodal lesions as defined in Section 14.5.2.2: all index lesion ≤ 15 mm in long axis), the 
SPD for these index nodal lesions may not be equal to zero and therefore a calculation of a 
SPD for all index lesions may be misleading. Therefore, by default, a specific response for 
extranodal index lesions needs to be evaluated, based on the SPD calculation restricted to all 
index extranodal lesions only (see Table 14-6).

Novartis
Confidential
Page 122
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Table 14-6
Radiological response criteria for index extranodal lesions in case of 
CR in index nodal lesions
Response Criteria1
Evaluation of index extranodal lesions
Complete Response (CR)
Complete disappearance of all index extranodal lesions
Partial Response (PR)
At least 50% decrease from baseline in the SPD restricted to all index 
extranodal lesions
Stable Disease (SD)
Failure to attain the criteria needed for CR or PR and failure to fulfill the criteria 
for PD
Progressive Disease (PD)
At least a 50% increase from nadir2 in the SPD restricted to all index 
extranodal lesions
1 At each assessment, response will be first assessed for meeting CR status. If CR status is not met, response will 
be assessed for PD status, then PR status and SD status.
2 Nadir is defined as the smallest sum of the product of the diameters restricted to all index extranodal lesions 
recorded so far, at or after baseline.
The algorithm for evaluating the response integrating index extranodal lesions and the SPD 
calculated on all index lesions (where appropriate) provides an overall response for index 
lesions (see Table 14-7).
(c) Evaluation of response for all index lesions
The evaluation of response for all index lesions is based on the combination of the response 
for index nodal lesions (CR or non-CR), the response for index extranodal lesions (as 
calculated in Table 14-6), and the status based on the SPD calculated on all index lesions 
(nodal and extranodal), as described in Table 14-7 and Appendix B.
Table 14-7
Radiological response for index lesions
Response for index 
nodal lesions1
Response for index 
extranodal lesions1
Status based on SPD 
calculation for all index lesions
Response for index 
lesions
CR
CR
Not calculated
CR
CR
SD/ PR
Not calculated
PR
CR
PD
PD
PD
CR
PD
PR
PR
CR
PD
SD
SD
Non-CR
Not evaluated
PD
PD
Non-CR
Not evaluated
PR
PR
Non-CR
Not evaluated
SD
SD
1 If no index nodal lesions are present at baseline, then index lesions response is equal to the index extranodal 
lesions response. A similar rule applied if no index extranodal lesions are present at baseline, then index lesions 
response is equal to the index nodal lesions response.
In case of a missing measurements of any of the index lesions, the radiological response for 
index lesions at that assessment will be “Unknown (UNK)”, unless progression was seen.
All lesions must have been measured with the same method as the one used at baseline, 
otherwise the radiological response for index lesions at that assessment will be “Unknown 
(UNK)”.

Novartis
Confidential
Page 123
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.5.3.4.2
Evaluation of non-index lesions (including nodal, splenic and/or hepatic 
nodules and other extranodal lesions)
At each reassessment, a non-index lesion (or a group of non-index lesions) will be given one 
of the following designations:

Normalization (non-index nodal lesion has regressed to normal size; non-index extranodal 
lesion is no longer present). Normalization of non-index nodal lesions should be 
determined based on their size at baseline as described in Section 14.5.2.2.

Improved, stable or worsened, but without unequivocal evidence of disease progression 
(non-index lesion is present but there is not sufficient worsening to declare PD based on 
the existing non-index lesions).

Unequivocal evidence of disease progression (worsening of existing non-index lesions is 
sufficient to declare PD)

Not assessed
Then, this status for each non-index lesion (or group of non-index lesions) will lead to a 
global response for non-index lesions (Table 14-8 and Appendix C):
Table 14-8
Response criteria for non-index lesions (nodal, splenic and/or hepatic 
nodules and other extranodal lesions)
Response Criteria
Evaluation of non-index lesions
Complete Response (CR)
Complete normalization of all non-index nodal and extranodal lesions: 
Radiological regression to normal size of all lymph nodes and complete 
disappearance of all extranodal (including splenic and/or hepatic nodules) lesions
Stable Disease (SD)
Failure to attain the criteria needed for CR and failure to fulfill the criteria for PD
Progressive Disease (PD)
Unequivocal disease progression of any existing non-index lesions (nodal or 
extranodal)
In case of a missing status of any of the non-index lesions, the radiological response for non-
index lesions at that assessment will be “Unknown (UNK)”, unless progression was seen.
All lesions must have been measured with the same method as the one used at baseline, 
otherwise the radiological response for non-index lesions at that assessment will be 
“Unknown (UNK)”.
14.5.3.4.3
New lesions
The appearance of any new nodal lesion >15 mm in any axis.
New nodal lesion is defined by:

either a previously normal lymph node becoming > 15 mm in any axis,

or a previously identified abnormal lymph node showing an increase of at least 50% in the 
long axis,

as assessed by investigator (or Central Review if applicable)
OR

any discrete extranodal (including splenic and/or hepatic nodules) lesions reliably 
appearing on CT scan or MRI after baseline is always considered as Progressive Disease 
(PD) and has to be recorded as a new lesion in the appropriate module of the CRF. 

Novartis
Confidential
Page 124
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Determination of new lymphoma involvement in organs other than lymph nodes or liver 
or spleen should be confirmed histologically and the site must document that in a 
comment to the corresponding CRF.
14.5.3.4.4
Overall radiological response
Overall radiological response is calculated as shown in Table 14-9.
Table 14-9
Overall radiological response at each assessment
Index lesions
Non-index lesions1
New lesions
Overall radiological response
CR
CR
No
CR
CR
SD
No
PR
PR
CR or SD
No
PR
SD
CR or SD
No
SD
PD
Any
Yes or No
PD
Any
PD
Yes or No
PD
Any
Any
Yes
PD
1 If no non-index lesions are present at baseline, then this column is not used in evaluating overall radiological 
response.
If the evaluation of any of the index or non-index lesions identified at baseline could not be 
made during follow-up or if the index or non-index response is “Unknown (UNK)”, the 
overall response status at that assessment must be “Unknown (UNK)” unless progression or a 
new lesion was seen.
14.5.3.5 Evaluation of overall disease response
The evaluation of overall disease response at each assessment is a composite of the individual 
radiological responses (index and non-index lesions, new lesions), laboratory test (bone 
marrow) and clinical responses (lymphoma related clinical symptoms).
14.5.3.5.1
Bone marrow re-assessment at time of radiological CR
In order to confirm a Complete disease response (CR), bone marrow biopsy or aspirate may 
be required when a radiological CR has been achieved (see Section 14.5.3.2.2). Details are 
provided in the Study Protocol. The infiltrate of lymphoma in bone marrow must have cleared 
on repeat bone marrow biopsy or aspirate. Patients who achieve a CR by other criteria but 
who have persistent morphologic positive or inconclusive bone marrow involvement will be 
considered partial responders. New or recurrent bone marrow involvement anytime during the 
follow up will be considered PD. Bone marrow biopsy or aspirate will be performed after the 
first assessment of CR or when clinically indicated.
The biopsy sample of bone marrow must be adequate (with a goal of > 20 mm unilateral core). 
If the sample is indeterminate by morphology, it should be negative by immunohistochemistry.

Novartis
Confidential
Page 125
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.5.3.5.2
Overall disease response
If a patient has an overall radiological response of CR as defined in Table 14-9, then this 
response must be confirmed by bone marrow biopsy or aspirate (if required as per the Study 
Protocol), presence of normal liver and spleen size, and evaluation of lymphoma related B-
symptoms. The patient’s overall response will be calculated as follows (see also Appendix D):
A patient will be deemed to have overall disease response of CR if bone marrow biopsy or 
aspirate becomes negative for tumor involvement (if the bone marrow was involved by 
lymphoma at baseline) and the liver and spleen are normal in size and there are no lymphoma 
related B-symptoms in addition to radiological CR.
If assessments of any of the following: lymphomatous infiltration of bone marrow (If required 
as per the Study Protocol), or evaluation of B-symptoms is not done, unknown or 
indeterminate or B-symptoms are still present when the overall radiological response is 
assessed as CR or the liver or spleen are enlarged, then the overall disease response will be 
assessed as PR until evaluation of these factors have shown normalized results and recorded 
on the corresponding CRF.
For patients whose radiological response is anything other than CR, assessment of bone 
marrow, liver, spleen and B-symptoms will not be required in evaluating overall response and 
overall disease response is the same as radiological response. However any new or recurrent 
bone marrow involvement at any time during follow-up will be considered PD.
Of note, appearance of B-symptoms or enlarged spleen or liver will not in themselves 
constitute documentation of progression. They are however expected to be associated with 
progressive disease. Every effort should be made to document that evidence radiologically 
and report the corresponding tumor assessments. Such tumor assessments are expected to be 
performed within 2 months of appearance of B-symptoms or enlarged spleen or liver.
14.5.4
Efficacy analysis definitions
14.5.4.1 Best overall disease response
The best overall disease response is the best disease response recorded from 
randomization/start of treatment until progressive disease or start of new anticancer therapy, 
whichever comes first.
A best overall disease response of SD will be declared when at least one SD assessment is 
available at least 6 weeks after randomization/start of treatment (and the patient would not 
qualify for CR or PR).
A patient will have a best overall disease response of PD if the progressive disease was 
observed less than 17 weeks after randomization/ start of treatment (and the patient does not 
qualify for CR, PR or SD).
The best overall disease response for a patient is always calculated, based on the sequence of 
overall disease responses. However, the overall disease response at a given assessment may 
be provided from different sources:

Novartis
Confidential
Page 126
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

Investigator overall disease response based on local radiological assessments, clinical and 
pathological (bone marrow in patients with CR) response

Central Blinded Review of radiological response, with or without blinded adjudication 
integrating clinical and pathological (bone marrow in patients with CR) response

Novartis calculated overall disease response, based on measurements / lesion status from 
either Investigator or Central Review and clinical and pathological (bone marrow in 
patients with CR) response
Based on the patients’ best overall disease response during the study, the following rate is 
then calculated:
Overall response rate (ORR) is the proportion of patients with a best overall disease 
response of CR and PR.
14.5.4.2 Time to event variables
Most of the time to event variables are defined in this section according to the International 
Working Group response criteria (Cheson et al 2007b). Further details on dates and censoring 
rules are provided respectively in Section 14.5.4.3 and Section 14.5.4.4.
14.5.4.2.1
Overall survival
Overall survival (OS) is defined as the time from the date of randomization/start of treatment 
to the date of death due to any cause. If a patient is not known to have died, survival will be 
censored at the date of last contact.
14.5.4.2.2
Progression-free survival
Progression-free survival (PFS) is defined as the time from the date of randomization/start 
of treatment to the date of event defined as the first documented progression or death due to 
any cause. If a patient has not had an event, progression-free survival is censored at the date 
of the last adequate assessment.
14.5.4.2.3
Time to progression
Time to progression (TTP) is defined as the time from the date of randomization/start of 
treatment to the date of first documented progression or death due to lymphoma. If a patient 
has not had an event, time to progression is censored at the date of the last adequate 
assessment.
14.5.4.2.4
Duration of response
Duration of overall response (CR or PR) applies only to patients whose best overall disease 
response was CR or PR. It is defined as the time from the date of first documented disease 
response (CR or PR) to the date of first documented progression or death due to lymphoma. If 
a patient has not had an event, duration of overall response is censored at the date of the last 
adequate assessment.

Novartis
Confidential
Page 127
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Duration of overall complete response (CR) applies only to patients whose best overall 
disease response was CR. It is defined as the time from the date of first documented disease 
complete response to the date of first documented progression or death due to lymphoma. If a 
patient has not had an event, duration of overall complete response is censored at the date of 
the last adequate assessment.
14.5.4.2.5
Time to response
Time to overall disease response (CR or PR) is defined as the time from the date of 
randomization / start of treatment to the date of first documented disease response (PR or CR). 
This analysis will include all patients/responders. If all patients are included, then patients 
who did not achieve a PR or CR will be censored:

At maximum follow-up (i.e. FPFV to LPLV used for the analysis) for patients who had a 
PFS event (i.e. either progressed or died due to any cause)

At the date of the last adequate assessment otherwise.
Time to overall disease complete response (CR) is defined as the time from the date of 
randomization / start of treatment to the date of first documented disease complete response 
(CR). This analysis will include all patients/responders. If all patients are included, then 
patients who did not achieve a CR will be censored:

At maximum follow-up (i.e. FPFV to LPLV used for the analysis) for patients who had a 
PFS event (i.e. either progressed or died due to any cause)

At the date of the last adequate assessment otherwise.
14.5.4.2.6
Lymphoma specific survival
Lymphoma specific survival (LSS) is defined as the time from the date of randomization/ 
start of treatment to the date of death documented as a result of lymphoma. If a patient has not 
had an event, lymphoma specific survival will be censored:

at the date of last contact if the patient is not known to have died,

at the date of death if the patient died for other reason than lymphoma.
14.5.4.2.7
Event free survival
Event-free survival (Time to treatment failure (TTF)) is defined as the time from the date 
of randomization to the earliest date of any of the following:

death

progressive disease as overall disease response assessed by the local investigator prior to 
treatment discontinuation

study treatment discontinuation due to:

disease progression

adverse event(s)

abnormal laboratory value(s)

abnormal test procedure results

subject withdrew consent

Novartis
Confidential
Page 128
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

lost to follow-up

death

new cancer therapy
Patients who discontinue study treatment for reasons other than those listed above (i.e., as a 
result of protocol violation, administrative problems) are censored at the date of the last 
adequate assessment prior to discontinuation. Patients with neither an event nor study 
treatment discontinuation are censored at the date of the last adequate assessment.
14.5.4.3 Definition of start and end dates for time to event variables
Assessment date
For each assessment (i.e. evaluation number), the assessment date is calculated as:

the latest date of all radiological measurement dates (e.g. CT-scan (or MRI), and 
excluding both bone marrow biopsy and B-symptoms assessment), if the overall disease 
response at that assessment is CR/PR/SD/UNK,

the earliest date of all measurement dates (e.g. CT-scan (or MRI), including bone marrow 
biopsy, but excluding B-symptoms assessments) if the overall disease response at that 
assessment is PD.
Start dates
For all “time to event” variables, other than the duration of responses, the date of 
randomization /start of treatment will be used as the start date.
For the calculation of duration of responses the following start date should be used:

Date of first documented response is the assessment date of the first overall disease 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively.
End dates
The end dates which are used to calculate ‘time to event’ variables are defined as follows:

Date of death as reported on the CRF (on the treatment completion page, the study 
evaluation completion page or survival follow-up page).

Date of last contact is defined as the last date the patient was known to be alive as 
derived from different CRF pages (see details in Section 14.5.5).

Date of progression is the first assessment date at which the overall disease response was 
recorded as PD.

Date of last adequate assessment is the date the last assessment with overall disease 
response of CR, PR or SD which was made before an event or a censoring reason occurred. 
If no post-baseline assessments are available (before an event or a censoring reason 
occurred) the date of randomization/start of treatment is used.

Novartis
Confidential
Page 129
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

Date of next scheduled assessment is the date of the last adequate assessment plus the 
protocol specified time interval for assessments. This date may be used if back-dating is 
considered when the event occurred beyond the acceptable time window for the next 
radiological assessment as per protocol.
Example (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months - missing - missing - PD. Date of next scheduled 
assessment would then correspond to 9 months.

Date of treatment discontinuation is the last known date subject took study drug.

Date of secondary anti-cancer therapy is defined as the start date of first additional 
(secondary) antineoplastic therapy or surgery (see details in Section 14.5.5)
14.5.4.4 Censoring and sensitivity analyses
14.5.4.4.1
Censoring reasons
This section outlines the possible censoring reasons for each time to event variables. In order 
to summarize the various reasons for censoring, the following categories (Table 14-10) will be 
calculated for each time to event variable based on the information reported on treatment 
completion page, the study evaluation page and the survival page.
Table 14-10
Censoring reasons
Time to event variables
Possible censoring reasons
OS
Alive
Lost to follow-up
PFS, TTP and duration of response
Ongoing without event
Lost to follow-up
Withdrew consent
Death due to reason other than lymphoma (only used for TTP and 
duration of response)
New anti-cancer therapy added (optional, see Table 14-11)
Event documented after two or more missing tumor assessments 
(optional, see Table 14-11)
Adequate assessment no longer available1
LSS
Alive
Lost to follow-up
Death due to reason other than lymphoma
TTF
Ongoing without event
Discontinuation for protocol deviation
Discontinuation for administrative problems
Study completed as per protocol
Event documented after two or more missing tumor assessments
Adequate assessment no longer available1
1 Adequate assessment is defined in Section 14.5.4.3. This reason corresponds to any censoring reasons after 
two or more missing tumor assessments. This reason will also be used for censor in case of no baseline 
assessment

Novartis
Confidential
Page 130
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.5.4.4.2
Event date, censoring date and sensitivity analyses
This section outlines the possible event and censoring dates for progression (Table 14-11), as 
well as addressing the issues of missing tumor assessments during the study. It is important 
that the protocol and analysis plan specify the primary analysis in detail with respect to the 
definition of event and censoring dates and also include a description of one or more 
sensitivity analyses to be performed.
Based on definitions outlined in Section 14.5.4.2, and using the draft FDA guideline on 
endpoints (FDA Guideline 2005) (Clinical Trial Endpoints for the Approval of Cancer Drugs 
and Biologics, April 2005) as a reference, the following analyses can be considered:
Table 14-11
Options for event dates used in PFS, TTP, duration of response
Situation
Options for end-date (progression)1
(1) = default unless specified differently in 
the protocol or analysis plan
Outcome
A
No baseline assessment
(1) Date of randomization/start of treatment2
Censor
B
Progression at or before next scheduled 
assessment
(1) Date of progression
(2) Date of next scheduled assessment1
Event
Event
C1
Progression or death after exactly one
missing assessment
(1) Date of progression (or death)
(2) Date of next scheduled assessment1
Event
Event
C2
Progression or death after two or more
missing assessments
(1) Date of last adequate assessment1
(2) Date of next scheduled assessment1
(3) Date of progression (or death)
Censor
Event
Event
D
No progression
(1) Date of last adequate assessment
Censor
E
Treatment discontinuation due to 
‘Disease progression’ without 
documented progression, i.e. clinical 
progression based on investigator claim
(1) N/A
(2) Date of discontinuation (visit date at which 
clinical progression was determined)
Ignored
Event
F
New anticancer therapy given
(1) Date of last adequate assessment
(2) Date of secondary anti-cancer therapy
(3) Date of secondary anti-cancer therapy
(4) N/A
Censor
Censor
Event
Ignored
G
Deaths due to reason other than 
lymphoma
(1) Date of last adequate assessment
Censor (only 
TTP and 
duration of 
response)
1 = Definitions can be found in Section 14.5.4.3.
2 = The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as 
defined in the protocol in which case this is a PFS event at the date of death.
Situations C (C1 and C2): Progression or death after one or more missing assessments: The 
primary analysis is usually using options (1) for situations C1 and C2, i.e.

(C1) taking the actual progression or death date, in the case of only one missing 
assessment.

(C2) censoring at the date of the last adequate assessment, in the case of two or more 
consecutive missing assessments.
In the case of two or more missing assessments (situation C2), option (3) may be considered 
jointly with option (1) in situation C1 as sensitivity analysis. A variant of this sensitivity 

Novartis
Confidential
Page 131
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
analysis consists of backdating the date of event to the next scheduled assessment as proposed 
with option (2) in situations C1 and C2.
Situation E: Treatment discontinuation due to ‘Disease progression’ without documented 
progression: By default, option (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment. However, option (2) 
may be used as sensitivity analysis. If progression is claimed based on clinical deterioration 
instead of tumor assessment by e.g. CT-scan, option (2) may be used for indications with high 
early progression rate or difficulties to assess the tumor due to clinical deterioration.
Situation F: New cancer therapy given: the handling of this situation must be specified in 
detail in the protocol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.
Additional suggestions for sensitivity analyses

Other suggestions for additional sensitivity analyses may include analyses to check for 
potential bias in follow-up schedules for tumor assessments, e.g.: By assigning the dates 
for censoring and events only at scheduled visit dates. The latter could be handled by 
replacing in Table 14-11 the “Date of last adequate assessment” by the “Date of previous 
scheduled assessment (from baseline)”, with the following definition:
Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly followed 
from baseline, immediately before or on the date of the last adequate assessment.

By considering any appearance or recurrence of B-symptoms or enlarged spleen/liver as a 
documented progression with a date of progression being the one of those symptoms.
The need for these types of sensitivity analyses will depend on the individual requirements for 
the specific study and disease area and have to be specified in the Study Protocol or RAP 
documentation.
14.5.5
Data handling and programming conventions
The following could be used for programming of efficacy results, but should be specified in 
the RAP documentation:
Calculation of ‘time to event’ variables
Time to event = end date – start date + 1 (in days)
When no post-baseline assessments are available, the date of randomization/start of treatment 
will be used as end date (duration = 1 day) when time is to be censored at last assessment, i.e. 
time to event variables can never be negative.
Date of last contact
The date of last contact will be derived for patients alive using the latest complete date among 
the following:

Novartis
Confidential
Page 132
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402

All assessment dates (e.g. vital signs assessment, performance status assessment, and also 
assessment date in third-party data such as tumor imaging, central laboratory, ECG etc.)

Medication dates including study medication, concomitant medications, antineoplastic 
therapies administered after study treatment discontinuation.

Adverse events dates

Last contact date collected on the ‘Survival information’ eCRF.

Randomization date.
Date of secondary anti-cancer therapy
The date of secondary anti-cancer therapy is the date of the 1
st antineoplastic therapy or 
surgery reported in the concomitant medications page, further antineoplastic therapy page or 
from other sources (e.g. Dosage administration record page).
Incomplete assessment dates
All investigation dates (e.g. X-ray, CT scan) must be completed with day, month and year.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section 14.5.4.3). If all measurement dates have 
no day recorded, the 1st of the month is used.
If the month is not completed, for any of the investigations, the respective assessment will be 
considered to be at the date which is exactly between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.
Incomplete dates for last contact or death
All dates must be completed with day, month and year. If the day is missing, the 15th of the 
month will be used for incomplete death dates or dates of last contact.
Study/project specific programming
The standard analysis programs need to be adapted for each study/project.

Novartis
Confidential
Page 133
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.5.6
References (available upon request)
Cheson BD (2007a) The international harmonization project for response criteria in 
lymphoma clinical trials. Hematol Oncol Clin N Am 21:841-854.
Cheson BD (2009) The case against heavy PETing. J Clin Oncol 27:1742-1743.
Cheson BD, Horning SJ, Coiffier B, et al (1999) Report of an International Workshop to 
standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253.
Cheson BD, Pfistner B, Juweid ME, et al (2007b) Revised response criteria for malignant 
lymphoma. J Clin Oncol 25:579-586.
FDA Guideline (2005) Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, April 2005.
Pursche S, Schelever E, von Bonin M, et al (2008) Influence of enzyme-inducing antiepileptic 
drugs on trough level of imatinib in glioblastoma patients. Curr. Clin. Pharmacol; 3 (3): 198-
203
Zhou S-F, Liu J-P, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes 
and its clinical impact. Drug Metabolism Reviews; 41(2): 89-295

Novartis
Confidential
Page 134
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
14.5.7
Appendices
Figure 14-1
Appendix A - Definition of index nodal lesion, non-index nodal lesion, 
index extranodal lesion, non-index extranodal lesion

Novartis
Confidential
Page 135
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Figure 14-2
Appendix B - Calculation of the response for index lesions

Novartis
Confidential
Page 136
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Figure 14-3
Appendix C - Calculation of the response for non-index lesions

Novartis
Confidential
Page 137
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Figure 14-4
Appendix D - Calculation of the overall disease response

Novartis
Confidential
Page 138
Amended Protocol Version 04 (Clean)
Protocol No. CBKM120Z2402
Appendix E - Adaptation for use in maintenance/adjuvant settings
For settings in which no measurable disease is present at baseline (e.g. maintenance), this 
guideline can be adapted. In such setting, as patients have no more measurable disease at 
baseline, the event of main interest is no more the Progressive Disease but the Relapsed 
Disease and the main endpoint is no more the Progression-free survival but the Disease-free 
survival. The definitions that need to be considered are presented below:
Relapsed Disease
The definition of Relapsed Disease can be derived from the definition of New Lesion (see 
Section 14.5.3.4.3) and is as follow:
Appearance of the following will always be considered as Relapsed Disease (RD)

any new nodal lesion > 15 mm in any axis (i.e. previously normal lymph node becoming > 
15 mm in any axis) on CT scan or MRI after baseline, or

any discrete extranodal lesion (including liver or spleen) reliably appearing on CT scan or 
MRI after baseline, or

≥ 50% increase in long axis from baseline of any residual lymph node or mass. A residual 
lymph node or mass is defined as a previously lymphoma-involved lymph node or mass 
(>10 mm in short axis (without any upper limit)) that was PET scan negative at baseline 
and only reliably detected by baseline CT or MRI.
Note: If a residual lymph node or mass at baseline decreases in size during treatment and 
becomes normal (i.e. complete disappearance of extranodal mass or ≤ 10 mm in short axis 
and ≤ 15 mm long axis for nodal mass), then reappearance of an extranodal lesion at the 
same site or increase of the same nodal mass to > 15 mm in the long axis, will be 
considered as Relapsed Disease and need to be recorded as a new lesion in the 
appropriate module of the CRF.
Disease-Free Survival
Disease-Free Survival (DFS) is the time from date of randomization/ start of treatment to the 
date of event defined as the first documented relapse of the disease or death due to any cause. 
If a patient has not had an event, disease-free survival is censored at the date of the last 
adequate assessment.